<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">105978</article-id><article-id pub-id-type="doi">10.7554/eLife.105978</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.105978.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Cap-independent co-expression of dsRNA-sensing and NF-κB pathway inhibitors enables controllable self-amplifying RNA expression with reduced immunotoxicity</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Lim</surname><given-names>Tony KY</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1843-0060</contrib-id><email>tony.ky.lim@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ritoux</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Paine</surname><given-names>Luke W</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0009-4099-4648</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ferguson</surname><given-names>Larissa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4274-8634</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Abdul</surname><given-names>Tawab</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Grundy</surname><given-names>Laura J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0003-8938-0862</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Smith</surname><given-names>Ewan St John</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2699-1979</contrib-id><email>es336@cam.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>Department of Pharmacology, University of Cambridge</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00tw3jy02</institution-id><institution>MRC Laboratory of Molecular Biology</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Comas-Garcia</surname><given-names>Mauricio</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000917t60</institution-id><institution>Universidad Autónoma de San Luis Potosí</institution></institution-wrap><country>Mexico</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Schoggins</surname><given-names>John W</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>The University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>29</day><month>08</month><year>2025</year></pub-date><volume>14</volume><elocation-id>RP105978</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2025-01-30"><day>30</day><month>01</month><year>2025</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2025-01-11"><day>11</day><month>01</month><year>2025</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.09.24.614636"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-04-03"><day>03</day><month>04</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.105978.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-07-15"><day>15</day><month>07</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.105978.2"/></event></pub-history><permissions><copyright-statement>© 2025, Lim et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Lim et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-105978-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-105978-figures-v2.pdf"/><abstract><p>Self-amplifying RNA (saRNA) holds promise for durable therapeutic gene expression, but its broader utility beyond vaccines is limited by potent innate immune responses triggered during replication. These responses shut down translation, induce cytotoxicity, degrade host mRNAs, and drive cytokine production. While exogenous immunosuppressants can blunt these effects, they complicate treatment and risk systemic side effects. To address this, we engineered ‘immune-evasive saRNA’ that intrinsically suppresses the innate immune pathways triggered by its own replication. This strategy leverages cap-independent translation to co-express a suite of inhibitors from a single saRNA transcript, targeting key innate immune pathways, including protein kinase R (PKR), oligoadenylate synthase (OAS)/RNase L, and nuclear factor-κB (NF-κB). In primary mouse fibroblast-like synoviocytes, a cell type central to the pathology of joint diseases, immune-evasive saRNA enables sustained transgene expression without external immunosuppressants, substantially reducing cytotoxicity and antiviral cytokine secretion. Crucially, this system offers both concentration-dependent control of expression and on-demand termination via a small-molecule antiviral. Together, these findings establish a framework for developing saRNA therapeutics with an improved tolerability profile that can be switched off once therapeutic outcomes are met, offering a path toward a controllable gene expression platform that fills the therapeutic gap between the transience of mRNA and the permanence of viral vectors.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>self-amplifying RNA</kwd><kwd>RNA therapeutics</kwd><kwd>fibroblast-like synoviocytes</kwd><kwd>alphavirus vectors</kwd><kwd>gene therapy</kwd><kwd>protein therapy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010665</institution-id><institution>Marie Skłodowska-Curie Actions</institution></institution-wrap></funding-source><award-id>European Postdoctoral Fellowship (UKRI Guarantee EP/X023117/1)</award-id><principal-award-recipient><name><surname>Lim</surname><given-names>Tony KY</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004325</institution-id><institution>AstraZeneca PLC</institution></institution-wrap></funding-source><award-id>PhD studentship G115018</award-id><principal-award-recipient><name><surname>Ritoux</surname><given-names>Anne</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004325</institution-id><institution>AstraZeneca PLC</institution></institution-wrap></funding-source><award-id>PhD studentship G113502</award-id><principal-award-recipient><name><surname>Paine</surname><given-names>Luke W</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MC-A023-5PB91</award-id><principal-award-recipient><name><surname>Ferguson</surname><given-names>Larissa</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100014013</institution-id><institution>UK Research and Innovation</institution></institution-wrap></funding-source><award-id>MICA ADVANTAGE visceral pain consortium MR/W002426/1</award-id><principal-award-recipient><name><surname>St John Smith</surname><given-names>Ewan</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012041</institution-id><institution>Versus Arthritis</institution></institution-wrap></funding-source><award-id>MICA ADVANTAGE visceral pain consortium MR/W002426/1</award-id><principal-award-recipient><name><surname>St John Smith</surname><given-names>Ewan</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.35802/225856</award-id><principal-award-recipient><name><surname>Grundy</surname><given-names>Laura J</given-names></name><name><surname>St John Smith</surname><given-names>Ewan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Engineering self-amplifying RNA to intrinsically disarm the innate immune pathways it triggers enables durable, externally controlled gene expression with reduced cytotoxicity and cytokine release, eliminating the need for exogenous immunosuppressants.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Self-amplifying RNA (saRNA) is a promising platform for therapeutic gene expression due to its ability to encode large genetic payloads and achieve sustained, non-integrating protein expression (<xref ref-type="bibr" rid="bib40">Frolov et al., 1996</xref>). Upon cellular internalization, saRNA utilizes host machinery to synthesize an RNA-dependent RNA polymerase (RdRp), which drives replication of the saRNA genome (<xref ref-type="bibr" rid="bib12">Bloom et al., 2021</xref>). This process involves the production of a negative-strand RNA intermediate that serves as a template for both genomic and subgenomic RNA synthesis (<xref ref-type="bibr" rid="bib99">Pietilä et al., 2017</xref>). Subgenomic RNA, encoding the gene of interest, is transcribed in excess of the genomic RNA, leading to robust and sustained protein expression (<xref ref-type="bibr" rid="bib85">Maruggi et al., 2019</xref>). However, the self-replication of saRNA also generates double-stranded RNA (dsRNA) intermediates, formed both during the synthesis of negative-strand RNA and during the transcription of positive-strand RNA from the negative-strand template (<xref ref-type="bibr" rid="bib99">Pietilä et al., 2017</xref>). These dsRNA intermediates are potent activators of cytosolic pattern recognition receptors, triggering innate immune responses (<xref ref-type="bibr" rid="bib1">Akhrymuk et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Gong et al., 2024</xref>). This recognition results in the shutdown of cap-dependent translation (<xref ref-type="bibr" rid="bib51">Gorchakov et al., 2004</xref>; <xref ref-type="bibr" rid="bib30">Dominguez et al., 2023</xref>; <xref ref-type="bibr" rid="bib39">Frolov and Schlesinger, 1994</xref>), degradation of cellular mRNA (<xref ref-type="bibr" rid="bib50">Gong et al., 2024</xref>; <xref ref-type="bibr" rid="bib119">Terenzi et al., 1999</xref>), induction of programmed cell death (<xref ref-type="bibr" rid="bib124">Venticinque and Meruelo, 2010</xref>; <xref ref-type="bibr" rid="bib41">Frolov et al., 1999</xref>; <xref ref-type="bibr" rid="bib79">Lundstrom et al., 2003</xref>), and release of cytokines and chemokines characteristic of viral infection (<xref ref-type="bibr" rid="bib123">Vanluchene et al., 2024</xref>; <xref ref-type="bibr" rid="bib98">Pepini et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Blakney et al., 2021b</xref>). In non-immunotherapeutic applications such as gene or protein therapy, these responses are particularly problematic as they limit transgene expression, reshape the host transcriptional landscape in ways that may undermine therapeutic effects, deplete transfected cells, and induce inflammation.</p><p>Strategies to mitigate saRNA-mediated innate immune responses have included the incorporation of modified nucleotides (<xref ref-type="bibr" rid="bib87">McGee et al., 2025</xref>), removal of dsRNA contaminants (<xref ref-type="bibr" rid="bib123">Vanluchene et al., 2024</xref>; <xref ref-type="bibr" rid="bib140">Zhong et al., 2021</xref>), and co-delivery of non-replicating mRNA encoding viral innate immune inhibiting proteins (<xref ref-type="bibr" rid="bib6">Beissert et al., 2017</xref>; <xref ref-type="bibr" rid="bib136">Yoshioka et al., 2013</xref>; <xref ref-type="bibr" rid="bib131">Xue et al., 2024</xref>). While these approaches can reduce initial innate immune responses to saRNA, they fall short in addressing the immune activation triggered by dsRNA intermediates that arise during saRNA replication (<xref ref-type="bibr" rid="bib12">Bloom et al., 2021</xref>). Sequence evolution of the RdRp shows some promise in reducing these responses, but even engineered RdRps still induce significant innate immune activation (<xref ref-type="bibr" rid="bib50">Gong et al., 2024</xref>; <xref ref-type="bibr" rid="bib72">Li et al., 2019</xref>). Encoding viral immune inhibitors within the saRNA construct using 2A self-cleaving peptides can improve protein expression in vitro but has limited impact on cytokine responses, despite reductions in NF-κB and IRF3 activation (<xref ref-type="bibr" rid="bib11">Blakney et al., 2021b</xref>). Although these strategies temper saRNA-induced innate immune responses to levels compatible with immunotherapy—where some immune activation is beneficial (<xref ref-type="bibr" rid="bib10">Blakney et al., 2021a</xref>)—they fall short of the stringent requirements for non-immunotherapeutic contexts, where immune activation can compromise therapeutic outcomes. In such cases, exogenous immunosuppressants can attenuate saRNA-induced immune responses to enable effective transgene expression (<xref ref-type="bibr" rid="bib123">Vanluchene et al., 2024</xref>; <xref ref-type="bibr" rid="bib136">Yoshioka et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Erasmus et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Kim et al., 2017</xref>), but this approach complicates treatment regimens and increases the risk of unintended side effects from systemic immune suppression.</p><p>To address these challenges, we developed a fully saRNA-based approach that mitigates innate immune responses triggered by saRNA replication, incorporating several key innovations. First, innate immune inhibitory proteins are expressed via cap-independent translation, bypassing the cap-dependent translation shutdown commonly triggered by saRNA. Cap-dependent translation requires the presence of a 5′ cap structure on mRNA, which recruits translation initiation factors and ribosomes (<xref ref-type="bibr" rid="bib88">Merrick, 2004</xref>). By contrast, cap-independent translation uses internal ribosome entry sites (IRES) to recruit ribosomes directly to the mRNA, enabling translation even when cap-dependent pathways are inhibited (<xref ref-type="bibr" rid="bib135">Yang and Wang, 2019</xref>). Second, by simultaneously targeting multiple dsRNA-sensing and inflammatory signaling pathways, our method provides a more comprehensive suppression of innate immune responses than single-target approaches. Third, encoding innate immune inhibitors directly within the saRNA ensures continuous protection against persistent innate immune activation caused by dsRNA intermediates during saRNA replication. We hypothesized that this cap-independent, multi-pronged, cis-encoded strategy would yield an ‘immune-evasive’ saRNA platform capable of sustained transgene expression with reduced immunotoxicity.</p><p>We evaluated this approach in primary mouse fibroblast-like synoviocytes (FLS), a key cell type in the pathology of joint diseases (<xref ref-type="bibr" rid="bib82">Maglaviceanu et al., 2021</xref>; <xref ref-type="bibr" rid="bib92">Mousavi et al., 2021</xref>). Using a novel microplate assay for longitudinal monitoring of saRNA translation control and cytotoxicity in live cells, we demonstrate that this strategy effectively reduces saRNA-induced cytotoxicity and cytokine production while enabling long-term transgene expression that does not require external immunosuppressants. This approach also enables external control of transgene expression with a small-molecule antiviral, allowing reversible or irreversible suppression depending on concentration, thereby offering both dosing flexibility and a mechanism for replicon removal once therapeutic goals are met. These findings establish a foundation for developing saRNA-based therapeutics that are durable, well-tolerated, and externally controllable for applications beyond vaccines.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>A microplate assay for longitudinal monitoring of subgenomic- and IRES-driven transgene expression and cell number</title><p>Because saRNA can shut down cap-dependent translation and induce cytotoxicity, we developed a microplate-based assay to simultaneously monitor subgenomic (cap-dependent) and IRES-mediated (cap-independent) transgene expression, together with cell number. Detailed assay development—including correction for spectral overlap and validation of BioTracker NIR680 as a cell number proxy—is provided in Appendix 1. To distinguish between translation initiation mechanisms, we designed dual-fluorescence saRNA reporter constructs (<xref ref-type="fig" rid="fig1">Figure 1a</xref>): mScarlet3 was expressed from the subgenomic RNA via cap-dependent initiation, while EGFP was expressed from an encephalomyocarditis virus (EMCV) IRES via cap-independent initiation. This assay permits repeated, non-destructive measurement of saRNA-driven transgene expression and cell number in primary mouse FLS, enabling longitudinal analysis of the effects of embedding inhibitors of innate immune pathways within saRNA.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Differential effects of moderate and strong double-stranded RNA (dsRNA)-sensing pathway inhibition on self-amplifying RNA (saRNA) transgene expression and cell number.</title><p>(<bold>a</bold>) Schematic of saRNA constructs co-expressing fluorescent reporters and dsRNA-sensing pathway inhibitors. nSP1–4 encodes the saRNA replicase. mScarlet3 indicates cap-dependent transgene expression and is expressed from subgenomic RNA (angled arrow denotes subgenomic promoter). EGFP indicates cap-independent transgene expression and is expressed from an IRES. A second IRES expresses varying levels of dsRNA-sensing pathway inhibition: ‘Conventional saRNA’ expresses moxBFP (control). ‘E3’ expresses vaccinia virus E3 (dsRNA-binding protein). ‘E3-NSs-L*’ expresses E3 plus Toscana virus NSs (ubiquitin ligase targeting PKR [protein kinase R]) and Theiler’s virus L* (RNase L inhibitor). saRNA was transfected into mouse primary fibroblast-like synoviocytes (FLS), labeled with BioTracker to indicate cell number. (<bold>b</bold>) Representative composite images of microplate wells showing EGFP (green) and mScarlet3 (red). (<bold>c</bold>) Representative images of microplate wells showing BioTracker. (<bold>d</bold>) Longitudinal quantification of EGFP (n=11). E3 provided the highest expression, while E3-NSs-L* expressed at intermediate levels. (<bold>e</bold>) Longitudinal quantification of mScarlet3 (n=11). E3 provided the highest expression, while E3-NSs-L* expressed at intermediate levels. (<bold>f</bold>) Longitudinal quantification of BioTracker (n=11). Conventional saRNA led to immediate and long-term reductions in signal. E3 initially maintained signal, but it gradually decreased over time. E3-NSs-L* preserved signal throughout the time course. For panels (b–c): Scale bar = 5 mm. For panels (d–f): Data are normalized to starting cell number (pre-transfection BioTracker signal). Statistical significance relative to mock transfection was assessed using two-way repeated-measures (RM) ANOVA with Greenhouse-Geisser correction and Dunnett’s multiple comparisons test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001. Data are presented as mean ± standard error of the mean (SEM). The mock transfection control data is also presented in <xref ref-type="fig" rid="fig5">Figure 5c–e</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Whole-plasmid sequencing results for self-amplifying RNA (saRNA) constructs depicted in <xref ref-type="fig" rid="fig1">Figure 1a</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-105978-fig1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-fig1-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Inhibiting dsRNA-sensing pathways or saRNA replication mitigates saRNA-induced cell loss.</title><p>(<bold>a</bold>) Area under the curve (AUC) analysis of BioTracker data shown in <xref ref-type="fig" rid="fig1">Figure 1f</xref>, integrating effects over 3 weeks (n=11). Signal preservation increased stepwise with greater dsRNA-sensing pathway inhibition. Statistical analysis was performed on AUC values using one-way RM ANOVA with Greenhouse-Geisser correction and Tukey’s multiple comparisons test to compare all groups. Mock transfection data is also presented in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a</xref>. (<bold>b</bold>) CellTag, a cell number normalization dye, quantified day 2 post-transfection (n=29). Signal preservation increased stepwise with greater dsRNA-sensing pathway inhibition. Data were normalized to mock transfection. Statistical analysis was performed using one-way RM ANOVA with Greenhouse-Geisser correction and Tukey’s multiple comparisons test to compare all groups. Data in this panel were pooled from in-cell western assays, incorporating data presented in <xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1c</xref>, <xref ref-type="fig" rid="fig6">Figure 6</xref>, and additional data not shown elsewhere. (<bold>c</bold>) Calcein AM, a viability dye, quantified one day after mock or conventional saRNA transfection, with or without the replicase inhibitor ML336 (n=4). Conventional saRNA reduced cell viability, an effect prevented by ML336. Data were normalized to pre-transfection levels. Statistical analysis was performed using two-way RM ANOVA with Greenhouse-Geisser correction, followed by Dunnett’s multiple comparisons test relative to the mock-transfected, vehicle-treated group. For all statistical reporting, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001. Data are presented as mean ± SEM.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Design of saRNA constructs for inhibiting multiple dsRNA-sensing pathways</title><p>To attenuate saRNA-induced innate immune responses, we designed constructs that inhibit dsRNA-sensing pathways. Cells detect cytosolic dsRNA through several pathways, including RIG-I (<xref ref-type="bibr" rid="bib101">Rehwinkel and Gack, 2020</xref>), melanoma differentiation-associated protein 5 (MDA-5) (<xref ref-type="bibr" rid="bib28">Dias Junior et al., 2019</xref>), protein kinase R (PKR) (<xref ref-type="bibr" rid="bib45">Gal-Ben-Ari et al., 2018</xref>), and oligoadenylate synthase (OAS)/RNase L pathways (<xref ref-type="bibr" rid="bib113">Silverman, 2007</xref>). To broadly inhibit these pathways, we designed an saRNA construct, referred to as ‘E3’, that co-expresses the vaccinia virus E3 protein (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). E3 protein is a pleiotropic inhibitor that binds and sequesters dsRNA, effectively blocking multiple dsRNA-sensing pathways (<xref ref-type="bibr" rid="bib118">Szczerba et al., 2022</xref>).</p><p>Given the key roles of PKR in cap-dependent translation shutdown and OAS/RNase L in cellular mRNA degradation in response to dsRNA, we sought to further inhibit these dsRNA-sensing pathways. We designed a second construct that, in additon to co-expressing vaccinia virus E3, includes Toscana virus NSs and Theiler’s virus L*. Toscana virus NSs is a ubiquitin ligase that promotes PKR degradation (<xref ref-type="bibr" rid="bib60">Kalveram and Ikegami, 2013</xref>), while Theiler’s virus L* is an inhibitor of mouse—but not human—RNase L (<xref ref-type="bibr" rid="bib32">Drappier et al., 2018</xref>; <xref ref-type="bibr" rid="bib117">Sorgeloos et al., 2013</xref>). To enable co-expression of E3, NSs, and L*, we incorporated 2A ‘self-cleaving’ peptide sequences between the proteins, allowing the polyprotein to be cleaved into separate proteins during translation. As prior experiments showed that using multiple identical 2A peptides can reduce protein expression (<xref ref-type="bibr" rid="bib76">Liu et al., 2017a</xref>), we utilized nonidentical 2A peptides. This construct, named ‘E3-NSs-L*’, provides a more comprehensive inhibition of dsRNA-sensing pathways than the E3 construct.</p><p>Because translation shutdown is one of the major cellular responses to saRNA replication, we expressed these dsRNA-sensing pathway inhibitors using ECMV IRES-mediated, cap-independent translation. During translation shutdown, global cap-dependent mRNA translation initiation is limited, freeing ribosomes that would otherwise be used for translating capped mRNAs (<xref ref-type="bibr" rid="bib3">Baird and Wek, 2012</xref>), thereby enhancing cap-independent translation (<xref ref-type="bibr" rid="bib65">Koch et al., 2020</xref>). By leveraging this mechanism, IRES-mediated expression of dsRNA-sensing pathway inhibitors ensures their levels increase as translation shutdown intensifies. In contrast, encoding these inhibitors via cap-dependent translation is expected to be less effective, as translation shutdown would lead to reduced inhibitor expression.</p><p>As a control, we designed a conventional saRNA construct that expresses a blue fluorescent protein (moxBFP) as a visual marker of IRES functionality in place of inhibitors of dsRNA-sensing pathways. Importantly, moxBFP expression did not overlap spectrally with the EGFP or mScarlet3 channels (<xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3b</xref>).</p></sec><sec id="s2-3"><title>Moderate dsRNA-sensing pathway inhibition enables high transgene expression at the cost of cell loss, while strong inhibition preserves cell number at lower expression levels</title><p>Following transfection of saRNA constructs, we monitored BioTracker, EGFP, and mScarlet3 fluorescence over 3 weeks (<xref ref-type="fig" rid="fig1">Figure 1b and c</xref>). Inhibiting dsRNA-sensing pathways with viral proteins significantly enhanced saRNA transgene expression (<xref ref-type="fig" rid="fig1">Figure 1d and e</xref>). Interestingly, the E3 construct produced the highest levels of EGFP and mScarlet3 expression, surpassing both conventional saRNA and the E3-NSs-L* construct. Conventional saRNA yielded low levels of transgene expression, while E3-NSs-L* showed intermediate expression.</p><p>Achieving durable transgene expression requires not only high expression but also preservation of cell viability, as constructs that induce cell death undermine this goal. Transfection of FLS with conventional saRNA caused both immediate and long-term reductions in cell number, as indicated by BioTracker (<xref ref-type="fig" rid="fig1">Figure 1f</xref>). While the E3 construct initially maintained cell number, it gradually diminished over time. In contrast, the E3-NSs-L* construct provided sustained protection against this decline. A time-integrated analysis of these data (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>) and CellTag-based normalization assays on day 2 post-transfection (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref>) further supported these results, revealing a stepwise increase in protection against cell loss with greater dsRNA-sensing pathway inhibition across the three constructs. Together, these results indicate that while the E3 construct enhances saRNA transgene expression, it also induces cell loss, underscoring the advantage of E3-NSs-L* for applications requiring sustained, non-cytotoxic gene expression.</p></sec><sec id="s2-4"><title>Inhibiting saRNA replication mitigates saRNA-induced cytotoxicity</title><p>In vitro transcription of saRNA often generates dsRNA byproducts, which can activate innate immune pathways and contribute to cytotoxicity (<xref ref-type="bibr" rid="bib140">Zhong et al., 2021</xref>; <xref ref-type="bibr" rid="bib2">Baiersdörfer et al., 2019</xref>). It remains unclear whether saRNA-induced cell loss arises primarily from these byproducts or from cytosolic dsRNA generated during saRNA replication. To investigate this, FLS were mock transfected or transfected with conventional saRNA in the presence or absence of 10 μM ML336, a potent inhibitor of the Venezuelan equine encephalitis virus (VEEV) RdRp that mediates self-amplification (<xref ref-type="bibr" rid="bib23">Chung et al., 2010</xref>). Without ML336, conventional saRNA-transfected cultures exhibited reduced viability as measured by calcein AM—a viability dye that live cells convert into a fluorescent signal (<xref ref-type="bibr" rid="bib15">Bratosin et al., 2005</xref>). In contrast, blocking saRNA replication with ML336 restored cell viability to levels comparable to mock transfection (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1c</xref>). These findings suggest that saRNA-induced cell loss is primarily driven by dsRNA generated during replication, rather than by dsRNA byproducts formed during in vitro transcription.</p></sec><sec id="s2-5"><title>Inhibiting dsRNA-sensing pathways reduces saRNA-induced cytotoxicity and improves cell viability</title><p>saRNA is known to induce programmed cell death (<xref ref-type="bibr" rid="bib39">Frolov and Schlesinger, 1994</xref>; <xref ref-type="bibr" rid="bib73">Li et al., 2020</xref>; <xref ref-type="bibr" rid="bib86">Mastrangelo et al., 2000</xref>), which often leads to cell detachment (<xref ref-type="bibr" rid="bib25">Costigan et al., 2023</xref>). Reductions in BioTracker signal are likely indicative of this process. However, since BioTracker is a lipophilic membrane dye, the reduction in signal may not necessarily correlate with cell viability or cytotoxicity. In addition to long-term cell tracking, lipophilic membrane dyes like BioTracker are often used to stain extracellular vesicles, which bud off from the plasma membrane (<xref ref-type="bibr" rid="bib78">Liu et al., 2022</xref>). During cellular stress, increased production of extracellular vesicles (<xref ref-type="bibr" rid="bib22">Chiaradia et al., 2021</xref>) could deplete the membrane-associated BioTracker dye from cells, resulting in a lower detectable signal. Therefore, the observed reduction in BioTracker signal could reflect enhanced extracellular vesicle production rather than cell death.</p><p>To provide more definitive evidence that inhibiting dsRNA-sensing pathways protects against saRNA-induced cytotoxicity, we conducted a longitudinal assay with annexin V staining over 6 days (<xref ref-type="fig" rid="fig2">Figure 2a</xref>), followed by calcein AM staining on day 7 (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). Annexin V, a membrane-impermeable protein, binds to phosphatidylserine, which translocates to the extracellular side of the cell membrane during early apoptosis, enabling the detection of apoptotic cells with intact membranes (<xref ref-type="bibr" rid="bib122">van Genderen et al., 2006</xref>). If the membrane is compromised, annexin V can enter cells and stain intracellular phosphatidylserine, indicating late apoptosis or necrosis (<xref ref-type="bibr" rid="bib27">Crowley, 2016</xref>). Calcein AM, on the other hand, accumulates in metabolically active cells with intact membranes, serving both as a marker of live cell number and an indicator of membrane integrity (<xref ref-type="bibr" rid="bib20">Chan et al., 2012</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>E3-NSs-L* prevents saRNA-induced elevations in annexin V staining and reductions in cell viability.</title><p>(<bold>a</bold>) Representative cropped microplate well images of Annexin V-CF800, indicating phosphatidylserine exposure or loss of membrane integrity. FLS were transfected with saRNA or treated with staurosporine, an apoptosis inducer. (<bold>b</bold>) Representative cropped microplate well images of calcein AM. Cultures are the same as in panel (a). (<bold>c</bold>) Quantification of Annexin V positive area, determined using Li thresholding and normalized to average mock transfection values (n=6). Annexin V positive area was increased by staurosporine, conventional saRNA, and E3—but not by E3-NSs-L*. Statistical significance relative to mock transfection was determined using two-way RM ANOVA with Bonferroni’s multiple comparisons test. Data are presented as mean ± SEM. (<bold>d</bold>) Quantification of calcein AM (n=6). Conventional saRNA and E3 reduced signal, an effect not observed with E3-NSs-L*. Data are normalized to starting cell number (pre-transfection BioTracker signal). Statistical significance was determined by one-way RM ANOVA with Greenhouse-Geisser correction and Tukey’s multiple comparisons test comparing all groups. All groups differed significantly from staurosporine (significance indicators omitted for clarity). Connecting lines indicate responses from the same biological replicate. For panels (a–b): Scale bar = 1.5 mm. For panels (c–d): *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig2-v2.tif"/></fig><p>The apoptosis-inducing agent staurosporine caused a transient increase in annexin V staining that decreased after the first day (<xref ref-type="fig" rid="fig2">Figure 2c</xref>), along with a marked reduction in calcein AM fluorescence compared to mock transfection (<xref ref-type="fig" rid="fig2">Figure 2d</xref>), consistent with extracellular phosphatidylserine translocation and/or increased membrane permeability, followed by cell detachment. Similarly, conventional saRNA induced a temporary increase in annexin V staining during the first 2 days post-transfection (<xref ref-type="fig" rid="fig2">Figure 2c</xref>) accompanied by reduced calcein AM staining (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). Co-expression of E3 prevented the initial increase in annexin V staining but elevated it from day 2 onward and also resulted in significantly reduced calcein AM intensity (<xref ref-type="fig" rid="fig2">Figure 2c and d</xref>). In contrast, E3-NSs-L* had no significant effect on annexin V or calcein AM staining compared to mock transfection, supporting the idea that broader inhibition of dsRNA-sensing pathways, achieved by combining E3, NSs, and L*, is more effective than E3 alone in preventing saRNA-induced cell death and preserving cell viability.</p></sec><sec id="s2-6"><title>dsRNA-sensing pathway inhibition prevents eIF2α phosphorylation, but fails to affect saRNA-induced reductions in eIF4E phosphorylation levels</title><p>After establishing the effects of moderate and strong inhibition of dsRNA-sensing pathways on cytotoxicity and transgene expression, we next investigated how modulating these pathways influences translational control at the molecular level. Eukaryotic translation initiation factor (eIF)2α is a central regulator of translation initiation; its phosphorylation serves as a cellular stress response to limit cellular cap-dependent protein synthesis (<xref ref-type="bibr" rid="bib3">Baird and Wek, 2012</xref>). Using in-cell western assays, we found that conventional saRNA increased eIF2α phosphorylation, but both E3 and E3-NSs-L* effectively blocked this phosphorylation (<xref ref-type="fig" rid="fig3">Figure 3a</xref>), consistent with previous reports of vaccinia virus E3’s inhibitory effect on eIF2α phosphorylation (<xref ref-type="bibr" rid="bib6">Beissert et al., 2017</xref>; <xref ref-type="bibr" rid="bib131">Xue et al., 2024</xref>). Interestingly, E3-NSs-L* also increased total eIF2α levels, an effect not observed with the E3 construct (<xref ref-type="fig" rid="fig3">Figure 3b</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>dsRNA-sensing pathway inhibitors suppress saRNA-induced eIF2α phosphorylation but not the reduction in eIF4E phosphorylation.</title><p>(<bold>a</bold>) Phosphorylated eIF2α levels examined by in-cell western (n=6). Conventional saRNA increased eIF2α phosphorylation, while E3 and E3-NSs-L* did not. Data are normalized to total eIF2α and presented as fold-change relative to mock transfection. (<bold>b</bold>) Total eIF2α levels examined by in-cell western (n=5). E3-NSs-L* increased total eIF2α. Data are normalized to CellTag and presented as fold-change relative to mock transfection. (<bold>c</bold>) Phosphorylated eIF4E levels, normalized to total eIF4E, examined by in-cell western (n=6). All constructs reduced eIF4E phosphorylation. (<bold>d</bold>) Total eIF4E levels, normalized to CellTag, examined by in-cell western (n=6). No significant differences were revealed (F(3,15) = 1.207, p=0.3410). For all panels: Statistical significance was determined by one-way RM ANOVA and Tukey’s multiple comparison test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. The mock transfection control data are also used in <xref ref-type="fig" rid="fig6">Figure 6a–d</xref>. Connecting lines indicate responses from the same biological replicate.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>E3-NSs-L* protects against saRNA-induced PKR upregulation, RNA degradation, and decreased protein synthesis rate.</title><p>(<bold>a</bold>) PKR levels examined by in-cell western (n=4). E3-NSs-L* inhibits PKR upregulation. Data are normalized to CellTag and presented as fold-change relative to mock transfection. (<bold>b</bold>) rRNA integrity assessed from total RNA using the RNA Integrity Number (RIN) algorithm (n=5). E3-transfected cells demonstrate lower RIN than E3-NSs-L*–transfected cells. Data are shown as a Gardner-Altman comparison plot, with the mean effect size ± 95% confidence interval (CI) illustrated on the right subpanel. Dotted lines indicate group means. Statistical significance was determined using a paired t-test (p=0.0054). (<bold>c</bold>) Protein translation rates measured by puromycin incorporation, normalized to CellTag (n=5). Conventional saRNA or E3 reduced protein synthesis rates, an effect not observed with E3-NSs-L*. For panels (a,c): Statistical significance was determined by one-way RM ANOVA with Tukey’s multiple comparisons test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001. Connecting lines indicate responses from the same biological replicate.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-fig3-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig3-figsupp1-v2.tif"/></fig></fig-group><p>We next examined the impact of saRNA on eIF4E, another key regulator of translation initiation (<xref ref-type="bibr" rid="bib84">Mars et al., 2024</xref>). Unlike eIF2α phosphorylation—which was inhibited by the E3 and E3-NSs-L* constructs—phosphorylation of eIF4E was reduced by all saRNA constructs (<xref ref-type="fig" rid="fig3">Figure 3c</xref>), including those targeting dsRNA-sensing pathways, while total eIF4E levels remained unchanged (<xref ref-type="fig" rid="fig3">Figure 3d</xref>). These results indicate that inhibiting dsRNA-sensing pathways does not prevent the saRNA-induced reduction in eIF4E phosphorylation.</p><p>Given that PKR phosphorylates eIF2α upon activation by dsRNA (<xref ref-type="bibr" rid="bib51">Gorchakov et al., 2004</xref>), we next assessed PKR levels following saRNA transfection. Consistent with previous reports (<xref ref-type="bibr" rid="bib50">Gong et al., 2024</xref>), transfection with conventional saRNA led to increased PKR levels (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1a</xref>). The E3 construct produced a similar increase, whereas co-expression of E3-NSs-L* mitigated this effect. This finding aligns with the established role of the Toscana virus NSs protein as a ubiquitin ligase that targets PKR for degradation (<xref ref-type="bibr" rid="bib60">Kalveram and Ikegami, 2013</xref>).</p></sec><sec id="s2-7"><title>Host mRNA degradation contributes to enhanced transgene expression under moderate dsRNA-sensing pathway inhibition</title><p>The increased transgene expression observed with the E3 construct compared to E3-NSs-L* cannot be attributed to differences in eIF2α or eIF4E-mediated translational control. Phosphorylation levels of both factors were comparable between the two constructs (<xref ref-type="fig" rid="fig3">Figure 3a and c</xref>), indicating that the enhanced transgene expression associated with the E3 construct arises from alternative mechanisms.</p><p>Upon detection of dsRNA, OAS enzymes synthesize 2′–5′-oligoadenylates, which activate RNase L, a ribonuclease that degrades single-stranded RNA. This leads to widespread host mRNA cleavage (<xref ref-type="bibr" rid="bib17">Burke et al., 2019</xref>), impaired nuclear export of transcripts (<xref ref-type="bibr" rid="bib18">Burke et al., 2021</xref>), and global arrest of protein synthesis (<xref ref-type="bibr" rid="bib31">Donovan et al., 2017</xref>). Several RNA viruses, including dengue and Zika, exploit this process by localizing their transcripts within replication organelles, shielding them from RNase L activity while maintaining efficient translation (<xref ref-type="bibr" rid="bib126">Whelan et al., 2019</xref>; <xref ref-type="bibr" rid="bib18">Burke et al., 2021</xref>). The VEEV-derived saRNA used in this study also replicates within these organelles (<xref ref-type="bibr" rid="bib97">Paul and Bartenschlager, 2013</xref>), likely protecting its transcripts from RNase L-mediated degradation in a similar fashion.</p><p>We hypothesized that RNase L activation by the E3 construct would preferentially deplete host mRNAs, reducing competition for the ribosomal machinery and thereby enhancing the relative translation of protected saRNA transcripts. In contrast, E3-NSs-L* expresses Theiler’s virus L*, an RNase L inhibitor (<xref ref-type="bibr" rid="bib32">Drappier et al., 2018</xref>), preventing host mRNA degradation and forcing saRNA to compete with host mRNA for ribosome access.</p><p>To evaluate whether RNase L activation contributes to the greater transgene expression observed with the E3 construct compared to E3-NSs-L*, we assessed ribosomal RNA (rRNA) integrity as a surrogate measure of RNase L activity (<xref ref-type="bibr" rid="bib113">Silverman, 2007</xref>). For this analysis, total RNA was extracted from FLS transfected with either E3 or E3-NSs-L*; the conventional saRNA construct was not examined, as its induction of translation shutdown is expected to alter dsRNA intermediate levels. rRNA integrity was then evaluated using the RNA integrity number (RIN) algorithm on capillary gel electropherograms of total RNA (<xref ref-type="bibr" rid="bib110">Schroeder et al., 2006</xref>). Cells transfected with E3 exhibited a moderate but statistically significant reduction in RIN compared to those transfected with E3-NSs-L* (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1b</xref>). This finding aligns with previous studies demonstrating that RNase L activation primarily depletes host mRNA levels before extensive rRNA degradation (<xref ref-type="bibr" rid="bib31">Donovan et al., 2017</xref>; <xref ref-type="bibr" rid="bib17">Burke et al., 2019</xref>; <xref ref-type="bibr" rid="bib61">Karasik et al., 2021</xref>), and supports the hypothesis that RNase L activation and subsequent reductions in host mRNA occur with the E3 construct but not with E3-NSs-L*.</p><p>We further evaluated global protein synthesis using surface sensing of translation (SUnSET) (<xref ref-type="bibr" rid="bib100">Ravi et al., 2020</xref>; <xref ref-type="bibr" rid="bib109">Schmidt et al., 2009</xref>), in which FLS were pulsed with puromycin, and newly synthesized peptides were detected via anti-puromycin immunoreactivity (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1c</xref>). Transfection with conventional saRNA led to a marked reduction in protein synthesis, consistent with translation shutdown. Co-expression of E3 partially restored translation; however, synthesis rates remained significantly lower than in mock-transfected cells, likely due to RNase L-mediated depletion of host mRNAs despite relief from translation shutdown. In contrast, transfection with E3-NSs-L* resulted in protein synthesis rates comparable to those of mock-transfected cells, consistent with effective inhibition of RNase L and preservation of host mRNA.</p><p>Together, these findings support a model in which RNase L activation by the E3 construct enhances transgene expression through selective depletion of host mRNA, thereby reducing competition for the ribosomal pool. Conversely, E3-NSs-L* suppresses RNase L activity, preserving host mRNA and limiting the availability of ribosomes for transgene expression.</p></sec><sec id="s2-8"><title>dsRNA-sensing pathway inhibition suppresses secretion of select antiviral cytokines while enhancing others</title><p>For therapeutic applications beyond vaccines and cancer immunotherapy, prolonged transgene expression is ideally achieved without triggering immune activation. While our data show that inhibition of dsRNA-sensing pathways can mitigate key saRNA-induced adverse effects, including cell death, translation shutdown, and host mRNA degradation, it remains unclear whether this strategy also attenuates cytokine secretion. To investigate this, we measured the concentrations of 13 antiviral cytokines in FLS culture supernatants using a multiplex bead-based immunoassay (<xref ref-type="fig" rid="fig4">Figure 4a</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Transfection with conventional saRNA elicited a broad cytokine response. Inhibition of dsRNA-sensing pathways selectively suppressed production of certain cytokines: Both E3 and E3-NSs-L* significantly reduced interferon (IFN)-α and IFN-β, while E3-NSs-L* significantly reduced tumor necrosis factor (TNF). Notably, the production of some cytokines was elevated: E3 significantly increased macrophage chemoattractant protein-1, and E3-NSs-L* significantly increased granulocyte-macrophage colony-stimulating factor, relative to mock-transfected controls. These findings indicate that even strong inhibition of dsRNA-sensing pathways only partially attenuates the cytokine response to saRNA. Further strategies are needed to reduce saRNA-induced cytokine secretion to levels acceptable for non-immunotherapeutic applications.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>saRNA-triggered cytokine responses are variably affected by dsRNA sensing inhibition, but broadly suppressed by NF-κB inhibition.</title><p>(<bold>a</bold>) Antiviral cytokine response quantified by multiplex bead-based immunoassay (n=6). Inhibition of dsRNA-sensing pathways reduced some cytokine responses while enhancing others. Cytokine levels were normalized to pre-transfection cell number (indicated by BioTracker), scaled within each biological replicate with the highest value set to 100%, and shown as a heatmap of group means. Plots of unscaled data are presented in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>. Statistical significance was assessed on unscaled data by one-way repeated-measures ANOVA for each cytokine. Treatment effect was significant for all cytokines after controlling for multiple comparisons using the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli (FDR = 5%). Tukey’s multiple comparisons test identified between-group differences. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001 vs. mock transfection; <sup>#</sup>p&lt;0.05, <sup>##</sup>p&lt;0.01, <sup>###</sup>p&lt;0.001 vs. conventional saRNA. The mock transfection control is shared with panel (c). (<bold>b</bold>) Schematic of saRNA constructs designed for inhibiting inflammatory signaling. dsRNA-sensing pathway inhibitors and EGFP are expressed via an IRES. A second IRES expresses variable amounts of inflammatory signaling pathway inhibition: ‘moxBFP’ expresses moxBFP (control). ‘srIκBα’ expresses srIκBα (inhibiting NF-κB). ‘srIκBα-Smad7-SOCS1’ expresses srIκBα plus Smad7 (inhibiting TGF-β) and SOCS1 (inhibiting IFN). (<bold>c</bold>) Antiviral cytokine response quantified by multiplex bead-based immunoassay (n=6). srIκBα and srIκBα-Smad7-SOCS1 broadly suppressed cytokine secretion. Data normalization, visualization, and statistical analysis were performed as described in panel (a), but scaling was applied independently to account for the different constructs tested. Plots of unscaled data are presented in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001 vs. mock transfection; <sup>#</sup>p&lt;0.05, <sup>##</sup>p&lt;0.01, <sup>###</sup>p&lt;0.001, <sup>####</sup>p&lt;0.0001 vs. moxBFP. The mock transfection control is shared with panel (a). Abbreviations: srIκBα, super repressor inhibitor of κBα; Smad7, mothers against decapentaplegic homolog 7; SOCS1, suppressor of cytokine signaling 1; IFN, interferon; CXCL, C-X-C motif chemokine ligand; TNF, tumor necrosis factor; MCP-1, monocyte chemoattractant protein-1; IL, interleukin; CCL5, chemokine ligand 5; GM-CSF, granulocyte-macrophage colony-stimulating factor.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Whole-plasmid sequencing results for plasmids depicted in <xref ref-type="fig" rid="fig4">Figure 4b</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-105978-fig4-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Detailed cytokine responses to saRNA constructs inhibiting dsRNA-sensing pathways.</title><p>(<bold>a–m</bold>) Unscaled data underlying the heatmap in <xref ref-type="fig" rid="fig4">Figure 4a</xref>, showing individual cytokine responses (n=6). Conventional saRNA triggered robust secretion of antiviral cytokines. E3 and E3-NSs-L*reduced IFN-α and IFN-β. E3-NSs-L* additionally suppressed TNF. However, E3 increased MCP-1, and E3-NSs-L* increased GM-CSF relative to conventional saRNA. Data were normalized to starting cell number (indicated by pre-transfection BioTracker signal). Statistical significance was assessed using one-way repeated-measures ANOVA for each cytokine. Multiple comparisons were controlled using the Benjamini-Krieger-Yekutieli false discovery rate (FDR) procedure (Q=5%). All cytokines passed the discovery threshold. Treatment effects were analyzed using Tukey’s multiple comparisons test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001. Connecting line indicates responses from the same biological replicate. Mock transfection controls are shared with <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-fig4-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Detailed cytokine responses to saRNA constructs inhibiting inflammatory signaling pathways.</title><p>(<bold>a–m</bold>) Unscaled data underlying the heatmap in <xref ref-type="fig" rid="fig4">Figure 4c</xref>, showing individual cytokine responses (n=6). moxBFP significantly increased all cytokines relative to mock transfection. Cytokine responses were broadly suppressed by both srIκBα and srIκBα-Smad7-SOCS1. Data were normalized to starting cell number (indicated by pre-transfection BioTracker signal). Statistical significance was assessed using one-way repeated-measures ANOVA for each cytokine. Multiple comparisons were controlled using the Benjamini-Krieger-Yekutieli false discovery rate (FDR) procedure (Q=5%). All cytokines passed the discovery threshold. Treatment effects were analyzed using Tukey’s multiple comparisons test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001. Connecting line indicates responses from the same biological replicate. Mock transfection controls are shared with <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-fig4-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Reduced antiviral gene expression and replicon activity observed with co-expression of inflammatory signaling inhibitors.</title><p>(<bold>a</bold>) Antiviral and proinflammatory transcripts quantified by qPCR (n=3). Conventional saRNA upregulated antiviral and proinflammatory transcripts. E3 and srIκBα-Smad7-SOCS1 elicited less upregulation, with the latter showing the greatest suppression. Statistical comparisons were performed on ΔCT values normalized to <italic>18S</italic> rRNA using one-way ANOVA with multiple comparisons controlled using the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli (FDR = 5%). All investigated transcripts passed significance thresholds for discovery. Treatment effects were analyzed using Holm-Šídák’s multiple comparisons test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 vs. mock transfection; <sup>#</sup>p&lt;0.05 vs. conventional saRNA. Mean –ΔΔCT values normalized to mock transfection are shown on the heatmap (larger values indicate higher expression). (<bold>b</bold>) EGFP, encoded on all saRNA constructs, quantified by qPCR (n=3). srIκBα-Smad7-SOCS1 demonstrated higher ΔCT values (indicating lower EGFP transcript levels) compared to conventional saRNA or E3. Expression was normalized to <italic>18</italic>S rRNA, and data are shown as ΔCT values. Statistical comparisons were performed on ΔCT values using one-way ANOVA with Tukey’s multiple comparisons test. (<bold>c</bold>) In vitro transcribed saRNA constructs were resolved by denaturing gel electrophoresis. Conventional saRNA (11,181 nt), E3 (11,030 nt), and E3-NSs-L* (12,562 nt) migrated as single bands corresponding to their expected sizes. In contrast, the moxBFP (13,282 nt), srIκBα (13,614 nt), and srIκBα-Smad7-SOCS1 (15,664 nt) constructs each exhibited two bands: one at the expected size and a smaller lower intensity band of consistent size across all three constructs, suggestive of a common truncated transcript. (<bold>d</bold>) Band intensity plots of moxBFP, srIκBα, and srIκBα-Smad7-SOCS1 derived from the gel shown in panel (c).</p><p><supplementary-material id="fig4s3sdata1"><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-fig4-figsupp3-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4s3sdata2"><label>Figure 4—figure supplement 3—source data 2.</label><caption><title>PDF file containing the original gel image for <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3c</xref>, with relevant bands labeled.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-105978-fig4-figsupp3-data2-v2.pdf"/></supplementary-material></p><p><supplementary-material id="fig4s3sdata3"><label>Figure 4—figure supplement 3—source data 3.</label><caption><title>Unmodified/uncropped original gel image as shown in <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3c</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-105978-fig4-figsupp3-data3-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig4-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-9"><title>Design of saRNA constructs for inhibiting multiple inflammatory signaling pathways</title><p>To further inhibit saRNA-induced cytokine release, we designed additional saRNA constructs that co-express cellular inhibitors of inflammatory signaling. In these constructs, dsRNA pathway inhibitors (vaccinia virus E3, Toscana virus NSs, Theiler’s virus L*) and EGFP were expressed from a single IRES (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). A second IRES was then used to express inflammatory signaling inhibitors.</p><p>Given that activation of nuclear factor-κB (NF-κB) is a hallmark of viral infection and a master regulator of cytokine and chemokine induction (<xref ref-type="bibr" rid="bib91">Mitchell and Carmody, 2018</xref>; <xref ref-type="bibr" rid="bib106">Santoro et al., 2003</xref>), we prioritized its inhibition using super repressor inhibitor of κBα (srIκBα). This dominant-active variant cannot be phosphorylated and thus resists ubiquitination and degradation, forming a stable cytoplasmic pool of IκBα that prevents NF-κB nuclear translocation and downstream signaling (<xref ref-type="bibr" rid="bib16">Brown et al., 1995</xref>; <xref ref-type="bibr" rid="bib68">Lee et al., 2009</xref>). We generated one construct expressing srIκBα alone (named ‘srIκBα’) and another expressing srIκBα in combination with Smad7 and suppressor of cytokine signaling 1 (SOCS1) using nonidentical 2A peptides (named ‘srIκBα-Smad7-SOCS1’). Smad7 negatively regulates both transforming growth factor-β (TGF-β) and NF-κB signaling pathways (<xref ref-type="bibr" rid="bib134">Yan et al., 2009</xref>), while SOCS1 inhibits type I, II, and III IFN pathways, as well as NF-κB signaling (<xref ref-type="bibr" rid="bib29">Dimitriou et al., 2008</xref>; <xref ref-type="bibr" rid="bib13">Blumer et al., 2017</xref>; <xref ref-type="bibr" rid="bib116">Sobah et al., 2021</xref>). Additionally, a control construct (‘moxBFP’) was generated that lacks inflammatory signaling inhibitors and instead expresses a blue fluorescent protein.</p></sec><sec id="s2-10"><title>Inhibiting NF-κB signaling broadly attenuates saRNA-induced antiviral cytokine secretion</title><p>Transfection with the moxBFP construct, which lacks inflammatory signaling inhibitors, led to a significant increase in the secretion of all measured cytokines (<xref ref-type="fig" rid="fig4">Figure 4c</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). In contrast, co-expression of srIκBα broadly reduced cytokine levels, significantly reducing the secretion of all cytokines except TNF, IFN-α, and interleukin (IL)-6. The srIκBα-Smad7-SOCS1 construct did not further enhance suppression relative to srIκBα alone, with the exception of IL-6, which was significantly reduced only by srIκBα-Smad7-SOCS1. These results indicate that NF-κB is a key driver of saRNA-induced cytokine production, and that co-expression of srIκBα is an effective strategy for attenuating this response.</p></sec><sec id="s2-11"><title>Reduced antiviral gene expression and replicon activity observed with co-expression of inflammatory signaling inhibitors</title><p>To evaluate whether co-expression of inflammatory signaling inhibitors could attenuate saRNA-induced induction of antiviral transcripts, we performed an RT-qPCR array on mock-transfected cells and cells transfected with conventional saRNA, E3, or srIκBα-Smad7-SOCS1 (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3a</xref>). Transfection with conventional saRNA led to marked upregulation of several antiviral and proinflammatory mRNA transcripts, including <italic>Adar</italic>, <italic>Isg20</italic>, <italic>Rigi</italic>, <italic>Ifih1</italic>, <italic>Tlr3</italic>, <italic>Eif2ak2</italic>, <italic>Zc3hav1,</italic> and <italic>Il6</italic>. In contrast, both the E3 and srIκBα-Smad7-SOCS1 constructs attenuated the induction of these transcripts, with srIκBα-Smad7-SOCS1 exhibiting broader suppression across the panel.</p><p>Because all saRNA constructs in this study encode EGFP, we quantified its transcript levels as a proxy for replicon amplification, although we note that this interpretation assumes a consistent genomic-to-subgenomic transcript ratio across constructs. FLS transfected with srIκBα-Smad7-SOCS1 exhibited significantly lower <italic>EGFP</italic> transcript levels than those transfected with conventional saRNA or E3 (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3b</xref>). This apparent reduction in replicon activity is likely multifactorial. For one, physical characteristics of the transcripts contribute: the srIκBα-Smad7-SOCS1 construct is ~40% longer, resulting in a lower molar input when transfected at equal RNA mass. Its greater length is also expected to increase replication time, potentially altering replication dynamics. For another, the moxBFP, srIκBα, and srIκBα-Smad7-SOCS1 constructs share a common truncated byproduct (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3c and d</xref>). This byproduct is expected to be replication-incompetent, as it lacks the conserved sequence element in the 3’ untranslated region necessary for negative-strand synthesis (<xref ref-type="bibr" rid="bib57">Hyde et al., 2015</xref>), thus further reducing the effective molar input of functional saRNA. And finally, biological effects of the co-expressed proteins may also limit replicon activity. For example, inhibition of RNase L by L* could increase competition for cellular resources and thereby reduce RdRp production.</p></sec><sec id="s2-12"><title>Co-expression of Smad7 and SOCS1 rescues srIκBα-induced cell loss and enhances transgene expression</title><p>We then examined the impact of inhibiting inflammatory signaling on cell number and transgene expression (<xref ref-type="fig" rid="fig5">Figure 5a and b</xref>). Interestingly, the srIκBα construct caused both immediate and sustained reductions in cell number, as quantified by BioTracker signal, whereas the srIκBα-Smad7-SOCS1 construct maintained cell number comparable to mock transfection throughout the experiment (<xref ref-type="fig" rid="fig5">Figure 5c</xref>). AUC analysis of the BioTracker data confirmed that srIκBα-Smad7-SOCS1 significantly mitigated the srIκBα-induced reduction in integrated BioTracker signal (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a</xref>). Additional experiments using CellTag and calcein AM staining corroborated these findings, showing that srIκBα negatively impacted both cell number (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1b</xref>) and viability (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1c</xref>), effects that were prevented by co-expression of Smad7 and SOCS1.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Differential effects of srIκBα and srIκBα-Smad7-SOCS1 on cell number and transgene expression.</title><p>(<bold>a</bold>) Representative images of microplate wells showing BioTracker. (<bold>b</bold>) Representative composite images of microplate wells showing EGFP (green) and mScarlet3 (red). (<bold>c</bold>) Longitudinal quantification of BioTracker (n=11). srIκBα reduces signal, an effect not observed with srIκBα-Smad7-SOCS1.(<bold>d</bold>) Longitudinal quantification of EGFP (n=11). Expression was low across constructs. (<bold>e</bold>) Longitudinal quantification of mScarlet3 (n=11). srIκBα-Smad7-SOCS1 produced 2–3 times greater fluorescence than other constructs. For panels (a–b): Scale bar = 5 mm. For panels (c–e): Data are normalized to starting cell number (pre-transfection BioTracker signal). A dotted line shows the response to conventional saRNA (for reference). Statistical significance of treatment effects at each time point compared to mock transfection was determined by two-way RM ANOVA with Greenhouse-Geisser correction and Dunnett’s multiple comparisons test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001. Data are presented as mean ± SEM. The mock transfection control data used in this figure is also presented in <xref ref-type="fig" rid="fig1">Figure 1d–f</xref>.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>srIκBα induces cell loss, an effect not observed with srIκBα-Smad7-SOCS1.</title><p>(<bold>a</bold>) AUC analysis of BioTracker fluorescence data shown in <xref ref-type="fig" rid="fig5">Figure 5c</xref>, integrating effects over 3 weeks (n=11). srIκBα reduces integrated signal, while srIκBα-Smad7-SOCS1 preserves it. Statistical analysis was performed on AUC values using one-way RM ANOVA with Greenhouse-Geisser correction and Tukey’s multiple comparisons test. Mock transfection data is also presented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>. (<bold>b</bold>) CellTag signal on day 2 post-transfection, normalized to mock transfection (n=20). srIκBα reduces signal, an effect not observed with srIκBα-Smad7-SOCS1. Statistical significance was determined by one-way RM ANOVA with Greenhouse-Geisser correction and Tukey’s multiple comparisons test. Data in this panel were pooled from in-cell western assays, incorporating data presented in <xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig6">6</xref>, as well as additional data not shown elsewhere. ***p&lt;0.001. (<bold>c</bold>) Calcein AM signal, 3 days post-transfection, normalized to moxBFP (n=4). The signal reduction observed with srIκBα is not seen with srIκBα-Smad7-SOCS1. Statistical significance was determined by a paired t-test. For all statistical reporting, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001. Data are presented as mean ± SEM or individual values with connecting lines indicating responses from the same biological replicate.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-fig5-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig5-figsupp1-v2.tif"/></fig></fig-group><p>All three constructs produced low levels of EGFP expression (<xref ref-type="fig" rid="fig5">Figure 5d</xref>), which was expected given that EGFP is the fourth cistron in a 2A-linked polyprotein (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). Previous studies have established that protein expression decreases significantly for downstream positions in such 2A-linked configurations (<xref ref-type="bibr" rid="bib76">Liu et al., 2017a</xref>). Notably, the srIκBα-Smad7-SOCS1 construct produced two- to threefold higher mScarlet3 fluorescence than either the moxBFP or srIκBα constructs (<xref ref-type="fig" rid="fig5">Figure 5e</xref>), demonstrating that the srIκBα-Smad7-SOCS1 construct supports robust transgene expression despite its multi-cistronic configuration.</p></sec><sec id="s2-13"><title>Smad7 and SOCS1 co-expression prevents srIκBα-induced alterations in translational control</title><p>We next investigated the molecular mechanisms by which srIκBα and srIκBα-Smad7-SOCS1 modulate translational control. Interestingly, srIκBα expression led to reductions in eIF2α phosphorylation, a change that was prevented by co-expression of Smad7 and SOCS1 (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). While neither construct affected total eIF2α levels or eIF4E phosphorylation compared to the moxBFP construct (<xref ref-type="fig" rid="fig6">Figure 6b and c</xref>), srIκBα caused a significant reduction in total eIF4E levels (<xref ref-type="fig" rid="fig6">Figure 6d</xref>). Given the critical role of eIF4E in cap-dependent translation, its depletion likely contributes to the poor transgene expression observed with srIκBα (<xref ref-type="fig" rid="fig5">Figure 5e</xref>). Importantly, Smad7 and SOCS1 co-expression preserved eIF4E levels, counteracting the disruption of cap-dependent translation caused by srIκBα.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>srIκBα reduces eIF2α phosphorylation and total eIF4E levels, effects not observed with srIκBα-Smad7-SOCS1.</title><p>(<bold>a</bold>) Phosphorylated eIF2α levels examined by in-cell western, normalized to total eIF2α levels (n=6). Phosphorylation was reduced by srIκBα but unchanged by srIκBα-Smad7-SOCS1. (<bold>b</bold>) Total eIF2α levels examined by in-cell western, normalized to CellTag (n=5). No significant differences were revealed (F(2,8) = 3.683, p=0.0735). (<bold>c</bold>) Phosphorylated eIF4E levels examined by in-cell western, normalized to total eIF4E levels (n=6). No significant differences were revealed (F(2,10) = 1.336, p=0.3059). (<bold>d</bold>) Total eIF4E levels examined by in-cell western, normalized to CellTag (n=6). srIκBα reduced total eIF4E, while srIκBα-Smad7-SOCS1 had no effect. For all panels: Data are presented as fold change relative to mock transfection. Statistical significance was determined by one-way RM ANOVA and Holm-Šídák’s multiple comparisons test to compare all groups. *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001. Connecting lines indicate responses from the same biological replicate. Mock transfection data used for normalization are the same as in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig6-v2.tif"/></fig></sec><sec id="s2-14"><title>Prolonged expression of moxBFP does not activate FLS, and srIκBα co-expression reduces basal activation</title><p>Fibroblast activation protein-α (FAP-α) is a serine protease expressed on the surface of FLS that contributes to extracellular matrix degradation and tissue remodeling (<xref ref-type="bibr" rid="bib5">Bauer et al., 2006</xref>; <xref ref-type="bibr" rid="bib139">Zhang et al., 2019</xref>). Its expression is minimal in normal adult FLS but increases significantly following inflammatory activation, such as in rheumatoid arthritis and osteoarthritis (<xref ref-type="bibr" rid="bib26">Croft et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Fan et al., 2023</xref>). Since viral infections can induce fibroblast activation (<xref ref-type="bibr" rid="bib14">Boyd et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">Krausgruber et al., 2020</xref>), we hypothesized that prolonged saRNA expression might similarly trigger FLS activation. To test this, we measured FAP-α levels using an in-cell western assay 11 days post-transfection. FLS transfected with moxBFP showed FAP-α levels comparable to mock-transfected controls, whereas cells transfected with srIκBα and srIκBα-Smad7-SOCS1 exhibited significantly lower FAP-α levels (<xref ref-type="fig" rid="fig7">Figure 7a and b</xref>). These findings suggest that prolonged saRNA expression from constructs encoding inhibitors of dsRNA-sensing pathways does not overtly trigger fibroblast activation, whereas co-expression of inhibitors of inflammatory signaling may reduce basal activation.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Long-term expression of saRNA constructs inhibiting inflammatory signaling reduces basal fibroblast activation factor-α (FAP-α) levels.</title><p>(<bold>a</bold>) Representative in-cell western images showing FAP-α, a marker of fibroblast activation, on day 11 post-transfection. Columns show different biological replicates, and rows show different treatments. The tiled composite on the right shows FAP-α signal normalized to CellTag signal (FAP-α/CellTag). (<bold>b</bold>) Quantification of FAP-α, normalized to CellTag (n=8). Both srIκBα and srIκBα-Smad7-SOCS1 significantly reduce FAP-α levels versus mock transfection, while moxBFP shows no significant difference. Statistical significance was determined by one-way RM ANOVA with Greenhouse-Geisser correction and Dunnett’s multiple comparisons test to compare groups to mock transfection. Connecting lines indicate responses from the same biological replicate. **p&lt;0.01.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="fig7">Figure 7</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig7-v2.tif"/></fig></sec><sec id="s2-15"><title>Reversible and irreversible external control of immune-evasive saRNA</title><p>The srIκBα-Smad7-SOCS1 construct represents a promising immune-evasive saRNA platform for gene therapy and other non-immunotherapeutic applications. It includes the E3-NSs-L* polyprotein, which protects against saRNA-induced cytotoxicity (<xref ref-type="fig" rid="fig1">Figure 1f</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1a and b</xref>; <xref ref-type="fig" rid="fig2">Figure 2b and d</xref>), translation shutdown (<xref ref-type="fig" rid="fig1">Figure 1e</xref>; <xref ref-type="fig" rid="fig3">Figure 3a</xref>), and host mRNA degradation (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1b and c</xref>). In parallel, co-expression of srIκBα attenuates saRNA-induced cytokine responses (<xref ref-type="fig" rid="fig4">Figure 4c</xref>), while Smad7 and SOCS1 mitigate srIκBα-associated reductions in cell viability (<xref ref-type="fig" rid="fig5">Figure 5c</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a–c</xref>) and eIF4E levels (<xref ref-type="fig" rid="fig6">Figure 6d</xref>). These combined features enable sustained cap-dependent transgene expression (<xref ref-type="fig" rid="fig5">Figure 5e</xref>) without triggering fibroblast activation (<xref ref-type="fig" rid="fig7">Figure 7b</xref>).</p><p>To improve safety and flexibility, we next explored whether transgene expression could be externally regulated using a small-molecule antiviral. ML336 is a potent inhibitor of the VEEV RdRp used by the saRNA replicon (<xref ref-type="bibr" rid="bib23">Chung et al., 2010</xref>). To assess its ability to modulate transgene expression, we conducted a concentration–response assay by adding ML336 to the culture medium at the time of transfection. ML336 suppressed mScarlet3 expression in a concentration-dependent manner with an IC<sub>50</sub> of 8.5 nM (<xref ref-type="fig" rid="fig8">Figure 8a</xref>), demonstrating tunable control of saRNA-driven transgene expression.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Reversible and irreversible control of saRNA replicon activity with ML336.</title><p>Panels (<bold>a–b</bold>) show the effect of ML336, a small-molecule replicase inhibitor, applied at the time of transfection with srIκBα-Smad7-SOCS1. (<bold>a</bold>) ML336 concentration–response curve for inhibiting mScarlet3 expression, measured 2 days post-transfection (n=5). IC<sub>50</sub> = 8.5 nM (95% CI: 6.1–11.9 nM). Data are normalized to vehicle-treated controls and fit to a variable-slope sigmoidal curve. (<bold>b</bold>) Reversibility of ML336-mediated inhibition of mScarlet3 expression determined by measuring fluorescence recovery, one day after compound washout from cultures in panel (a). mScarlet3 inhibition is reversible at intermediate concentrations (10 nM–1 μM) but irreversible at high concentrations (&gt;1 μM). Data are normalized to each biological replicate’s maximum recovery and fit to a bell-shaped concentration–response curve.</p><p>Panels (<bold>c–g</bold>) show the effect of ML336 on an established srIκBα-Smad7-SOCS1 replicon. FLS were continously treated (indicated by shading) with vehicle or 1 μM ML336, starting 1 day post-transfection. (<bold>c</bold>) Representative composite images of microplate wells showing EGFP (green) and mScarlet3 (red). Scale bar = 5 mm. (<bold>d</bold>) Representative images of microplate wells showing calcein AM at end of time course. Scale bar = 5 mm. (<bold>e</bold>) Quantification of EGFP (n=6). By day 7, EGFP signal is reduced by ML336. (<bold>f</bold>) Quantification of mScarlet3 (n=6). By day 3, mScarlet3 signal is reduced by ML336. (<bold>g</bold>) Quantification of calcein AM (n=6). Vehicle, but not ML336 treatment, reduced calcein AM signal relative to mock transfection. Statistical significance was assessed by one-way RM ANOVA with Greenhouse-Geisser correction and Tukey’s multiple comparisons test. **p&lt;0.01, ***p&lt;0.001. All fluorescence data were normalized to pre-transfection cell number indicated by BioTracker signal. Connecting lines indicate responses from the same biological replicate. For panels (e−f): Statistical significance relative to vehicle-treated cells was determined by two-way RM ANOVA with Greenhouse-Geisser correction and Dunnett’s multiple comparisons test. <sup>#</sup>p&lt;0.05, <sup>##</sup>p&lt;0.01, <sup>###</sup>p&lt;0.001. Data are presented as mean ± SEM.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="fig8">Figure 8</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-fig8-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig8-v2.tif"/></fig><p>We then investigated whether this inhibition was reversible or tied to permanent loss of replicon activity. In a washout experiment, cultures from the initial concentration–response assay were washed 2 days post-transfection, and mScarlet3 fluorescence was quantified the following day. Recovery of mScarlet3 expression occurred at intermediate ML336 concentrations (10 nM–1 μM), peaking at 100 nM (<xref ref-type="fig" rid="fig8">Figure 8b</xref>), a range that likely reflects conditions where genomic RNA replication persists at low levels but subgenomic RNA synthesis is curtailed. In contrast, recovery did not occur at concentrations above 1 μM. This suggests that inhibition of transgene expression is reversible at intermediate ML336 concentrations, while sustained replicase inhibition at higher concentrations leads to irreversible replicon loss and permanent termination of transgene expression.</p><p>To determine whether ML336 could inhibit an already active replicon, we allowed replicon activity to proceed for 1 day before administering 1 μM ML336 or vehicle control. Cultures were then monitored over a 12-day period (<xref ref-type="fig" rid="fig8">Figure 8c</xref>). Continued ML336 treatment led to a sustained decline in both EGFP (<xref ref-type="fig" rid="fig8">Figure 8e</xref>) and mScarlet3 expression (<xref ref-type="fig" rid="fig8">Figure 8f</xref>), confirming effective external control of an established immune-evasive replicon.</p><p>Importantly, prolonged ML336 exposure did not compromise cell viability relative to mock-transfected controls (<xref ref-type="fig" rid="fig8">Figure 8d and g</xref>). By contrast, vehicle-treated cultures—where saRNA replication remained unchecked—showed significantly reduced calcein AM signal. This difference may reflect altered cell proliferation over the course of the experiment, consistent with our earlier finding that saRNA reduces eIF4E phosphorylation (<xref ref-type="fig" rid="fig3">Figure 3c</xref>), a key regulator of cell growth and proliferation (<xref ref-type="bibr" rid="bib93">Muta et al., 2011</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Although saRNA is known to disrupt translational control, the precise mechanisms and downstream effects remain incompletely characterized. saRNA-induced translation shutdown is thought to be mediated by phosphorylation of eIF2α (<xref ref-type="bibr" rid="bib6">Beissert et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">Frolova et al., 2023</xref>; <xref ref-type="bibr" rid="bib90">Minnaert et al., 2021</xref>), following the activation of PKR in response to dsRNA replicative intermediates (<xref ref-type="bibr" rid="bib51">Gorchakov et al., 2004</xref>; <xref ref-type="bibr" rid="bib6">Beissert et al., 2017</xref>). Our findings support this model and further show that saRNA reduces eIF4E phosphorylation, a phenomenon previously observed with alphavirus replicons, though its mechanism remains unclear (<xref ref-type="bibr" rid="bib8">Berglund et al., 2007</xref>; <xref ref-type="bibr" rid="bib43">Fros and Pijlman, 2016</xref>). Reduced eIF4E phosphorylation suppresses cap-dependent translation initiation (<xref ref-type="bibr" rid="bib108">Scheper and Proud, 2002</xref>), thereby favoring cap-independent translation (<xref ref-type="bibr" rid="bib33">Dyer et al., 2003</xref>). Together, eIF2α phosphorylation and reduced eIF4E activity likely explain why IRES-driven transgenes achieve higher expression than their cap-dependent counterparts when using conventional saRNA (<xref ref-type="bibr" rid="bib34">Erasmus et al., 2020</xref>; <xref ref-type="bibr" rid="bib21">Chang et al., 2022</xref>).</p><p>In addition to disrupting translation initiation, saRNA replication induces host translation shutoff through activation of RNase L. Many viruses exploit host shutoff—the global suppression of host gene expression—as a strategy to redirect cellular resources toward their replication (<xref ref-type="bibr" rid="bib47">Gaucherand and Gaglia, 2022</xref>). Our study suggests that saRNA also co-opts this mechanism. dsRNA intermediates generated during saRNA replication activate the OAS/RNase L pathway. RNase L activation then degrades host mRNAs without impairing the translation machinery (<xref ref-type="bibr" rid="bib31">Donovan et al., 2017</xref>). saRNA transcripts, on the other hand, are largely protected from degradation due to their localization within viral replication organelles known as spherules (<xref ref-type="bibr" rid="bib99">Pietilä et al., 2017</xref>; <xref ref-type="bibr" rid="bib90">Minnaert et al., 2021</xref>). This favors their translation over degraded host transcripts.</p><p>The degradation of host transcripts not only adversely affects the host translational landscape, but also contributes to cytotoxicity. The cleaving of actively translated mRNAs leads to ribosome stalling at 3’ ends and ribosome collisions (<xref ref-type="bibr" rid="bib53">Guydosh et al., 2017</xref>; <xref ref-type="bibr" rid="bib128">Xi et al., 2024</xref>), activation of the ribotoxic stress response (<xref ref-type="bibr" rid="bib115">Snieckute et al., 2022</xref>), and ultimately, apoptosis (<xref ref-type="bibr" rid="bib71">Li et al., 2004</xref>; <xref ref-type="bibr" rid="bib128">Xi et al., 2024</xref>). Similarly, PKR likely contributes to saRNA-induced cytotoxicity. Previous studies have shown that microinjected dsRNA induces apoptosis in a PKR-dependent manner in HeLa cells, with RIG-I and MDA-5 being dispensable (<xref ref-type="bibr" rid="bib142">Zuo et al., 2022</xref>). Many additional studies further support PKR as a central mediator of apoptosis in response to cytosolic dsRNA (<xref ref-type="bibr" rid="bib130">Xu et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Gil and Esteban, 2000</xref>; <xref ref-type="bibr" rid="bib138">Zhang and Samuel, 2007</xref>). Notably, apotosis mediated by PKR can occur independently of eIF2α phosphorylation (<xref ref-type="bibr" rid="bib125">von Roretz and Gallouzi, 2010</xref>), suggesting that inhibiting PKR may not fully prevent its cytotoxic actions.</p><p>The cytotoxic effects triggered by dsRNA-sensing pathways are highlighted by the E3 construct, which alleviates translation shutdown but does not prevent RNase L activation or PKR upregulation. While RNase L activity enables high transgene expression, it comes at a cost: long-term cytotoxicity. This dual-edged effect may make the E3 construct particularly well suited for immunotherapeutic applications such as vaccines or oncolytic-like therapies, where robust transgene expression and immunogenic cell death are advantageous (<xref ref-type="bibr" rid="bib69">Leitner et al., 2004</xref>; <xref ref-type="bibr" rid="bib127">Wu et al., 2023</xref>). In contrast, applications requiring both sustained transgene expression and cell viability demand strategies that address not only saRNA-induced alterations in translational control but also cytotoxicity. The E3-NSs-L* polyprotein, which combines broad inhibition of dsRNA-sensing pathways with targeted suppression of RNase L and ubiquitin‑ligase–mediated degradation of PKR, effectively protects against both mechanisms, making it an essential component of immune-evasive saRNA.</p><p>However, inhibiting dsRNA-sensing pathways was not effective at preventing saRNA-induced cytokine responses. This agrees with prior reports showing that dsRNA activates NF-κB even in the absence of PKR and RNase L (<xref ref-type="bibr" rid="bib58">Iordanov et al., 2001</xref>), suggesting that alternative pathways contribute to NF-κB activation. One such mechanism may involve eIF4E, whose activity is governed by its phosphorylation status and serves as a rate-limiting step in cap-dependent protein synthesis (<xref ref-type="bibr" rid="bib84">Mars et al., 2024</xref>). In this study, we found that saRNA induces a reduction in eIF4E phosphorylation. Reduced eIF4E phosphorylation has been shown to decrease the levels of the short-lived IκBα protein (<xref ref-type="bibr" rid="bib54">Herdy et al., 2012</xref>), an inhibitor of NF-κB that sequesters it in the cytoplasm and prevents nuclear translocation. Decreased IκBα levels thus allow NF-κB to translocate to the nucleus, initiating cytokine expression and inflammatory responses (<xref ref-type="bibr" rid="bib77">Liu et al., 2017b</xref>). This mechanistic insight provided a clear rationale for the next step in our design of the immune-evasive saRNA platform: inhibition of the NF-κB pathway with srIκBα.</p><p>Importantly, while NF-κB is best known for promoting inflammatory cytokine production, it also supports cell survival by inducing anti-apoptotic genes, though its effects vary by tissue type and biological context (<xref ref-type="bibr" rid="bib80">Luo et al., 2005</xref>). In FLS, overexpression of srIκBα reduces cytokine production but increases sensitivity to TNF-induced apoptosis (<xref ref-type="bibr" rid="bib89">Miagkov et al., 1998</xref>; <xref ref-type="bibr" rid="bib137">Zhang et al., 2000</xref>), consistent with our findings that saRNA encoding srIκBα lowered both cytokine responses and cell viability. This phenomenon is not unique to FLS; NF-κB inhibition with srIκBα also renders liver hepatocytes more susceptible to pro-apoptotic stimuli (<xref ref-type="bibr" rid="bib129">Xu et al., 1998</xref>), raising safety concerns given that RNA delivery systems such as lipid nanoparticles (LNPs) tend to accumulate in the liver (<xref ref-type="bibr" rid="bib104">Sago et al., 2019</xref>). Therefore, when designing immune-evasive saRNA constructs, the use of srIκBα to suppress cytokine responses may require co-expression of anti-apoptotic proteins to offset the loss of NF-κB-mediated survival signaling. In our case, Smad7 and SOCS1 restored FLS viability when co-expressing srIκBα. While we did not assess the individual contributions of each protein, both are known to have anti-apoptotic properties in certain contexts. Smad7 can inhibit TGF-β-induced apoptosis (<xref ref-type="bibr" rid="bib96">Patil et al., 2000</xref>; <xref ref-type="bibr" rid="bib132">Yamamura et al., 2000</xref>), while SOCS1 can suppress apoptosis triggered by IFN-α, IFN-β (<xref ref-type="bibr" rid="bib141">Zitzmann et al., 2007</xref>), IFN-γ (<xref ref-type="bibr" rid="bib83">Mann-Chandler et al., 2005</xref>), and TNF-α (<xref ref-type="bibr" rid="bib133">Yan et al., 2008</xref>; <xref ref-type="bibr" rid="bib81">Madonna et al., 2012</xref>; <xref ref-type="bibr" rid="bib63">Kimura et al., 2004</xref>). These anti-apoptotic effects likely enable Smad7 and SOCS1 to mitigate srIκBα-induced reductions in FLS cell viability.</p><p>We also found that co-expression of Smad7 and SOCS1 significantly enhanced cap-dependent transgene expression. Although we did not distinguish the individual contributions of each protein, this effect is likely mediated by SOCS1. This hypothesis is supported by previous studies showing that ruxolitinib—a small-molecule inhibitor of Janus kinase (JAK) 1 and JAK2 (<xref ref-type="bibr" rid="bib49">Goker Bagca and Biray Avci, 2020</xref>)—increases saRNA transgene expression when added to saRNA polyplexes (<xref ref-type="bibr" rid="bib11">Blakney et al., 2021b</xref>). As SOCS1 is an endogenous inhibitor of JAK1 and JAK2 (<xref ref-type="bibr" rid="bib74">Liau et al., 2018</xref>), it offers a genetically encoded alternative to the small-molecule approach of ruxolitinib for enhancing saRNA-driven transgene expression. The mechanisms underlying this enhancement are unclear, and our study found no evidence implicating eIF2α or eIF4E in this effect. Potentially, it may arise from non-canonical translational control mechanisms, or from increased subgenomic RNA levels. Since our study did not examine amplification dynamics, future investigations will clarify these possibilities.</p><p>Although our study focused on engineering immune-evasive saRNA to support sustained transgene expression in non-immunotherapeutic settings, the platform may also offer benefits for vaccine development. Both preclinical and clinical data indicate that saRNA vaccines often trigger an intense innate immune response, which can hinder antigen expression (<xref ref-type="bibr" rid="bib30">Dominguez et al., 2023</xref>; <xref ref-type="bibr" rid="bib11">Blakney et al., 2021b</xref>; <xref ref-type="bibr" rid="bib6">Beissert et al., 2017</xref>). Additionally, saRNA vaccination is associated with pronounced inflammation (<xref ref-type="bibr" rid="bib4">Bathula et al., 2024</xref>; <xref ref-type="bibr" rid="bib120">Tregoning et al., 2023</xref>), contributing to commonly reported adverse events such as pain, headache, tenderness, arthralgia, fever, and chills (<xref ref-type="bibr" rid="bib94">Oda et al., 2024</xref>; <xref ref-type="bibr" rid="bib107">Saraf et al., 2024</xref>). By dampening the self-adjuvanting (immunostimulatory) effects of saRNA replication, the immune-evasive saRNA platform could enhance antigen production while reducing reactogenicity—offering a promising strategy for next-generation saRNA vaccines.</p><p>For applications requiring sustained therapeutic gene expression, a key advantage of the immune-evasive saRNA platform over traditional viral vectors is its potential for precise external control. While viral vectors can support long-term transgene expression, they generally lack external shut-off mechanisms or straightforward means for vector elimination—often relying on more extreme strategies such as suicide genes to ensure safety (<xref ref-type="bibr" rid="bib46">Gargett and Brown, 2014</xref>; <xref ref-type="bibr" rid="bib52">Greco et al., 2015</xref>). In contrast, saRNA replicons can be modulated using small-molecule inhibitors targeting the RdRp. Here, we demonstrate that ML336, a potent and well-tolerated VEEV RdRp inhibitor (<xref ref-type="bibr" rid="bib23">Chung et al., 2010</xref>; <xref ref-type="bibr" rid="bib111">Schroeder et al., 2014</xref>; <xref ref-type="bibr" rid="bib114">Skidmore et al., 2020</xref>), enables concentration-dependent tuning of immune-evasive saRNA-driven transgene expression, including reversible inhibition at intermediate concentrations and irreversible termination at higher concentrations. Critically, ML336 remains effective even when administered after replicon activity is established and does not compromise cell viability. These features collectively position RdRp inhibitors as a practical and versatile means to externally control immune-evasive saRNA—either to transiently suppress transgene expression or to permanently eliminate the replicon once therapeutic goals are achieved.</p><p>Another important advantage of the immune-evasive saRNA platform is that it does not require exogenous immunosuppressants, which are commonly needed in non-immunotherapeutic applications of conventional saRNA (<xref ref-type="bibr" rid="bib123">Vanluchene et al., 2024</xref>; <xref ref-type="bibr" rid="bib140">Zhong et al., 2021</xref>; <xref ref-type="bibr" rid="bib136">Yoshioka et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Erasmus et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Kim et al., 2017</xref>). By restricting immune suppression to transfected cells, this localized strategy has the potential to reduce treatment complexity and mitigate off-target risks associated with systemic immunosuppression. However, the downside of this all-in-one design is that it requires manufacturing long RNA molecules. Producing long RNA with high yield and integrity presents technical challenges (<xref ref-type="bibr" rid="bib103">Rosa et al., 2021</xref>). Larger RNAs are more prone to secondary structure formation, increasing the likelihood of abortive transcription during in vitro synthesis (<xref ref-type="bibr" rid="bib7">Beissert et al., 2020</xref>). Overcoming this limitation may be achievable through optimization of in vitro transcription conditions (<xref ref-type="bibr" rid="bib105">Samnuan et al., 2022</xref>), or by applying computational strategies. For instance, deep-learning models developed for structural biology (<xref ref-type="bibr" rid="bib112">Shen et al., 2024</xref>; <xref ref-type="bibr" rid="bib59">Kagaya et al., 2025</xref>) could be leveraged using transfer learning (<xref ref-type="bibr" rid="bib95">Ouellet et al., 2023</xref>; <xref ref-type="bibr" rid="bib37">Ferguson et al., 2025</xref>) to guide the rational design of transcripts with minimal secondary structure and improved full-length yield.</p><p>Further future directions include characterizing the in vivo effectiveness of the immune-evasive saRNA platform. In a living organism, saRNA-transfected cells must contend with two forms of cytotoxicity. They face not only intrinsic cytotoxicity related to saRNA replication (addressed in this study), but also extrinsic cytotoxicity mediated by immune cells. Though our study demonstrates that immune-evasive saRNA dramatically reduces cytokine release compared to conventional saRNA, the residual levels may still be sufficient to recruit immune effector cells. Furthermore, the co-expression of several viral proteins, along with the VEEV RdRp, increases the likelihood that viral peptides will be presented on major histocompatibility complex class I molecules. This, in turn, is expected to promote recognition and elimination of saRNA-transfected cells by cytotoxic T lymphocytes, thereby limiting therapeutic durability. Elucidating the spatiotemporal dynamics of transfected cell fate and their interactions with immune cells with techniques like multiphoton microscopy (<xref ref-type="bibr" rid="bib75">Lim and Ruthazer, 2021</xref>) will be critical for addressing this challenge and testing mitigation strategies. Overcoming both intrinsic and extrinsic cytotoxicity will be essential for achieving long-term persistence of saRNA-transfected cells and realizing the platform’s full therapeutic potential.</p><p>Beyond elimination of saRNA-transfected cells by immune effector cells, another key consideration for future translation is determining whether the immune-evasive saRNA platform exhibits a distinct in vivo expression profile compared to conventional saRNA. Although both mRNA-LNPs and saRNA-LNPs share similar biodistribution—primarily accumulating in the liver—conventional saRNA typically fails to drive hepatic expression and instead induces transgene expression in the spleen, lungs, and muscle (<xref ref-type="bibr" rid="bib64">Kimura et al., 2023</xref>; <xref ref-type="bibr" rid="bib4">Bathula et al., 2024</xref>). One possibility for this discrepancy is that it arises from cell type-dependent differences in the detection or downstream response to cytosolic dsRNA intermediates generated by saRNA. As we observed in FLS, replication of conventional saRNA triggers translation shut down and cytotoxicity. These effects, mediated by cytosolic dsRNA-sensing pathways, ultimately limit transgene expression. Potentially, the same mechanisms may restrict saRNA-driven expression in other cell types. If so, by suppressing dsRNA-sensing pathways, the immune-evasive saRNA platform may broaden the range of cell types permissive to saRNA-driven expression. Further investigation into the in vivo expression profile and cell-type specificity will be essential, not only to harness this potential but also to identify any unanticipated effects before clinical translation.</p><p>Our findings present a fully saRNA-based approach that addresses a key barrier to the use of saRNA in non-immunotherapeutic applications: innate immune activation triggered by replicon activity. By encoding proteins that inhibit both dsRNA-sensing pathways and NF-κB signaling directly within the saRNA—expressed via cap-independent translation—we achieved sustained transgene expression with reduced immunotoxicity, eliminating the need for exogenous immunosuppressants (<xref ref-type="fig" rid="fig9">Figure 9</xref>). Furthermore, the use of ML336 enables on-demand regulation or termination of transgene expression, enhancing both the safety and versatility of this approach. Though our study was a proof-of-concept performed in vitro using primary mouse cells, given the established success of saRNA in preclinical models (<xref ref-type="bibr" rid="bib50">Gong et al., 2024</xref>; <xref ref-type="bibr" rid="bib11">Blakney et al., 2021b</xref>; <xref ref-type="bibr" rid="bib6">Beissert et al., 2017</xref>; <xref ref-type="bibr" rid="bib34">Erasmus et al., 2020</xref>) and approved human vaccines (<xref ref-type="bibr" rid="bib55">Ho et al., 2024</xref>; <xref ref-type="bibr" rid="bib107">Saraf et al., 2024</xref>), we anticipate that this approach will be readily translatable to future in vivo studies. Ultimately, continued refinement of the immune-evasive saRNA platform and delivery strategies will be crucial for realizing its potential to bridge the therapeutic gap between the transience of mRNA and the permanence of viral vectors.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Diagrammatic comparison of conventional and immune-evasive self-amplifying RNA (saRNA).</title><p>Conventional saRNA activates multiple innate immune responses upon replication, leading to translation shutdown, host mRNA degradation, cytotoxicity, and cytokine secretion. These immunotoxic effects restrict its therapeutic utility to vaccine applications and often necessitate co-administration of exogenous immunosuppressants to enable effective transgene expression. In contrast, immune-evasive saRNA co-expresses inhibitors of key dsRNA-sensing and inflammatory signaling pathways via cap-independent translation, intrinsically suppressing these immune responses. This enables sustained transgene expression while reducing immunotoxicity and eliminating the need for exogenous immunosuppressive agents. Transgene expression can be externally regulated or terminated using small-molecule inhibitors of the saRNA replicase, such as ML336, providing control over the duration of therapy and a means to mitigate potential adverse effects.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-fig9-v2.tif"/></fig></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"> TagGFP2 Simplicon Plasmid (E3L)</td><td align="left" valign="bottom"> Merck-Millipore</td><td align="left" valign="bottom">SCR725</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pIRES2-EGFP</td><td align="left" valign="bottom">Clontech</td><td align="char" char="." valign="bottom">6029-1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pDx_mScarlet3</td><td align="left" valign="bottom">Addgene</td><td align="char" char="." valign="bottom">189754 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:189754">Addgene_189754</ext-link>)</td><td align="left" valign="bottom">A gift from Dorus Gadella</td></tr><tr><td align="left" valign="bottom">Gene (Engineered fluorescent protein)</td><td align="left" valign="bottom">moxBFP</td><td align="left" valign="bottom">FPbase</td><td align="left" valign="bottom">SSTDU</td><td align="left" valign="bottom">Amino acid sequence</td></tr><tr><td align="left" valign="bottom">Gene (Engineered fluorescent protein)</td><td align="left" valign="bottom">mEGFP</td><td align="left" valign="bottom">FPbase</td><td align="left" valign="bottom">QKFJN</td><td align="left" valign="bottom">Amino acid sequence</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Orthopoxvirus vaccinia</italic>—Strain: Western Reserve)</td><td align="left" valign="bottom">Vaccinia Virus E3 protein</td><td align="left" valign="bottom">UniProt</td><td align="left" valign="bottom">P21605-1 [1991-05-01 v1]</td><td align="left" valign="bottom">Amino acid sequence</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Phlebovirus toscanaense</italic>)</td><td align="left" valign="bottom">Toscana virus NSs protein</td><td align="left" valign="bottom">UniProt</td><td align="left" valign="bottom">P21699 [1991-05-01 v1]</td><td align="left" valign="bottom">Amino acid sequence</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Cardiovirus theileri</italic>—Strain: DA)</td><td align="left" valign="bottom">Theiler’s virus L* protein</td><td align="left" valign="bottom">UniProt</td><td align="left" valign="bottom">P0DJX4 [2013-07-24 v1]</td><td align="left" valign="bottom">Amino acid sequence</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Alphapermutotetravirus thoseae</italic>)</td><td align="left" valign="bottom">T2A</td><td align="left" valign="bottom">UniProt</td><td align="left" valign="bottom">Q9YK87 (139–156) [1999-05-01 v1]</td><td align="left" valign="bottom">Amino acid sequence</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Teschovirus asilesi</italic>)</td><td align="left" valign="bottom">P2A</td><td align="left" valign="bottom">UniProt</td><td align="left" valign="bottom">A0A077CZU0 (977–995) [2014-10-29 v1]</td><td align="left" valign="bottom">Amino acid sequence</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Aphthovirus burrowsi</italic>)</td><td align="left" valign="bottom">E2A</td><td align="left" valign="bottom">UniProt</td><td align="left" valign="bottom">K9MZ26 (991–1010) [2013-03-06 v1]</td><td align="left" valign="bottom">Amino acid sequence</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">IκBα</td><td align="left" valign="bottom">UniProt</td><td align="left" valign="bottom">Q9Z1E3 [2004-10-25 v2]</td><td align="left" valign="bottom">Amino acid sequence</td></tr><tr><td align="left" valign="bottom">Gene (Engineered mouse protein)</td><td align="left" valign="bottom">srIκBα</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Substituted serines 32 and 36 with alanines</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Smad7</td><td align="left" valign="bottom">UniProt</td><td align="left" valign="bottom">O35253-1 [1998-01-01 v1]</td><td align="left" valign="bottom">Amino acid sequence</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">SOCS1</td><td align="left" valign="bottom">UniProt</td><td align="left" valign="bottom">O35716 [1998-01-01 v1]</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GenSmart</td><td align="left" valign="bottom">GenScript</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_026296">SCR_026296</ext-link></td><td align="left" valign="bottom">Used to codon optimize amino acid sequences for mouse expression</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">VEE-mScarlet3-IRES-EGFP-IRES-moxBFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:242407">Addgene_242407</ext-link></td><td align="left" valign="bottom">Deposited with Addgene: 242407</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Conventional saRNA construct</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">saRNA transcribed from VEE-mScarlet3-IRES-EGFP-IRES-moxBFP</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">VEE-mScarlet3-IRES-EGFP-IRES-E3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:242408">Addgene_242408</ext-link></td><td align="left" valign="bottom">Deposited with Addgene: 242408</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">E3 saRNA construct</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">saRNA transcribed from VEE-mScarlet3-IRES-EGFP-IRES-E3</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">VEE-mScarlet3-IRES-EGFP-IRES-E3-NSs-L*</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:242409">Addgene_242409</ext-link></td><td align="left" valign="bottom">Deposited with Addgene: 242409</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">E3-NSs-L* saRNA construct</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">saRNA transcribed from VEE-mScarlet3-IRES-EGFP-IRES-E3-NSs-L*</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">VEE-mScarlet3-IRES-E3-NSs-L*-EGFP-IRES-moxBFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:242410">Addgene_242410</ext-link></td><td align="left" valign="bottom">Deposited with Addgene: 242410</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">moxBFP saRNA construct</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">saRNA transcribed from VEE-mScarlet3-IRES-E3-NSs-L*-EGFP-IRES-moxBFP</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">VEE-mScarlet3-IRES-E3-NSs-L*-EGFP-IRES- srIκBα</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:242411">Addgene_242411</ext-link></td><td align="left" valign="bottom">Deposited with Addgene: 242411</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">srIκBα saRNA construct</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">saRNA transcribed from VEE-mScarlet3-IRES-E3-NSs-L*-EGFP-IRES- srIκBα</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">VEE-mScarlet3-IRES-E3-NSs-L*-EGFP-IRES- srIκBα-Smad7-SOCS1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:242412">Addgene_242412</ext-link></td><td align="left" valign="bottom">Deposited with Addgene: 242412</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">srIκBα-Smad7-SOCS1 saRNA construct</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">saRNA transcribed from VEE-mScarlet3-IRES-E3-NSs-L*-EGFP-IRES- srIκBα-Smad7-SOCS1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">VEE-mScarlet3-IRES-PuroR</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:242415">Addgene_242415</ext-link></td><td align="left" valign="bottom">Deposited with Addgene: 242415</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">VEE-EGFP-IRES-PuroR</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:242414">Addgene_242414</ext-link></td><td align="left" valign="bottom">Deposited with Addgene: 242414</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">VEE-moxBFP-IRES-PuroR</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:242413">Addgene_242413</ext-link></td><td align="left" valign="bottom">Deposited with Addgene: 242413</td></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">Phusion High-Fidelity DNA Polymerase</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">F530S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">NEBuilder HiFi DNA Assembly Cloning Kit</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">E5520S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">5-alpha Competent <italic>E. coli</italic> (High Efficiency)</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">C2987H</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">T7 RiboMAX Large Scale RNA Production System</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">P1300</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">PureLink HiPure Plasmid FP Maxiprep kit</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">K210027</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">Vaccinia Capping System</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">M2080S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">mRNA Cap 2´-O-Methyltransferase</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">M0366S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">Antarctic Phosphatase</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">M0289S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">NorthernMax-Gly Sample Loading Dye</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">AM8551</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Lipofectamine MessengerMAX Transfection Reagent</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">LMRNA001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">C57BL/6J</td><td align="left" valign="bottom">Envigo</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">tSA201</td><td align="left" valign="bottom">ECACC</td><td align="char" char="." valign="bottom">96121229 (<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_2737">RRID:CVCL_2737</ext-link>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">BioTracker NIR680</td><td align="left" valign="bottom">Merck</td><td align="left" valign="bottom">SCT112</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ML336</td><td align="left" valign="bottom">Cayman Chemical</td><td align="char" char="." valign="bottom">9001920</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Puromycin</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">J67236.XF</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">6-well black glass bottom plate</td><td align="left" valign="bottom">CellVis</td><td align="left" valign="bottom">P06-1.5H-N</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">24-well black glass bottom plate</td><td align="left" valign="bottom">Grenier Bio-One</td><td align="char" char="." valign="bottom">662892</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Live Cell Imaging Solution</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">A59688DJ</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Poly-D-lysine–coated glass-bottom 35 mm dishes</td><td align="left" valign="bottom">MatTek</td><td align="left" valign="bottom">P35GC-1.5-14-C</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Linear unmixing script for Odyssey M images</td><td align="left" valign="bottom">This paper; <xref ref-type="bibr" rid="bib36">Ferguson, 2025</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Available at <ext-link ext-link-type="uri" xlink:href="https://github.com/lariferg/spectral_unmixing">https://github.com/lariferg/spectral_unmixing</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">NIH</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_003070">SCR_003070</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Annexin V-CF800</td><td align="left" valign="bottom">Biotium</td><td align="char" char="." valign="bottom">29078</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-cadherin-11 rabbit polyclonal</td><td align="left" valign="bottom">Affinity Biosciences</td><td align="left" valign="bottom">DF3523 (<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_590743">RRID:AB_2835743</ext-link>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Phospho-eIF2α (Ser51) rabbit monoclonal</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">3398 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2096481">AB_2096481</ext-link>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-eIF2α mouse monoclonal</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">2103 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_836874">AB_836874</ext-link>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-PKR rabbit polyclonal</td><td align="left" valign="bottom">Proteintech</td><td align="char" char="ndash" valign="bottom">18244-1-AP (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2246451">AB_2246451</ext-link>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Phospho-eIF4E (S209) rabbit monoclonal</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab76256 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_1523534">AB_1523534</ext-link>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-eIF4E mouse monoclonal</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">MA1-089 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2536738">AB_2536738</ext-link>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-fibroblast activation protein mouse monoclonal</td><td align="left" valign="bottom">InVivoMAb</td><td align="left" valign="bottom">BE0374 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2927511">AB_2927511</ext-link>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-puromycin mouse monoclonal</td><td align="left" valign="bottom">Absolute Antibody</td><td align="char" char="." valign="bottom">3RH11 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2620162">AB_2620162</ext-link>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse IRDye 800CW secondary</td><td align="left" valign="bottom">LI-COR</td><td align="char" char="ndash" valign="bottom">926-32210 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_621842">AB_621842</ext-link>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-rabbit IRDye 800CW secondary</td><td align="left" valign="bottom">LI-COR</td><td align="char" char="ndash" valign="bottom">926-32213 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_621848">AB_621848</ext-link>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-mouse IRDye 680RD secondary</td><td align="left" valign="bottom">LI-COR</td><td align="char" char="ndash" valign="bottom">926-68072 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10953628">AB_10953628</ext-link>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">CellTag 700</td><td align="left" valign="bottom">LI-COR</td><td align="char" char="." valign="bottom">926-41090</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">DyLight Antibody Labeling Kit</td><td align="left" valign="bottom">Thermo Scientific</td><td align="char" char="." valign="bottom">53062</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Empiria Studio</td><td align="left" valign="bottom">LI-COR</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_014281">SCR_014281</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">LEGENDplex Mouse Anti-Virus Response Panel</td><td align="left" valign="bottom">BioLegend</td><td align="char" char="." valign="bottom">740621</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Qognit</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">3D printed vacuum manifold for LEGENDplex filter plates</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Available at the NIH 3D Print Exchange under accession number 3DPX-021388</td></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">RNeasy Mini Kit</td><td align="left" valign="bottom">QIAGEN</td><td align="char" char="." valign="bottom">74104</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">TaqMan Fast Advanced Cells-to-CT Kit</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">A35377</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">TaqMan array plates</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="." valign="bottom">4413261</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">StepOne Software</td><td align="left" valign="bottom">Life Technologies</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_014281">SCR_014281</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Plasmid cloning and construct design</title><p>The commercially available TagGFP2 E3L Simplicon vector (SCR725, Merck) served as the saRNA backbone in this study. After removal of the TagGFP2-IRES-E3 sequence, various constructs were generated by combining different elements using restriction digests (FastDigest, Thermo Scientific), overlap extension PCR (Phusion, Thermo Scientific), and HiFi assembly (NEBuilder, New England Biolabs).</p><p>Genetic elements were sourced as follows: mScarlet3 from pDx_mScarlet3 (a gift from Dorus Gadella [Addgene plasmid #189754]) (<xref ref-type="bibr" rid="bib44">Gadella et al., 2023</xref>), IRES-EGFP from pIRES2-EGFP (Clontech), and IRES-E3 and IRES-PuroR (puromycin resistance) from the original TagGFP2 E3L Simplicon vector.</p><p>Custom gene synthesis (GeneArt, Thermo Scientific) was used to produce IRES-moxBFP, IRES-E3-T2A-NSs-P2A-L*-E2A-mEGFP, and IRES-srIκBα-P2A-Smad7-T2A-SOCS1 sequences. The IRES sequence was derived from pIRES2-EGFP (Clontech). Other sequences were obtained from public databases: moxBFP (FPbase ID: SSTDU) (<xref ref-type="bibr" rid="bib24">Costantini et al., 2015</xref>), mEGFP (FPbase ID: QKFJN), Vaccinia virus E3 protein (UniProt: P21605-1), Toscana virus NSs protein (UniProt: P21699), Theiler’s virus L* protein (UniProt: P0DJX4), mouse Smad7 (UniProt: O35253-1), and mouse SOCS1 (UniProt: O35716). srIκBα was engineered from mouse IκBα (UniProt: Q9Z1E3) by substituting serines 32 and 36 with alanines. 2A peptide sequences were preceded by GSG linkers: T2A (UniProt: Q9YK87 [139-156]); P2A (UniProt: A0A077CZU0 [977-995]); E2A (UniProt: K9MZ26 [991–1010]). All synthesized sequences were codon-optimized for mouse expression (GenSmart, GenScript).</p><p>Plasmids were cloned in DH5α competent <italic>Escherichia coli</italic> (High Efficiency, New England Biolabs) and purified by maxiprep (PureLink HiPure, Invitrogen). All plasmid sequences were verified using nanopore whole-plasmid sequencing (Plasmidsaurus).</p></sec><sec id="s4-2"><title>RNA synthesis</title><p>Plasmids were linearized with XbaI (FastDigest, Thermo Scientific) at 37°C for 3 hr. The linear plasmids were purified by phenol-chloroform extraction followed by sodium acetate-ethanol precipitation. Uncapped RNA was synthesized in vitro using the T7 RiboMAX Large Scale RNA Production System (Promega) at 37°C for 2 hr. After purification by ammonium acetate precipitation, the RNA was denatured by heating to 65°C for 5 min before rapidly cooling on ice. Cap-1 structures were then generated using the Vaccinia Capping System in conjunction with mRNA cap 2'-<italic>O</italic>-methyltransferase (both from New England Biolabs) for 45 min at 37°C. Following another round of ammonium acetate precipitation, the RNA was treated with Antarctic phosphatase (New England Biolabs) for 30 min at 37°C. After a final ammonium acetate precipitation, RNA was resuspended in THE RNA Storage Solution (Invitrogen). RNA concentration was quantified using an N60 NanoPhotometer (Implen) and adjusted to a final concentration of 0.5 μg/μL. RNA was aliquoted and stored at –80°C until further use.</p><p>The integrity of the in vitro transcribed RNA was assessed by denaturing agarose gel electrophoresis (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3c</xref>). Constructs designed to inhibit dsRNA-sensing pathways (conventional saRNA, E3, and E3-NSs-L*) produced a single band at the expected size. In contrast, constructs targeting inflammatory signaling (moxBFP, srIκBα, and srIκBα-Smad7-SOCS1) displayed two bands: one corresponding to the full-length transcript and a smaller, low-intensity band of consistent size across all three constructs (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3d</xref>). The presence of this truncated species likely reflects premature termination at a cryptic terminator introduced during construct assembly.</p></sec><sec id="s4-3"><title>Denaturing RNA gel electrophoresis</title><p>In vitro transcribed RNA (1 μg) was mixed with 5 μL of NorthernMax-Gly Sample Loading Dye (Invitrogen) and 5 μL of nuclease-free water for glyoxal-based denaturation. The RNA ladder (RiboRuler High Range RNA Ladder, Thermo Scientific) was prepared by combining 2 μL of ladder, 3 μL of water, and 5 μL of loading dye. A loading dye-only control was also prepared using 5 μL of water and 5 μL of loading dye. All samples were incubated at 50°C for 30 min, then cooled on ice (<xref ref-type="bibr" rid="bib38">Floor, 2019</xref>; <xref ref-type="bibr" rid="bib102">Rio, 2015</xref>).</p><p>Samples were then loaded onto a 0.8% agarose gel prepared with diethyl pyrocarbonate-treated electrophoresis buffer consisting of 100 mM PIPES, 300 mM Bis-Tris, and 10 mM EDTA. Electrophoresis was performed at 5V/cm, and gels were imaged using an Odyssey Fc imager (LI-COR) with acquisition in the 600 nm channel over 10 min.</p></sec><sec id="s4-4"><title>Primary mouse FLS culture</title><p>Mouse tissue collection was conducted in accordance with Schedule 1 of the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 and under Project Licence PP5814995 (granted to Ewan St. John Smith by the UK Home Office), with approval from the University of Cambridge Animal Welfare Ethical Review Body.</p><p>Primary FLS cultures were derived from wild-type C57BL/6J mice (Envigo, Bicester, UK), aged 5–12 weeks. Both male and female mice were used, although sex-based differences were not examined. Animals were group housed (≤5 per cage) in a temperature-controlled room (21°C) on a 12 hr light/dark cycle, with ad libitum access to food and water. Bedding, a red shelter, and enrichment materials were provided. Mice were euthanized via rising concentrations of CO<sub>2</sub> gas, and death was confirmed by dislocation of the atlanto-occipital joint using digital pressure to the lateral neck.</p><p>FLS were isolated from patellar explants used a modified version of a previously described protocol (<xref ref-type="bibr" rid="bib19">Chakrabarti et al., 2020</xref>). Briefly, knee joints were exposed by incising the overlying skin with dissecting scissors. The patellar tendon was grasped near the patella using Dumont tweezers and severed with surrounding tissues using spring scissors. The patella was then excised by cutting the quadriceps tendon, and any excess muscle or tendons was carefully removed.</p><p>Both patellae from each animal were placed into a microcentrifuge tube containing ice-cold sterile phosphate-buffered saline (PBS), then transferred to a 24-well tissue culture plate (Costar) containing FLS culture medium: DMEM/F-12 (Invitrogen) supplemented with 25% fetal bovine serum (Sigma), 1×GlutaMAX (Gibco), and 100 μg/mL Primocin (InvivoGen). Explants were maintained in a humidified incubator at 37°C with 5% CO<sub>2</sub>, with media changes every 1–2 days.</p><p>FLS outgrowth typically reached ~70% confluence by around 10 days in culture. At this point, the patellae were transferred to fresh wells for continued cell harvest. Adherent cells from the initial wells were dissociated using 0.1% trypsin-EDTA (Sigma) and passaged into a single well of a six-well plate (Costar). Cells were subsequently expanded into T25 flasks (BioLite, Thermo Scientific or CELLSTAR, Greiner Bio-One), with passaging upon confluence. From passage 2 onward, Versene solution (Gibco) was used for cell dissociation. All experiments used FLS between passages 3 and 8.</p><p>For downstream assays, cells from each animal were divided across multiple wells of 6-well or 24-well plates to permit within-animal, repeated-measures analysis. In cases where individual yields were insufficient, cells from multiple animals were pooled prior to plating. Media was refreshed every 2–3 days following plating.</p></sec><sec id="s4-5"><title>tSA201 culture</title><p>tSA201 cells (96121229, ECACC) were cultured in media consisting of DMEM (Invitrogen) supplemented with 10% fetal bovine serum (Sigma), 1× nonessential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), 1× GlutaMAX (Gibco), and 100 μg/mL normocin (InvivoGen). Adherent cultures were incubated in a humidified incubator at 37°C with 5% CO<sub>2</sub>. Cultures were confirmed to be free of mycoplasma (MycoStrip, Invivogen).</p></sec><sec id="s4-6"><title>Immunocytochemistry and confocal microscopy</title><p>Cells were plated on poly-D-lysine-coated glass-bottom 35 mm dishes (P35GC-1.5-14-C, MatTek) and fixed with 4% paraformaldehyde for 10 min at room temperature without permeabilization. After fixation, cells were washed twice with PBS, followed by blocking with 10% normal goat serum in PBS for 1 hr at room temperature.</p><p>Cells were then incubated overnight at 4°C in blocking buffer, either without primary antibody (no primary control) or with cadherin-11 (extracellular) rabbit polyclonal antibody (1:200, DF3523, Affinity Biosciences). After three washes with PBS, cells were incubated for 1 hr at room temperature in blocking buffer containing 1 μg/mL Hoechst 33342, BioTracker NIR680 (1:2000, Merck), and goat anti-rabbit Alexa Fluor 488 secondary antibody (1:500, Invitrogen).</p><p>After four additional PBS washes, cells were imaged in PBS using a Leica Stellaris 5 confocal microscope equipped with a ×40 oil immersion objective. Tile-scanned images were stitched using Las X microscopy software (Leica) to generate high-resolution panoramic images.</p></sec><sec id="s4-7"><title>BioTracker staining</title><p>BioTracker NIR680 was diluted 1:2000 in unsupplemented DMEM/F-12. T25 flasks containing FLS were washed once with HBSS (with calcium and magnesium; Gibco), then incubated with the diluted dye for 30 min at 37°C. After incubation, the flasks were washed three times with FLS media, with each wash lasting 10 min at 37°C. FLS were then dissociated using Versene and plated onto 6- or 24-well plates.</p></sec><sec id="s4-8"><title>FLS transfection</title><p>For transfection in six-well plates, the medium was removed and replaced with 1 mL of Opti-MEM I (Gibco). In a microcentrifuge tube, 500 ng of saRNA was diluted in 200 μL of Opti-MEM I. In a separate tube, 3 μL of Lipofectamine MessengerMAX (Invitrogen) was diluted in 100 μL of Opti-MEM I. After gentle mixing, the solutions were combined and incubated at room temperature for 5 min, then added dropwise to the cells. The cells were incubated with the complexes for 2 hr at 37°C, after which the medium was removed and replaced with fresh FLS media. For transfection in 24-well plates, all volumes and amounts of saRNA were reduced fivefold.</p></sec><sec id="s4-9"><title>Microplate imaging</title><p>Black glass-bottom 6-well plates (P06-1.5H-N, Cellvis) or 24-well plates (662892, Greiner Bio-One) were used for microplate imaging. Prior to imaging, the FLS media was replaced with Live Cell Imaging Solution (Invitrogen). Imaging was performed using an Odyssey M laser scanner (LI-COR), using LI-COR acquisition software, a plate offset of +1.45 mm, and 100 μm resolution.</p><p>EGFP, mScarlet3, and BioTracker NIR680 were imaged using the 488, 520, and 700 channels, respectively. Spectral cross-excitation between EGFP and mScarlet3 in the 488 and 520 channels was corrected through linear unmixing analysis, as described below. Fluorescence intensity was quantified in ImageJ by measuring the integrated density within equal-area regions of interest for each well. Fluorescence values (EGFP, mScarlet3, and BioTracker) were normalized to the day 0 BioTracker signal measured before transfection to account for variations in starting cell number.</p></sec><sec id="s4-10"><title>Linear unmixing analysis</title><p>saRNA constructs encoding individual fluorescent proteins (moxBFP, EGFP, or mScarlet3) were designed to assess cross-excitation among the fluorescent proteins used in this study. tSA201 cells were seeded in black glass-bottom six-well plates coated with poly-D-lysine (Sigma) and transfected with the respective saRNA constructs. Cells were imaged the following day using an Odyssey M laser scanner, with fluorescence captured through the 488 and 520 channels.</p><p>Expression of moxBFP was undetectable in both the 488 and 520 channels, and therefore it was excluded from further analysis. Bleed-through of EGFP into the 520 channel and mScarlet3 into the 488 channel was quantified using ImageJ, with cross-excitation determined to be 11.32% and 0.94%, respectively. The emission signals were assumed to be linearly proportional to the sum of the intensities of each fluorophore, and the unmixed EGFP and mScarlet3 signals were calculated using Python.</p></sec><sec id="s4-11"><title>Annexin V assay</title><p>FLS were stained with BioTracker NIR680 and plated on black glass-bottom 24-well plates (Sensoplate, Greiner Bio-One). Cells were transfected with saRNA or treated with 0.5 μM staurosporine (Cayman Chemical) as a positive control.</p><p>Annexin V-CF800 conjugate (Biotium) was diluted to 250 ng/mL in Live Cell Imaging Solution (Invitrogen). On each day of the assay, wells were washed with Live Cell Imaging Solution and replaced with diluted Annexin V-CF800 solution. Plates were incubated at 37°C for 15 min. Following incubation, plates were washed three times with Live Cell Imaging Solution before imaging the 700 and 800 channels with an Odyssey M imager set to +1.45 mm image offset and 100 μm resolution.</p><p>Image analysis was performed using ImageJ. To correct for unidirectional spectral bleed-through of BioTracker NIR680 into the 800-channel, subtractive compensation was applied by dividing the 700-channel image by a factor of 800 and then subtracting it from the 800-channel image. Due to the presence of a small number of high-intensity speckles in the 800-channel image, area rather than fluorescence intensity was quantified. The display range of the 800-channel image was set between 0.25 and 2.5, and the image was thresholded using the method of Li (<xref ref-type="bibr" rid="bib70">Li and Lee, 1993</xref>). The area of thresholded pixels within each well was then quantified and adjusted based on the BioTracker signal before transfection to account for variations in cell number. Data were then normalized to the average of the mock transfection condition.</p></sec><sec id="s4-12"><title>Calcein AM staining</title><p>Calcein AM (Invitrogen) staining was performed according to the manufacturer’s protocol. Briefly, cells were washed with HBSS and incubated with 2 μM calcein AM (diluted in HBSS) at 37°C for 30 min. Following three washes, cells were imaged in Live Cell Imaging Solution, and the 488-channel image was captured using an Odyssey M imager.</p><p>Although calcein AM and EGFP have overlapping spectra, calcein AM fluorescence was typically much higher than EGFP, making EGFP’s contribution to the measured Calcein AM signal negligible in most cases. However, when the E3 construct was used, EGFP expression was sufficient to interfere with the signal. To address this, in experiments that included use of the E3 construct, a 488-channel image was captured prior to calcein AM application and subtracted from the post-application image to accurately measure calcein AM fluorescence.</p><p>Fluorescence intensity was quantified using ImageJ. In experiments where BioTracker was used, fluorescence values were corrected by the pre-transfection BioTracker signal to account for differences in starting cell number.</p></sec><sec id="s4-13"><title>In-cell western assay</title><p>Cells were plated on black, glass-bottom 24-well plates. Alongside mock and saRNA transfections, one well was reserved for background subtraction, which received no treatment. Unless specified otherwise, experiments were conducted on day 2 post-transfection. Cells were fixed with 4% paraformaldehyde for 10 min at room temperature, followed by two washes with Tris-buffered saline (TBS). Permeabilization was then performed using 0.1% Triton X-100 in TBS for 10 min, followed by two additional TBS washes. After permeabilization, cells were blocked with Intercept TBS Blocking Buffer (LI-COR) for 1 hr at room temperature with gentle agitation.</p><p>Primary antibodies were diluted in Intercept Blocking Buffer and incubated with the cells overnight at 4°C. The background subtraction well was incubated with blocking buffer alone, without primary antibodies. The following primary antibodies were used: Phospho-eIF2α (Ser51) (D9G8) XP rabbit monoclonal (1:200, #3398, Cell Signaling Technology), eIF2α (L57A5) mouse monoclonal (1:200, #2103, Cell Signaling Technology), PKR rabbit polyclonal (1:500, #18244-1-AP, Proteintech), Phospho-eIF4E (S209) rabbit monoclonal (1:200, #ab76256, Abcam), eIF4E mouse monoclonal (5D11) (1:200, #MA1-089, Invitrogen), and FAP (73.3) mouse monoclonal (20 μg/mL, #BE0374, InVivoMAb). All primary antibodies were unconjugated, except for the FAP antibody, which was conjugated to DyLight 800 using the DyLight Antibody Labeling Kit (#53062, Thermo Scientific) according to manufacturer’s protocols.</p><p>After washing the wells four times with TBS supplemented with 0.1% Tween 20 (TBST), cells were incubated for 1 hr at room temperature with the appropriate secondary antibodies or normalization stain, with gentle agitation. The secondary antibodies used were goat anti-mouse IRDye 800CW (1:800), donkey anti-rabbit IRDye 800CW (1:800), donkey anti-mouse IRDye 680RD (1:800), and CellTag 700 (1:500), all from LI-COR. The background subtraction well received secondary antibody but no CellTag. Following four additional washes with TBST, the plate was inverted and gently tapped on absorbent paper to remove excess liquid. The plate was then imaged using the Odyssey M imager with LI-COR Acquisition software using a plate offset of +1.45 and 100 μm resolution. Signal quantification was carried out using Empiria Studio software (LI-COR).</p></sec><sec id="s4-14"><title>SUnSET assay</title><p>FLS were plated in black, glass-bottom 24-well plates, with one well reserved for background subtraction (no treatment). Two days post-transfection, cells were treated with 1 μM puromycin (Sigma) for 30 min at 37 °C. The background control well did not receive puromycin. Following incubation, cells were washed twice with HBSS and fixed in 5% neutral-buffered formalin (in PBS) for 20 min at room temperature. Cells were then washed three times with PBS, permeabilized with 0.2% Triton X-100 for 10 min, and blocked with Intercept Blocking Buffer for 1 hr at room temperature.</p><p>Anti-puromycin antibody (3RH11, Absolute Antibody) was diluted 1:250 in blocking buffer and incubated with cells overnight at 4 °C. The following day, cells were washed four times with TBST, then incubated with goat anti-mouse IRDye 800CW (1:800) and CellTag 700 (1:500) diluted in blocking buffer. The background subtraction well did not receive CellTag. After four additional washes with TBST, plates were inverted, tapped dry on absorbent paper, and imaged using the Odyssey M imager. Signal quantification was performed using Empiria Studio software.</p></sec><sec id="s4-15"><title>rRNA integrity analysis</title><p>FLS were plated in six-well plates and either transfected with saRNA or subjected to mock transfection. After 26–30 hr (allowing for saRNA replication but before substantial cell loss), cells were harvested by scraping in 350 μL RLT buffer (QIAGEN) supplemented with 10 μL/mL β-mercaptoethanol (Sigma). Cell lysates were homogenized using QIAshredder columns (QIAGEN), and total RNA was extracted using the RNeasy Mini Kit (QIAGEN) according to the manufacturer’s instructions. RNA quantity and quality were initially assessed using a N60 nanophotometer (Implen). Samples were aliquoted and stored at –80°C until further analysis. For detailed quality assessment, samples were transported on dry ice and analyzed using the RNA Pico Kit on the 2100 Bioanalyzer System (Agilent), performed by Cambridge Genomic Services. RIN values were determined for each sample.</p></sec><sec id="s4-16"><title>Multiplex bead-based immunoassay</title><p>FLS were stained with BioTracker and seeded onto six-well plates. After transfection, the saRNA-lipofectamine complexes were replaced with 2 mL of fresh FLS media. Two days later, supernatants were collected and stored at –80°C until analysis. On the day of analysis, the supernatant was thawed on ice, and levels of 13 cytokines (IFN-γ, CXCL1, TNF-α, MCP-1, IL-12p70, CCL5, IL-1β, CXCL10, GM-CSF, IL-10, IFN-β, IFN-α, and IL-6) were measured using the LEGENDplex Mouse Anti-Virus Response Panel (740621, BioLegend) following the manufacturer’s protocol. Samples were run in duplicate. A custom 3D-printed PETG vacuum manifold (designed with Fusion 360) was used for vacuum filtration, and beads were analyzed using a CytoFLEX LX flow cytometer (Beckman Coulter). Data analysis was performed with the LEGENDplex Qognit Data Analysis Suite (BioLegend). To account for differences in cell number between wells, cytokine levels were normalized to the BioTracker signal before transfection.</p></sec><sec id="s4-17"><title>ML336 experiments</title><p>ML336 (Cayman Chemical) was dissolved in DMSO (Sigma) to a stock concentration of 10 mM and stored in aliquots at –20°C. ML336 was added to cell cultures at the indicated final concentrations. Vehicle controls received either 0.01% or 0.1% DMSO, corresponding to the maximum DMSO concentrations used in the respective ML336-treated conditions.</p><p>In concentration–response experiments, ML336 was applied during transfection. mScarlet3 fluorescence was measured on day 2 post-transfection. Data were fit to a variable-slope sigmoidal model, and a single data point was excluded due to pipetting error. In washout experiments, media was replaced 3 times on day 2 post-transfection and mScarlet3 signal was measured the following day. In these experiments, data were fit to a bell-shaped concentration–response curve.</p></sec><sec id="s4-18"><title>RT-qPCR experiments</title><p>FLS were seeded in 96-well plates, and transfections were performed using a 30-fold downscaling of the volumes used in six-well formats. At 2 days post-transfection, cDNA was synthesized directly from cell lysates using the TaqMan Fast Advanced Cells-to-CT Kit (Invitrogen), according to the manufacturer’s protocol and stored at –80 °C until analysis. For each biological replicate, a single well that received no treatment and was processed without reverse transcriptase (RT) served as a shared no-RT control.</p><p>For each treatment condition, a reaction mix containing cDNA, RT-PCR grade water (Invitrogen), and TaqMan Fast Advanced Master Mix (Applied Biosystems) was prepared and dispensed into the corresponding wells of custom 96-well 0.1 mL TaqMan array plates (Thermo Fisher). All conditions for a given biological replicate were run on the same plate to minimize inter-plate variability. Plates were run in duplicate, and each plate included no-template and no-RT controls, along with cDNA from mock-transfected cells, and cells transfected with conventional saRNA, E3, or srIκBα-Smad7-SOCS1 constructs.</p><p>Each array included the following TaqMan Gene Expression Assays: <italic>18S</italic> (Hs99999901_s1), <italic>Adar</italic> (Mm00508001_m1), <italic>Isg20</italic> (Mm00469585_m1), <italic>Rigi</italic> (Mm01216853_m1), <italic>Ifih1</italic> (Mm00459183_m1), <italic>Oas1e</italic> (Mm00653062_m1), <italic>Tlr3</italic> (Mm01207404_m1), <italic>Eif2ak2</italic> (Mm01235643_m1), <italic>ZC3hav1</italic> (Mm00512227_m1), <italic>Rnasel</italic> (Mm00712008_m1), <italic>EGFP</italic> (Mr04329676_mr), <italic>Ifnb1</italic> (Mm00439552_s1), <italic>Ifna2</italic> (Mm00833961_s1), <italic>Ifng</italic> (Mm01168134_m1), <italic>Tnf</italic> (Mm00443258_m1), and <italic>Il6</italic> (Mm00446190_m1).</p><p>Reactions were run for 40 cycles on a StepOnePlus Real-Time PCR System (Applied Biosystems), using manufacturer-recommended conditions. A consistent ΔRn threshold was applied across all plates and replicates. ΔCT values were calculated relative to <italic>18S</italic>. Transcripts not detected in all samples were excluded from analysis, with the exception of EGFP. These excluded transcripts included <italic>Oas1e</italic>, <italic>Ifnb1</italic>, <italic>Ifna2</italic>, <italic>Ifng</italic>, and <italic>Tnf</italic>. Statistical significance was evaluated using ΔCT values, and mean –ΔΔCT values relative to the mock condition are shown as a heatmap for visualization.</p></sec><sec id="s4-19"><title>Statistical analysis</title><p>All statistical analyses and curve fitting were conducted using GraphPad Prism 9, with specific tests detailed in the corresponding figure legends. All statistical tests were two-sided tests.</p></sec><sec id="s4-20"><title>Materials availability statement</title><p>All key plasmids generated in this study have been deposited with the Addgene repository. Accession numbers have been provided in the Key Resources Table.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Software, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Visualization, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Mouse tissue collection was conducted in accordance with Schedule 1 of the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 and under Project Licence PP5814995 (granted to Ewan St. John Smith by the UK Home Office), with approval from the University of Cambridge Animal Welfare Ethical Review Body.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-105978-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated in this study have been deposited in the Figshare repository and are publicly available at <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.6084/m9.figshare.27091972">http://doi.org/10.6084/m9.figshare.27091972</ext-link>. Whole-plasmid sequencing results of the key plasmids generated in this study are provided in the article's source data files. The Python code used for the spectral unmixing analysis is available on GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/lariferg/spectral_unmixing">https://github.com/lariferg/spectral_unmixing</ext-link>, copy archived at <xref ref-type="bibr" rid="bib36">Ferguson, 2025</xref>). The 3D model for the 3D printed vacuum manifold designed for LEGENDplex filter plates is available from the NIH 3D Print Exchange under accession number 3DPX-021388. All other relevant data are included within the article, appendix, and associated source data files.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>TKY</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>Immune-Evasive Self-amplifying RNA Complete Dataset (eLife 2025)</data-title><source>figshare</source><pub-id pub-id-type="doi">10.6084/m9.figshare.27091972</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>TKY</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Vacuum manifold for BioLegend LEGENDplex bead-based immunoassay (96-well filter plate)</data-title><source>NIH 3D</source><pub-id pub-id-type="accession" xlink:href="https://3d.nih.gov/entries/3DPX-021388">3DPX-021388</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors gratefully acknowledge the Cambridge Advanced Imaging Centre, the flow cytometry facility from the School of the Biological Sciences, and Cambridge Genomic Services for their support &amp;and assistance in this work. The authors would like to thank Dr. Paul Miller for providing the pDx_mScarlet3 plasmid and Dr. Alex Cloake for providing the pIRES2-EGFP plasmid used in this study. TKYL acknowledges support from a Horizon Europe Marie Skłodowska-Curie Actions European Postdoctoral Fellowship (UKRI Guarantee) (EP/X023117/1). AR and LWP disclose support from AstraZeneca PhD studentships (G115018 and G113502, respectively). LF discloses support from funding provided by the MRC (MC-A023-5PB91). EStJS acknowledges funding from the UKRI and Versus Arthritis (MR/W002426/1) as part of the ADVANTAGE visceral pain consortium through the Advanced Pain Discovery Platform (APDP) and EStJS and LJG acknowledge the Wellcome Trust (225856/Z/22/Z). The eLife publication fees for this article were supported by the University of Cambridge’s open access funding.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhrymuk</surname><given-names>I</given-names></name><name><surname>Frolov</surname><given-names>I</given-names></name><name><surname>Frolova</surname><given-names>EI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Both RIG-I and MDA5 detect alphavirus replication in concentration-dependent mode</article-title><source>Virology</source><volume>487</volume><fpage>230</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2015.09.023</pub-id><pub-id pub-id-type="pmid">26550947</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baiersdörfer</surname><given-names>M</given-names></name><name><surname>Boros</surname><given-names>G</given-names></name><name><surname>Muramatsu</surname><given-names>H</given-names></name><name><surname>Mahiny</surname><given-names>A</given-names></name><name><surname>Vlatkovic</surname><given-names>I</given-names></name><name><surname>Sahin</surname><given-names>U</given-names></name><name><surname>Karikó</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA</article-title><source>Molecular Therapy. Nucleic Acids</source><volume>15</volume><fpage>26</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2019.02.018</pub-id><pub-id pub-id-type="pmid">30933724</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baird</surname><given-names>TD</given-names></name><name><surname>Wek</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Eukaryotic initiation factor 2 phosphorylation and translational control in metabolism</article-title><source>Advances in Nutrition</source><volume>3</volume><fpage>307</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.3945/an.112.002113</pub-id><pub-id pub-id-type="pmid">22585904</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bathula</surname><given-names>NV</given-names></name><name><surname>Friesen</surname><given-names>JJ</given-names></name><name><surname>Casmil</surname><given-names>IC</given-names></name><name><surname>Wayne</surname><given-names>CJ</given-names></name><name><surname>Liao</surname><given-names>S</given-names></name><name><surname>Soriano</surname><given-names>SKV</given-names></name><name><surname>Ho</surname><given-names>CH</given-names></name><name><surname>Strumpel</surname><given-names>A</given-names></name><name><surname>Blakney</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Delivery vehicle and route of administration influences self-amplifying RNA biodistribution, expression kinetics, and reactogenicity</article-title><source>Journal of Controlled Release</source><volume>374</volume><fpage>28</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.07.078</pub-id><pub-id pub-id-type="pmid">39097193</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Jendro</surname><given-names>MC</given-names></name><name><surname>Wadle</surname><given-names>A</given-names></name><name><surname>Kleber</surname><given-names>S</given-names></name><name><surname>Stenner</surname><given-names>F</given-names></name><name><surname>Dinser</surname><given-names>R</given-names></name><name><surname>Reich</surname><given-names>A</given-names></name><name><surname>Faccin</surname><given-names>E</given-names></name><name><surname>Gödde</surname><given-names>S</given-names></name><name><surname>Dinges</surname><given-names>H</given-names></name><name><surname>Müller-Ladner</surname><given-names>U</given-names></name><name><surname>Renner</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes</article-title><source>Arthritis Research &amp; Therapy</source><volume>8</volume><elocation-id>R171</elocation-id><pub-id pub-id-type="doi">10.1186/ar2080</pub-id><pub-id pub-id-type="pmid">17105646</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beissert</surname><given-names>T</given-names></name><name><surname>Koste</surname><given-names>L</given-names></name><name><surname>Perkovic</surname><given-names>M</given-names></name><name><surname>Walzer</surname><given-names>KC</given-names></name><name><surname>Erbar</surname><given-names>S</given-names></name><name><surname>Selmi</surname><given-names>A</given-names></name><name><surname>Diken</surname><given-names>M</given-names></name><name><surname>Kreiter</surname><given-names>S</given-names></name><name><surname>Türeci</surname><given-names>Ö</given-names></name><name><surname>Sahin</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Improvement of in vivo expression of genes delivered by self-amplifying rna using vaccinia virus immune evasion proteins</article-title><source>Human Gene Therapy</source><volume>28</volume><fpage>1138</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1089/hum.2017.121</pub-id><pub-id pub-id-type="pmid">28877647</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beissert</surname><given-names>T</given-names></name><name><surname>Perkovic</surname><given-names>M</given-names></name><name><surname>Vogel</surname><given-names>A</given-names></name><name><surname>Erbar</surname><given-names>S</given-names></name><name><surname>Walzer</surname><given-names>KC</given-names></name><name><surname>Hempel</surname><given-names>T</given-names></name><name><surname>Brill</surname><given-names>S</given-names></name><name><surname>Haefner</surname><given-names>E</given-names></name><name><surname>Becker</surname><given-names>R</given-names></name><name><surname>Türeci</surname><given-names>Ö</given-names></name><name><surname>Sahin</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A trans-amplifying RNA vaccine strategy for induction of potent protective immunity</article-title><source>Molecular Therapy</source><volume>28</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.09.009</pub-id><pub-id pub-id-type="pmid">31624015</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berglund</surname><given-names>P</given-names></name><name><surname>Finzi</surname><given-names>D</given-names></name><name><surname>Bennink</surname><given-names>JR</given-names></name><name><surname>Yewdell</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Viral alteration of cellular translational machinery increases defective ribosomal products</article-title><source>Journal of Virology</source><volume>81</volume><fpage>7220</fpage><lpage>7229</lpage><pub-id pub-id-type="doi">10.1128/JVI.00137-07</pub-id><pub-id pub-id-type="pmid">17459927</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertrand</surname><given-names>R</given-names></name><name><surname>Solary</surname><given-names>E</given-names></name><name><surname>O’Connor</surname><given-names>P</given-names></name><name><surname>Kohn</surname><given-names>KW</given-names></name><name><surname>Pommier</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Induction of a common pathway of apoptosis by staurosporine</article-title><source>Experimental Cell Research</source><volume>211</volume><fpage>314</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1006/excr.1994.1093</pub-id><pub-id pub-id-type="pmid">8143779</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blakney</surname><given-names>AK</given-names></name><name><surname>Ip</surname><given-names>S</given-names></name><name><surname>Geall</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>An update on self-amplifying mRNA vaccine development</article-title><source>Vaccines</source><volume>9</volume><elocation-id>97</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9020097</pub-id><pub-id pub-id-type="pmid">33525396</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blakney</surname><given-names>AK</given-names></name><name><surname>McKay</surname><given-names>PF</given-names></name><name><surname>Bouton</surname><given-names>CR</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Samnuan</surname><given-names>K</given-names></name><name><surname>Shattock</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Innate inhibiting proteins enhance expression and immunogenicity of self-amplifying RNA</article-title><source>Molecular Therapy</source><volume>29</volume><fpage>1174</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2020.11.011</pub-id><pub-id pub-id-type="pmid">33352107</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloom</surname><given-names>K</given-names></name><name><surname>van den Berg</surname><given-names>F</given-names></name><name><surname>Arbuthnot</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Self-amplifying RNA vaccines for infectious diseases</article-title><source>Gene Therapy</source><volume>28</volume><fpage>117</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1038/s41434-020-00204-y</pub-id><pub-id pub-id-type="pmid">33093657</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumer</surname><given-names>T</given-names></name><name><surname>Coto-Llerena</surname><given-names>M</given-names></name><name><surname>Duong</surname><given-names>FHT</given-names></name><name><surname>Heim</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SOCS1 is an inducible negative regulator of interferon λ (IFN-λ)-induced gene expression <italic>in vivo</italic></article-title><source>The Journal of Biological Chemistry</source><volume>292</volume><fpage>17928</fpage><lpage>17938</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.788877</pub-id><pub-id pub-id-type="pmid">28900038</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyd</surname><given-names>DF</given-names></name><name><surname>Allen</surname><given-names>EK</given-names></name><name><surname>Randolph</surname><given-names>AG</given-names></name><name><surname>Guo</surname><given-names>X-ZJ</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><name><surname>Sanders</surname><given-names>CJ</given-names></name><name><surname>Bajracharya</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>NK</given-names></name><name><surname>Guy</surname><given-names>CS</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Novak</surname><given-names>T</given-names></name><name><surname>Newhams</surname><given-names>MM</given-names></name><name><surname>Fabrizio</surname><given-names>TP</given-names></name><name><surname>Wohlgemuth</surname><given-names>N</given-names></name><name><surname>Mourani</surname><given-names>PM</given-names></name><collab>PALISI Pediatric Intensive Care Influenza Investigators</collab><name><surname>Wight</surname><given-names>TN</given-names></name><name><surname>Schultz-Cherry</surname><given-names>S</given-names></name><name><surname>Cormier</surname><given-names>SA</given-names></name><name><surname>Shaw-Saliba</surname><given-names>K</given-names></name><name><surname>Pekosz</surname><given-names>A</given-names></name><name><surname>Rothman</surname><given-names>RE</given-names></name><name><surname>Chen</surname><given-names>K-F</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Webby</surname><given-names>RJ</given-names></name><name><surname>Zhong</surname><given-names>N</given-names></name><name><surname>Crawford</surname><given-names>JC</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Exuberant fibroblast activity compromises lung function via ADAMTS4</article-title><source>Nature</source><volume>587</volume><fpage>466</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2877-5</pub-id><pub-id pub-id-type="pmid">33116313</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bratosin</surname><given-names>D</given-names></name><name><surname>Mitrofan</surname><given-names>L</given-names></name><name><surname>Palii</surname><given-names>C</given-names></name><name><surname>Estaquier</surname><given-names>J</given-names></name><name><surname>Montreuil</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Novel fluorescence assay using calcein-AM for the determination of human erythrocyte viability and aging</article-title><source>Cytometry. Part A</source><volume>66A</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1002/cyto.a.20152</pub-id><pub-id pub-id-type="pmid">15915509</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Gerstberger</surname><given-names>S</given-names></name><name><surname>Carlson</surname><given-names>L</given-names></name><name><surname>Franzoso</surname><given-names>G</given-names></name><name><surname>Siebenlist</surname><given-names>U</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation</article-title><source>Science</source><volume>267</volume><fpage>1485</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1126/science.7878466</pub-id><pub-id pub-id-type="pmid">7878466</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>JM</given-names></name><name><surname>Moon</surname><given-names>SL</given-names></name><name><surname>Matheny</surname><given-names>T</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>RNase L reprograms translation by widespread mRNA turnover escaped by antiviral mRNAs</article-title><source>Molecular Cell</source><volume>75</volume><fpage>1203</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.07.029</pub-id><pub-id pub-id-type="pmid">31494035</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>JM</given-names></name><name><surname>Gilchrist</surname><given-names>AR</given-names></name><name><surname>Sawyer</surname><given-names>SL</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>RNase L limits host and viral protein synthesis via inhibition of mRNA export</article-title><source>Science Advances</source><volume>7</volume><elocation-id>eabh2479</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abh2479</pub-id><pub-id pub-id-type="pmid">34088676</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>S</given-names></name><name><surname>Hore</surname><given-names>Z</given-names></name><name><surname>Pattison</surname><given-names>LA</given-names></name><name><surname>Lalnunhlimi</surname><given-names>S</given-names></name><name><surname>Bhebhe</surname><given-names>CN</given-names></name><name><surname>Callejo</surname><given-names>G</given-names></name><name><surname>Bulmer</surname><given-names>DC</given-names></name><name><surname>Taams</surname><given-names>LS</given-names></name><name><surname>Denk</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>ESJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sensitization of knee-innervating sensory neurons by tumor necrosis factor-α-activated fibroblast-like synoviocytes: an in vitro, coculture model of inflammatory pain</article-title><source>Pain</source><volume>161</volume><fpage>2129</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000001890</pub-id><pub-id pub-id-type="pmid">32332252</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>LL</given-names></name><name><surname>Wilkinson</surname><given-names>AR</given-names></name><name><surname>Paradis</surname><given-names>BD</given-names></name><name><surname>Lai</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Rapid image-based cytometry for comparison of fluorescent viability staining methods</article-title><source>Journal of Fluorescence</source><volume>22</volume><fpage>1301</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1007/s10895-012-1072-y</pub-id><pub-id pub-id-type="pmid">22718197</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Music</surname><given-names>N</given-names></name><name><surname>Cheung</surname><given-names>M</given-names></name><name><surname>Rossignol</surname><given-names>E</given-names></name><name><surname>Bedi</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>H</given-names></name><name><surname>Safari</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Otten</surname><given-names>GR</given-names></name><name><surname>Settembre</surname><given-names>EC</given-names></name><name><surname>Palladino</surname><given-names>G</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Self-amplifying mRNA bicistronic influenza vaccines raise cross-reactive immune responses in mice and prevent infection in ferrets</article-title><source>Molecular Therapy - Methods &amp; Clinical Development</source><volume>27</volume><fpage>195</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2022.09.013</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiaradia</surname><given-names>E</given-names></name><name><surname>Tancini</surname><given-names>B</given-names></name><name><surname>Emiliani</surname><given-names>C</given-names></name><name><surname>Delo</surname><given-names>F</given-names></name><name><surname>Pellegrino</surname><given-names>RM</given-names></name><name><surname>Tognoloni</surname><given-names>A</given-names></name><name><surname>Urbanelli</surname><given-names>L</given-names></name><name><surname>Buratta</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Extracellular vesicles under oxidative stress conditions: biological properties and physiological roles</article-title><source>Cells</source><volume>10</volume><elocation-id>1763</elocation-id><pub-id pub-id-type="doi">10.3390/cells10071763</pub-id><pub-id pub-id-type="pmid">34359933</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>D</given-names></name><name><surname>Schroeder</surname><given-names>CE</given-names></name><name><surname>Sotsky</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>T</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Tower</surname><given-names>NA</given-names></name><name><surname>Noah</surname><given-names>JW</given-names></name><name><surname>McKellip</surname><given-names>S</given-names></name><name><surname>Sosa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><chapter-title>ML336: development of quinazolinone-based inhibitors against venezuelan equine encephalitis virus</chapter-title><person-group person-group-type="editor"><name><surname>Sotsky</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>T</given-names></name></person-group><source>Probe Reports from the NIH Molecular Libraries Program</source><publisher-name>National Center for Biotechnology Information (US</publisher-name></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costantini</surname><given-names>LM</given-names></name><name><surname>Baloban</surname><given-names>M</given-names></name><name><surname>Markwardt</surname><given-names>ML</given-names></name><name><surname>Rizzo</surname><given-names>MA</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Verkhusha</surname><given-names>VV</given-names></name><name><surname>Snapp</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A palette of fluorescent proteins optimized for diverse cellular environments</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7670</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8670</pub-id><pub-id pub-id-type="pmid">26158227</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costigan</surname><given-names>A</given-names></name><name><surname>Hollville</surname><given-names>E</given-names></name><name><surname>Martin</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Discriminating between apoptosis, necrosis, necroptosis, and ferroptosis by microscopy and flow cytometry</article-title><source>Current Protocols</source><volume>3</volume><elocation-id>e951</elocation-id><pub-id pub-id-type="doi">10.1002/cpz1.951</pub-id><pub-id pub-id-type="pmid">38112058</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croft</surname><given-names>AP</given-names></name><name><surname>Campos</surname><given-names>J</given-names></name><name><surname>Jansen</surname><given-names>K</given-names></name><name><surname>Turner</surname><given-names>JD</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>Attar</surname><given-names>M</given-names></name><name><surname>Savary</surname><given-names>L</given-names></name><name><surname>Wehmeyer</surname><given-names>C</given-names></name><name><surname>Naylor</surname><given-names>AJ</given-names></name><name><surname>Kemble</surname><given-names>S</given-names></name><name><surname>Begum</surname><given-names>J</given-names></name><name><surname>Dürholz</surname><given-names>K</given-names></name><name><surname>Perlman</surname><given-names>H</given-names></name><name><surname>Barone</surname><given-names>F</given-names></name><name><surname>McGettrick</surname><given-names>HM</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name><name><surname>Wei</surname><given-names>K</given-names></name><name><surname>Raychaudhuri</surname><given-names>S</given-names></name><name><surname>Korsunsky</surname><given-names>I</given-names></name><name><surname>Brenner</surname><given-names>MB</given-names></name><name><surname>Coles</surname><given-names>M</given-names></name><name><surname>Sansom</surname><given-names>SN</given-names></name><name><surname>Filer</surname><given-names>A</given-names></name><name><surname>Buckley</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Distinct fibroblast subsets drive inflammation and damage in arthritis</article-title><source>Nature</source><volume>570</volume><fpage>246</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1263-7</pub-id><pub-id pub-id-type="pmid">31142839</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crowley</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Quantitation of apoptosis and necrosis by annexin v binding, propidium iodide uptake, and flow cytometry</article-title><source>Cold Spring Harb Protoc</source><volume>1</volume><elocation-id>e7288</elocation-id><pub-id pub-id-type="doi">10.1101/pdb.prot087288</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dias Junior</surname><given-names>AG</given-names></name><name><surname>Sampaio</surname><given-names>NG</given-names></name><name><surname>Rehwinkel</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A balancing act: MDA5 in antiviral immunity and autoinflammation</article-title><source>Trends in Microbiology</source><volume>27</volume><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2018.08.007</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitriou</surname><given-names>ID</given-names></name><name><surname>Clemenza</surname><given-names>L</given-names></name><name><surname>Scotter</surname><given-names>AJ</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Guerra</surname><given-names>FM</given-names></name><name><surname>Rottapel</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins</article-title><source>Immunological Reviews</source><volume>224</volume><fpage>265</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00659.x</pub-id><pub-id pub-id-type="pmid">18759933</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominguez</surname><given-names>F</given-names></name><name><surname>Palchevska</surname><given-names>O</given-names></name><name><surname>Frolova</surname><given-names>EI</given-names></name><name><surname>Frolov</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Alphavirus-based replicons demonstrate different interactions with host cells and can be optimized to increase protein expression</article-title><source>Journal of Virology</source><volume>97</volume><elocation-id>e0122523</elocation-id><pub-id pub-id-type="doi">10.1128/jvi.01225-23</pub-id><pub-id pub-id-type="pmid">37877718</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donovan</surname><given-names>J</given-names></name><name><surname>Rath</surname><given-names>S</given-names></name><name><surname>Kolet-Mandrikov</surname><given-names>D</given-names></name><name><surname>Korennykh</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Rapid RNase L-driven arrest of protein synthesis in the dsRNA response without degradation of translation machinery</article-title><source>RNA</source><volume>23</volume><fpage>1660</fpage><lpage>1671</lpage><pub-id pub-id-type="doi">10.1261/rna.062000.117</pub-id><pub-id pub-id-type="pmid">28808124</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drappier</surname><given-names>M</given-names></name><name><surname>Jha</surname><given-names>BK</given-names></name><name><surname>Stone</surname><given-names>S</given-names></name><name><surname>Elliott</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Vertommen</surname><given-names>D</given-names></name><name><surname>Weiss</surname><given-names>SR</given-names></name><name><surname>Silverman</surname><given-names>RH</given-names></name><name><surname>Michiels</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A novel mechanism of RNase L inhibition: Theiler’s virus L* protein prevents 2-5A from binding to RNase L</article-title><source>PLOS Pathogens</source><volume>14</volume><elocation-id>e1006989</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006989</pub-id><pub-id pub-id-type="pmid">29652922</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyer</surname><given-names>JR</given-names></name><name><surname>Michel</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Castellucci</surname><given-names>VF</given-names></name><name><surname>Wayne</surname><given-names>NL</given-names></name><name><surname>Sossin</surname><given-names>WS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>An activity-dependent switch to cap-independent translation triggered by eIF4E dephosphorylation</article-title><source>Nature Neuroscience</source><volume>6</volume><fpage>219</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/nn1018</pub-id><pub-id pub-id-type="pmid">12592407</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erasmus</surname><given-names>JH</given-names></name><name><surname>Archer</surname><given-names>J</given-names></name><name><surname>Fuerte-Stone</surname><given-names>J</given-names></name><name><surname>Khandhar</surname><given-names>AP</given-names></name><name><surname>Voigt</surname><given-names>E</given-names></name><name><surname>Granger</surname><given-names>B</given-names></name><name><surname>Bombardi</surname><given-names>RG</given-names></name><name><surname>Govero</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>Q</given-names></name><name><surname>Durnell</surname><given-names>LA</given-names></name><name><surname>Coler</surname><given-names>RN</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Crowe</surname><given-names>JE</given-names></name><name><surname>Reed</surname><given-names>SG</given-names></name><name><surname>Thackray</surname><given-names>LB</given-names></name><name><surname>Carnahan</surname><given-names>RH</given-names></name><name><surname>Van Hoeven</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Intramuscular delivery of replicon RNA Encoding ZIKV-117 human monoclonal antibody protects against zika virus infection</article-title><source>Molecular Therapy - Methods &amp; Clinical Development</source><volume>18</volume><fpage>402</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2020.06.011</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Mo</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Pang</surname><given-names>Z</given-names></name><name><surname>Pan</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Cao</surname><given-names>D</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>F</given-names></name><name><surname>Yue</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Inhibition of fibroblast activation protein ameliorates cartilage matrix degradation and osteoarthritis progression</article-title><source>Bone Research</source><volume>11</volume><elocation-id>3</elocation-id><pub-id pub-id-type="doi">10.1038/s41413-022-00243-8</pub-id><pub-id pub-id-type="pmid">36588124</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>Spectral unmixing for Odyssey M</data-title><version designator="1.0">1.0</version><source>Zenodo</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.16787751">https://doi.org/10.5281/zenodo.16787751</ext-link></element-citation></ref><ref id="bib37"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>L</given-names></name><name><surname>Ouellet</surname><given-names>S</given-names></name><name><surname>Vandewyer</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wunna</surname><given-names>Z</given-names></name><name><surname>Lim</surname><given-names>TKY</given-names></name><name><surname>Schafer</surname><given-names>WR</given-names></name><name><surname>Beets</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>DeorphaNN: virtual screening of GPCR peptide agonists using AlphaFold-predicted active-state complexes and deep learning embeddings</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2025.03.19.644234</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Floor</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><source>Denaturing Agarose Gels for Large RNAs with Glyoxal V1</source><publisher-name>protocols.io</publisher-name><pub-id pub-id-type="doi">10.17504/protocols.io.4p2gvqe</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frolov</surname><given-names>I</given-names></name><name><surname>Schlesinger</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Comparison of the effects of Sindbis virus and Sindbis virus replicons on host cell protein synthesis and cytopathogenicity in BHK cells</article-title><source>Journal of Virology</source><volume>68</volume><fpage>1721</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1128/JVI.68.3.1721-1727.1994</pub-id><pub-id pub-id-type="pmid">8107233</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frolov</surname><given-names>I</given-names></name><name><surname>Hoffman</surname><given-names>TA</given-names></name><name><surname>Prágai</surname><given-names>BM</given-names></name><name><surname>Dryga</surname><given-names>SA</given-names></name><name><surname>Huang</surname><given-names>HV</given-names></name><name><surname>Schlesinger</surname><given-names>S</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Alphavirus-based expression vectors: strategies and applications</article-title><source>PNAS</source><volume>93</volume><fpage>11371</fpage><lpage>11377</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.21.11371</pub-id><pub-id pub-id-type="pmid">8876142</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frolov</surname><given-names>I</given-names></name><name><surname>Agapov</surname><given-names>E</given-names></name><name><surname>Hoffman</surname><given-names>TA</given-names><suffix>Jr</suffix></name><name><surname>Prágai</surname><given-names>BM</given-names></name><name><surname>Lippa</surname><given-names>M</given-names></name><name><surname>Schlesinger</surname><given-names>S</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Selection of RNA replicons capable of persistent noncytopathic replication in mammalian cells</article-title><source>Journal of Virology</source><volume>73</volume><fpage>3854</fpage><lpage>3865</lpage><pub-id pub-id-type="doi">10.1128/JVI.73.5.3854-3865.1999</pub-id><pub-id pub-id-type="pmid">10196280</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frolova</surname><given-names>EI</given-names></name><name><surname>Palchevska</surname><given-names>O</given-names></name><name><surname>Dominguez</surname><given-names>F</given-names></name><name><surname>Frolov</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Alphavirus-induced transcriptional and translational shutoffs play major roles in blocking the formation of stress granules</article-title><source>Journal of Virology</source><volume>97</volume><fpage>e00979</fpage><lpage>e00923</lpage><pub-id pub-id-type="doi">10.1128/jvi.00979-23</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fros</surname><given-names>JJ</given-names></name><name><surname>Pijlman</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Alphavirus infection: host cell shut-off and inhibition of antiviral responses</article-title><source>Viruses</source><volume>8</volume><elocation-id>166</elocation-id><pub-id pub-id-type="doi">10.3390/v8060166</pub-id><pub-id pub-id-type="pmid">27294951</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gadella</surname><given-names>TWJ</given-names></name><name><surname>van Weeren</surname><given-names>L</given-names></name><name><surname>Stouthamer</surname><given-names>J</given-names></name><name><surname>Hink</surname><given-names>MA</given-names></name><name><surname>Wolters</surname><given-names>AHG</given-names></name><name><surname>Giepmans</surname><given-names>BNG</given-names></name><name><surname>Aumonier</surname><given-names>S</given-names></name><name><surname>Dupuy</surname><given-names>J</given-names></name><name><surname>Royant</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>mScarlet3: a brilliant and fast-maturing red fluorescent protein</article-title><source>Nature Methods</source><volume>20</volume><fpage>541</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1038/s41592-023-01809-y</pub-id><pub-id pub-id-type="pmid">36973546</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gal-Ben-Ari</surname><given-names>S</given-names></name><name><surname>Barrera</surname><given-names>I</given-names></name><name><surname>Ehrlich</surname><given-names>M</given-names></name><name><surname>Rosenblum</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>PKR: a kinase to remember</article-title><source>Frontiers in Molecular Neuroscience</source><volume>11</volume><elocation-id>480</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2018.00480</pub-id><pub-id pub-id-type="pmid">30686999</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gargett</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells</article-title><source>Frontiers in Pharmacology</source><volume>5</volume><elocation-id>235</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2014.00235</pub-id><pub-id pub-id-type="pmid">25389405</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaucherand</surname><given-names>L</given-names></name><name><surname>Gaglia</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The role of viral RNA degrading factors in shutoff of host gene expression</article-title><source>Annual Review of Virology</source><volume>9</volume><fpage>213</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-100120-012345</pub-id><pub-id pub-id-type="pmid">35671567</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gil</surname><given-names>J</given-names></name><name><surname>Esteban</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The interferon-induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-alpha receptors</article-title><source>Oncogene</source><volume>19</volume><fpage>3665</fpage><lpage>3674</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203710</pub-id><pub-id pub-id-type="pmid">10951573</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goker Bagca</surname><given-names>B</given-names></name><name><surname>Biray Avci</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>54</volume><fpage>51</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2020.06.013</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Yong</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>A novel self-amplifying mRNA with decreased cytotoxicity and enhanced protein expression by macrodomain mutations</article-title><source>Advanced Science</source><volume>11</volume><elocation-id>e2402936</elocation-id><pub-id pub-id-type="doi">10.1002/advs.202402936</pub-id><pub-id pub-id-type="pmid">39313862</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorchakov</surname><given-names>R</given-names></name><name><surname>Frolova</surname><given-names>E</given-names></name><name><surname>Williams</surname><given-names>BRG</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Frolov</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>PKR-dependent and -independent mechanisms are involved in translational shutoff during Sindbis virus infection</article-title><source>Journal of Virology</source><volume>78</volume><fpage>8455</fpage><lpage>8467</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.16.8455-8467.2004</pub-id><pub-id pub-id-type="pmid">15280454</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greco</surname><given-names>R</given-names></name><name><surname>Oliveira</surname><given-names>G</given-names></name><name><surname>Stanghellini</surname><given-names>MTL</given-names></name><name><surname>Vago</surname><given-names>L</given-names></name><name><surname>Bondanza</surname><given-names>A</given-names></name><name><surname>Peccatori</surname><given-names>J</given-names></name><name><surname>Cieri</surname><given-names>N</given-names></name><name><surname>Marktel</surname><given-names>S</given-names></name><name><surname>Mastaglio</surname><given-names>S</given-names></name><name><surname>Bordignon</surname><given-names>C</given-names></name><name><surname>Bonini</surname><given-names>C</given-names></name><name><surname>Ciceri</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Improving the safety of cell therapy with the TK-suicide gene</article-title><source>Frontiers in Pharmacology</source><volume>6</volume><elocation-id>e0095</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2015.00095</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guydosh</surname><given-names>NR</given-names></name><name><surname>Kimmig</surname><given-names>P</given-names></name><name><surname>Walter</surname><given-names>P</given-names></name><name><surname>Green</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Regulated Ire1-dependent mRNA decay requires no-go mRNA degradation to maintain endoplasmic reticulum homeostasis in <italic>S. pombe</italic></article-title><source>eLife</source><volume>6</volume><elocation-id>e29216</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.29216</pub-id><pub-id pub-id-type="pmid">28945192</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herdy</surname><given-names>B</given-names></name><name><surname>Jaramillo</surname><given-names>M</given-names></name><name><surname>Svitkin</surname><given-names>YV</given-names></name><name><surname>Rosenfeld</surname><given-names>AB</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Walsh</surname><given-names>D</given-names></name><name><surname>Alain</surname><given-names>T</given-names></name><name><surname>Sean</surname><given-names>P</given-names></name><name><surname>Robichaud</surname><given-names>N</given-names></name><name><surname>Topisirovic</surname><given-names>I</given-names></name><name><surname>Furic</surname><given-names>L</given-names></name><name><surname>Dowling</surname><given-names>RJO</given-names></name><name><surname>Sylvestre</surname><given-names>A</given-names></name><name><surname>Rong</surname><given-names>L</given-names></name><name><surname>Colina</surname><given-names>R</given-names></name><name><surname>Costa-Mattioli</surname><given-names>M</given-names></name><name><surname>Fritz</surname><given-names>JH</given-names></name><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>E</given-names></name><name><surname>Mohr</surname><given-names>I</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Translational control of the activation of transcription factor NF-κB and production of type I interferon by phosphorylation of the translation factor eIF4E</article-title><source>Nature Immunology</source><volume>13</volume><fpage>543</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/ni.2291</pub-id><pub-id pub-id-type="pmid">22544393</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>NT</given-names></name><name><surname>Hughes</surname><given-names>SG</given-names></name><name><surname>Ta</surname><given-names>VT</given-names></name><name><surname>Phan</surname><given-names>LT</given-names></name><name><surname>Đỗ</surname><given-names>Q</given-names></name><name><surname>Nguyễn</surname><given-names>TV</given-names></name><name><surname>Phạm</surname><given-names>ATV</given-names></name><name><surname>Thị Ngọc Đặng</surname><given-names>M</given-names></name><name><surname>Nguyễn</surname><given-names>LV</given-names></name><name><surname>Trịnh</surname><given-names>QV</given-names></name><name><surname>Phạm</surname><given-names>HN</given-names></name><name><surname>Chử</surname><given-names>MV</given-names></name><name><surname>Nguyễn</surname><given-names>TT</given-names></name><name><surname>Lương</surname><given-names>QC</given-names></name><name><surname>Tường Lê</surname><given-names>VT</given-names></name><name><surname>Nguyễn</surname><given-names>TV</given-names></name><name><surname>Trần</surname><given-names>LTL</given-names></name><name><surname>Thi Van Luu</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>AN</given-names></name><name><surname>Nguyen</surname><given-names>NTH</given-names></name><name><surname>Vu</surname><given-names>HS</given-names></name><name><surname>Edelman</surname><given-names>JM</given-names></name><name><surname>Parker</surname><given-names>S</given-names></name><name><surname>Sullivan</surname><given-names>B</given-names></name><name><surname>Sullivan</surname><given-names>S</given-names></name><name><surname>Ruan</surname><given-names>Q</given-names></name><name><surname>Clemente</surname><given-names>B</given-names></name><name><surname>Luk</surname><given-names>B</given-names></name><name><surname>Lindert</surname><given-names>K</given-names></name><name><surname>Berdieva</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Sekulovich</surname><given-names>R</given-names></name><name><surname>Greener</surname><given-names>B</given-names></name><name><surname>Smolenov</surname><given-names>I</given-names></name><name><surname>Chivukula</surname><given-names>P</given-names></name><name><surname>Nguyễn</surname><given-names>VT</given-names></name><name><surname>Nguyen</surname><given-names>XH</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials</article-title><source>Nature Communications</source><volume>15</volume><elocation-id>4081</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-47905-1</pub-id><pub-id pub-id-type="pmid">38744844</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honig</surname><given-names>MG</given-names></name><name><surname>Hume</surname><given-names>RI</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Fluorescent carbocyanine dyes allow living neurons of identified origin to be studied in long-term cultures</article-title><source>The Journal of Cell Biology</source><volume>103</volume><fpage>171</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1083/jcb.103.1.171</pub-id><pub-id pub-id-type="pmid">2424918</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyde</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Trobaugh</surname><given-names>DW</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Weaver</surname><given-names>SC</given-names></name><name><surname>Klimstra</surname><given-names>WB</given-names></name><name><surname>Wilusz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The 5’ and 3’ ends of alphavirus RNAs--Non-coding is not non-functional</article-title><source>Virus Research</source><volume>206</volume><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2015.01.016</pub-id><pub-id pub-id-type="pmid">25630058</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iordanov</surname><given-names>MS</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name><name><surname>Magun</surname><given-names>BE</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Activation of NF-kappaB by double-stranded RNA (dsRNA) in the absence of protein kinase R and RNase L demonstrates the existence of two separate dsRNA-triggered antiviral programs</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.1.61-72.2001</pub-id><pub-id pub-id-type="pmid">11113181</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagaya</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Ibtehaz</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Punuru</surname><given-names>PD</given-names></name><name><surname>Kihara</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>NuFold: end-to-end approach for RNA tertiary structure prediction with flexible nucleobase center representation</article-title><source>Nature Communications</source><volume>16</volume><elocation-id>881</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-025-56261-7</pub-id><pub-id pub-id-type="pmid">39837861</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalveram</surname><given-names>B</given-names></name><name><surname>Ikegami</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Toscana virus NSs protein promotes degradation of double-stranded RNA-dependent protein kinase</article-title><source>Journal of Virology</source><volume>87</volume><fpage>3710</fpage><lpage>3718</lpage><pub-id pub-id-type="doi">10.1128/JVI.02506-12</pub-id><pub-id pub-id-type="pmid">23325696</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karasik</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>GD</given-names></name><name><surname>DePass</surname><given-names>AV</given-names></name><name><surname>Guydosh</surname><given-names>NR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Activation of the antiviral factor RNase L triggers translation of non-coding mRNA sequences</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>6007</fpage><lpage>6026</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab036</pub-id><pub-id pub-id-type="pmid">33556964</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YG</given-names></name><name><surname>Baltabekova</surname><given-names>AZ</given-names></name><name><surname>Zhiyenbay</surname><given-names>EE</given-names></name><name><surname>Aksambayeva</surname><given-names>AS</given-names></name><name><surname>Shagyrova</surname><given-names>ZS</given-names></name><name><surname>Khannanov</surname><given-names>R</given-names></name><name><surname>Ramanculov</surname><given-names>EM</given-names></name><name><surname>Shustov</surname><given-names>AV</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Recombinant vaccinia virus-coded interferon inhibitor B18R: expression, refolding and a use in a mammalian expression system with a RNA-vector</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0189308</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0189308</pub-id><pub-id pub-id-type="pmid">29216299</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>A</given-names></name><name><surname>Naka</surname><given-names>T</given-names></name><name><surname>Nagata</surname><given-names>S</given-names></name><name><surname>Kawase</surname><given-names>I</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>SOCS-1 suppresses TNF-alpha-induced apoptosis through the regulation of Jak activation</article-title><source>International Immunology</source><volume>16</volume><fpage>991</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxh102</pub-id><pub-id pub-id-type="pmid">15173123</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Leal</surname><given-names>JM</given-names></name><name><surname>Simpson</surname><given-names>A</given-names></name><name><surname>Warner</surname><given-names>NL</given-names></name><name><surname>Berube</surname><given-names>BJ</given-names></name><name><surname>Archer</surname><given-names>JF</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Kurtz</surname><given-names>R</given-names></name><name><surname>Hinkley</surname><given-names>T</given-names></name><name><surname>Nicholes</surname><given-names>K</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Duthie</surname><given-names>MS</given-names></name><name><surname>Berglund</surname><given-names>P</given-names></name><name><surname>Reed</surname><given-names>SG</given-names></name><name><surname>Khandhar</surname><given-names>AP</given-names></name><name><surname>Erasmus</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation</article-title><source>Molecular Therapy</source><volume>31</volume><fpage>2360</fpage><lpage>2375</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2023.06.017</pub-id><pub-id pub-id-type="pmid">37403357</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>A</given-names></name><name><surname>Aguilera</surname><given-names>L</given-names></name><name><surname>Morisaki</surname><given-names>T</given-names></name><name><surname>Munsky</surname><given-names>B</given-names></name><name><surname>Stasevich</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Quantifying the dynamics of IRES and cap translation with single-molecule resolution in live cells</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>27</volume><fpage>1095</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.1038/s41594-020-0504-7</pub-id><pub-id pub-id-type="pmid">32958947</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krausgruber</surname><given-names>T</given-names></name><name><surname>Fortelny</surname><given-names>N</given-names></name><name><surname>Fife-Gernedl</surname><given-names>V</given-names></name><name><surname>Senekowitsch</surname><given-names>M</given-names></name><name><surname>Schuster</surname><given-names>LC</given-names></name><name><surname>Lercher</surname><given-names>A</given-names></name><name><surname>Nemc</surname><given-names>A</given-names></name><name><surname>Schmidl</surname><given-names>C</given-names></name><name><surname>Rendeiro</surname><given-names>AF</given-names></name><name><surname>Bergthaler</surname><given-names>A</given-names></name><name><surname>Bock</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural cells are key regulators of organ-specific immune responses</article-title><source>Nature</source><volume>583</volume><fpage>296</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2424-4</pub-id><pub-id pub-id-type="pmid">32612232</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DM</given-names></name><name><surname>Kiener</surname><given-names>HP</given-names></name><name><surname>Agarwal</surname><given-names>SK</given-names></name><name><surname>Noss</surname><given-names>EH</given-names></name><name><surname>Watts</surname><given-names>GFM</given-names></name><name><surname>Chisaka</surname><given-names>O</given-names></name><name><surname>Takeichi</surname><given-names>M</given-names></name><name><surname>Brenner</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cadherin-11 in synovial lining formation and pathology in arthritis</article-title><source>Science</source><volume>315</volume><fpage>1006</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1126/science.1137306</pub-id><pub-id pub-id-type="pmid">17255475</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YR</given-names></name><name><surname>Kweon</surname><given-names>SH</given-names></name><name><surname>Kwon</surname><given-names>KB</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Yoon</surname><given-names>TR</given-names></name><name><surname>Park</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inhibition of IL-1beta-mediated inflammatory responses by the IkappaB alpha super-repressor in human fibroblast-like synoviocytes</article-title><source>Biochemical and Biophysical Research Communications</source><volume>378</volume><fpage>90</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.11.002</pub-id><pub-id pub-id-type="pmid">19007749</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leitner</surname><given-names>WW</given-names></name><name><surname>Hwang</surname><given-names>LN</given-names></name><name><surname>Bergmann-Leitner</surname><given-names>ES</given-names></name><name><surname>Finkelstein</surname><given-names>SE</given-names></name><name><surname>Frank</surname><given-names>S</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines</article-title><source>Vaccine</source><volume>22</volume><fpage>1537</fpage><lpage>1544</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2003.10.013</pub-id><pub-id pub-id-type="pmid">15063579</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Minimum cross entropy thresholding</article-title><source>Pattern Recognition</source><volume>26</volume><fpage>617</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1016/0031-3203(93)90115-D</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Xiang</surname><given-names>Y</given-names></name><name><surname>Sabapathy</surname><given-names>K</given-names></name><name><surname>Silverman</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>1123</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1074/jbc.M305893200</pub-id><pub-id pub-id-type="pmid">14570908</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Teague</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Porter</surname><given-names>E</given-names></name><name><surname>Dobosh</surname><given-names>B</given-names></name><name><surname>Wagner</surname><given-names>T</given-names></name><name><surname>Irvine</surname><given-names>DJ</given-names></name><name><surname>Weiss</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>In vitro evolution of enhanced RNA replicons for immunotherapy</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>6932</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-43422-0</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Momin</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Wittrup</surname><given-names>KD</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Irvine</surname><given-names>DJ</given-names></name><name><surname>Weiss</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity</article-title><source>Nature Cancer</source><volume>1</volume><fpage>882</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1038/s43018-020-0095-6</pub-id><pub-id pub-id-type="pmid">34447945</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liau</surname><given-names>NPD</given-names></name><name><surname>Laktyushin</surname><given-names>A</given-names></name><name><surname>Lucet</surname><given-names>IS</given-names></name><name><surname>Murphy</surname><given-names>JM</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Whitlock</surname><given-names>E</given-names></name><name><surname>Callaghan</surname><given-names>K</given-names></name><name><surname>Nicola</surname><given-names>NA</given-names></name><name><surname>Kershaw</surname><given-names>NJ</given-names></name><name><surname>Babon</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The molecular basis of JAK/STAT inhibition by SOCS1</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>1558</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-04013-1</pub-id><pub-id pub-id-type="pmid">29674694</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>TK</given-names></name><name><surname>Ruthazer</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Microglial trogocytosis and the complement system regulate axonal pruning in vivo</article-title><source>eLife</source><volume>10</volume><elocation-id>e62167</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.62167</pub-id><pub-id pub-id-type="pmid">33724186</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>O</given-names></name><name><surname>Wall</surname><given-names>JBJ</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Ruth Vaseghi</surname><given-names>H</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>2193</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-02460-2</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Joo</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>NF-κB signaling in inflammation</article-title><source>Signal Transduction and Targeted Therapy</source><volume>2</volume><elocation-id>17023</elocation-id><pub-id pub-id-type="doi">10.1038/sigtrans.2017.23</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Tracking tools of extracellular vesicles for biomedical research</article-title><source>Frontiers in Bioengineering and Biotechnology</source><volume>10</volume><elocation-id>943712</elocation-id><pub-id pub-id-type="doi">10.3389/fbioe.2022.943712</pub-id><pub-id pub-id-type="pmid">36466335</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundstrom</surname><given-names>K</given-names></name><name><surname>Abenavoli</surname><given-names>A</given-names></name><name><surname>Malgaroli</surname><given-names>A</given-names></name><name><surname>Ehrengruber</surname><given-names>MU</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Novel Semliki Forest virus vectors with reduced cytotoxicity and temperature sensitivity for long-term enhancement of transgene expression</article-title><source>Molecular Therapy</source><volume>7</volume><fpage>202</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/s1525-0016(02)00056-4</pub-id><pub-id pub-id-type="pmid">12597908</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>JL</given-names></name><name><surname>Kamata</surname><given-names>H</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy</article-title><source>The Journal of Clinical Investigation</source><volume>115</volume><fpage>2625</fpage><lpage>2632</lpage><pub-id pub-id-type="doi">10.1172/JCI26322</pub-id><pub-id pub-id-type="pmid">16200195</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madonna</surname><given-names>S</given-names></name><name><surname>Scarponi</surname><given-names>C</given-names></name><name><surname>Pallotta</surname><given-names>S</given-names></name><name><surname>Cavani</surname><given-names>A</given-names></name><name><surname>Albanesi</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasis</article-title><source>Cell Death &amp; Disease</source><volume>3</volume><elocation-id>e334</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2012.69</pub-id><pub-id pub-id-type="pmid">22739986</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maglaviceanu</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Kapoor</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Fibroblast-like synoviocytes: Role in synovial fibrosis associated with osteoarthritis</article-title><source>Wound Repair and Regeneration</source><volume>29</volume><fpage>642</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1111/wrr.12939</pub-id><pub-id pub-id-type="pmid">34021514</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann-Chandler</surname><given-names>MN</given-names></name><name><surname>Kashyap</surname><given-names>M</given-names></name><name><surname>Wright</surname><given-names>HV</given-names></name><name><surname>Norozian</surname><given-names>F</given-names></name><name><surname>Barnstein</surname><given-names>BO</given-names></name><name><surname>Gingras</surname><given-names>S</given-names></name><name><surname>Parganas</surname><given-names>E</given-names></name><name><surname>Ryan</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>IFN-gamma induces apoptosis in developing mast cells</article-title><source>Journal of Immunology</source><volume>175</volume><fpage>3000</fpage><lpage>3005</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.5.3000</pub-id><pub-id pub-id-type="pmid">16116187</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mars</surname><given-names>JC</given-names></name><name><surname>Culjkovic-Kraljacic</surname><given-names>B</given-names></name><name><surname>Borden</surname><given-names>KLB</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>eIF4E orchestrates mRNA processing, RNA export and translation to modify specific protein production</article-title><source>Nucleus</source><volume>15</volume><elocation-id>2360196</elocation-id><pub-id pub-id-type="doi">10.1080/19491034.2024.2360196</pub-id><pub-id pub-id-type="pmid">38880976</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruggi</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Ulmer</surname><given-names>JB</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>mRNA as a transformative technology for vaccine development to control infectious diseases</article-title><source>Molecular Therapy</source><volume>27</volume><fpage>757</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.01.020</pub-id><pub-id pub-id-type="pmid">30803823</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastrangelo</surname><given-names>AJ</given-names></name><name><surname>Hardwick</surname><given-names>JM</given-names></name><name><surname>Bex</surname><given-names>F</given-names></name><name><surname>Betenbaugh</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Part I. Bcl-2 and Bcl-x(L) limit apoptosis upon infection with alphavirus vectors</article-title><source>Biotechnology and Bioengineering</source><volume>67</volume><fpage>544</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">10649229</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGee</surname><given-names>JE</given-names></name><name><surname>Kirsch</surname><given-names>JR</given-names></name><name><surname>Kenney</surname><given-names>D</given-names></name><name><surname>Cerbo</surname><given-names>F</given-names></name><name><surname>Chavez</surname><given-names>EC</given-names></name><name><surname>Shih</surname><given-names>TY</given-names></name><name><surname>Douam</surname><given-names>F</given-names></name><name><surname>Wong</surname><given-names>WW</given-names></name><name><surname>Grinstaff</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency</article-title><source>Nature Biotechnology</source><volume>43</volume><fpage>720</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1038/s41587-024-02306-z</pub-id><pub-id pub-id-type="pmid">38977924</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merrick</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Cap-dependent and cap-independent translation in eukaryotic systems</article-title><source>Gene</source><volume>332</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2004.02.051</pub-id><pub-id pub-id-type="pmid">15145049</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miagkov</surname><given-names>AV</given-names></name><name><surname>Kovalenko</surname><given-names>DV</given-names></name><name><surname>Brown</surname><given-names>CE</given-names></name><name><surname>Didsbury</surname><given-names>JR</given-names></name><name><surname>Cogswell</surname><given-names>JP</given-names></name><name><surname>Stimpson</surname><given-names>SA</given-names></name><name><surname>Baldwin</surname><given-names>AS</given-names></name><name><surname>Makarov</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint</article-title><source>PNAS</source><volume>95</volume><fpage>13859</fpage><lpage>13864</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.23.13859</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minnaert</surname><given-names>A-K</given-names></name><name><surname>Vanluchene</surname><given-names>H</given-names></name><name><surname>Verbeke</surname><given-names>R</given-names></name><name><surname>Lentacker</surname><given-names>I</given-names></name><name><surname>De Smedt</surname><given-names>SC</given-names></name><name><surname>Raemdonck</surname><given-names>K</given-names></name><name><surname>Sanders</surname><given-names>NN</given-names></name><name><surname>Remaut</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: getting the message across</article-title><source>Advanced Drug Delivery Reviews</source><volume>176</volume><elocation-id>113900</elocation-id><pub-id pub-id-type="doi">10.1016/j.addr.2021.113900</pub-id><pub-id pub-id-type="pmid">34324884</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>JP</given-names></name><name><surname>Carmody</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><chapter-title>Chapter two - NF-κb and the transcriptional control of inflammation</chapter-title><person-group person-group-type="editor"><name><surname>Loos</surname><given-names>F</given-names></name></person-group><source>International Review of Cell and Molecular Biology: Transcriptional Gene Regulation in Health and Disease</source><publisher-name>Academic Press</publisher-name><fpage>41</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/bs.ircmb.2017.07.007</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mousavi</surname><given-names>MJ</given-names></name><name><surname>Karami</surname><given-names>J</given-names></name><name><surname>Aslani</surname><given-names>S</given-names></name><name><surname>Tahmasebi</surname><given-names>MN</given-names></name><name><surname>Vaziri</surname><given-names>AS</given-names></name><name><surname>Jamshidi</surname><given-names>A</given-names></name><name><surname>Farhadi</surname><given-names>E</given-names></name><name><surname>Mahmoudi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transformation of fibroblast-like synoviocytes in rheumatoid arthritis; from a friend to foe</article-title><source>Auto- Immunity Highlights</source><volume>12</volume><elocation-id>3</elocation-id><pub-id pub-id-type="doi">10.1186/s13317-020-00145-x</pub-id><pub-id pub-id-type="pmid">33546769</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muta</surname><given-names>D</given-names></name><name><surname>Makino</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Yano</surname><given-names>S</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Kuratsu</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Inhibition of eIF4E phosphorylation reduces cell growth and proliferation in primary central nervous system lymphoma cells</article-title><source>Journal of Neuro-Oncology</source><volume>101</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1007/s11060-010-0233-6</pub-id><pub-id pub-id-type="pmid">20499137</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oda</surname><given-names>Y</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><name><surname>Kanai</surname><given-names>M</given-names></name><name><surname>Iwama</surname><given-names>Y</given-names></name><name><surname>Okura</surname><given-names>I</given-names></name><name><surname>Minamida</surname><given-names>T</given-names></name><name><surname>Yagi</surname><given-names>Y</given-names></name><name><surname>Kurosawa</surname><given-names>T</given-names></name><name><surname>Greener</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Walson</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial</article-title><source>The Lancet. Infectious Diseases</source><volume>24</volume><fpage>351</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00650-3</pub-id><pub-id pub-id-type="pmid">38141632</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouellet</surname><given-names>S</given-names></name><name><surname>Ferguson</surname><given-names>L</given-names></name><name><surname>Lau</surname><given-names>AZ</given-names></name><name><surname>Lim</surname><given-names>TKY</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>CysPresso: a classification model utilizing deep learning protein representations to predict recombinant expression of cysteine-dense peptides</article-title><source>BMC Bioinformatics</source><volume>24</volume><elocation-id>200</elocation-id><pub-id pub-id-type="doi">10.1186/s12859-023-05327-8</pub-id><pub-id pub-id-type="pmid">37193950</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patil</surname><given-names>S</given-names></name><name><surname>Wildey</surname><given-names>GM</given-names></name><name><surname>Brown</surname><given-names>TL</given-names></name><name><surname>Choy</surname><given-names>L</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name><name><surname>Howe</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-beta -induced growth inhibition and apoptosis</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>38363</fpage><lpage>38370</lpage><pub-id pub-id-type="doi">10.1074/jbc.M004861200</pub-id><pub-id pub-id-type="pmid">10995749</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>D</given-names></name><name><surname>Bartenschlager</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Architecture and biogenesis of plus-strand RNA virus replication factories</article-title><source>World Journal of Virology</source><volume>2</volume><fpage>32</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.5501/wjv.v2.i2.32</pub-id><pub-id pub-id-type="pmid">24175228</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pepini</surname><given-names>T</given-names></name><name><surname>Pulichino</surname><given-names>A-M</given-names></name><name><surname>Carsillo</surname><given-names>T</given-names></name><name><surname>Carlson</surname><given-names>AL</given-names></name><name><surname>Sari-Sarraf</surname><given-names>F</given-names></name><name><surname>Ramsauer</surname><given-names>K</given-names></name><name><surname>Debasitis</surname><given-names>JC</given-names></name><name><surname>Maruggi</surname><given-names>G</given-names></name><name><surname>Otten</surname><given-names>GR</given-names></name><name><surname>Geall</surname><given-names>AJ</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Ulmer</surname><given-names>JB</given-names></name><name><surname>Iavarone</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Induction of an IFN-Mediated Antiviral response by a self-amplifying RNA vaccine: implications for vaccine design</article-title><source>Journal of Immunology</source><volume>198</volume><fpage>4012</fpage><lpage>4024</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601877</pub-id><pub-id pub-id-type="pmid">28416600</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietilä</surname><given-names>MK</given-names></name><name><surname>Hellström</surname><given-names>K</given-names></name><name><surname>Ahola</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Alphavirus polymerase and RNA replication</article-title><source>Virus Research</source><volume>234</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2017.01.007</pub-id><pub-id pub-id-type="pmid">28104453</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravi</surname><given-names>V</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Sundaresan</surname><given-names>NR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Measuring protein synthesis in cultured cells and mouse tissues using the non-radioaassctive SUnSET Assay</article-title><source>Current Protocols in Molecular Biology</source><volume>133</volume><elocation-id>e127</elocation-id><pub-id pub-id-type="doi">10.1002/cpmb.127</pub-id><pub-id pub-id-type="pmid">33217166</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehwinkel</surname><given-names>J</given-names></name><name><surname>Gack</surname><given-names>MU</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>RIG-I-like receptors: their regulation and roles in RNA sensing</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><fpage>537</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0288-3</pub-id><pub-id pub-id-type="pmid">32203325</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rio</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Denaturation and electrophoresis of RNA with glyoxal</article-title><source>Cold Spring Harbor Protocols</source><volume>2015</volume><fpage>223</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1101/pdb.prot081000</pub-id><pub-id pub-id-type="pmid">25646499</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosa</surname><given-names>SS</given-names></name><name><surname>Prazeres</surname><given-names>DMF</given-names></name><name><surname>Azevedo</surname><given-names>AM</given-names></name><name><surname>Marques</surname><given-names>MPC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>mRNA vaccines manufacturing: challenges and bottlenecks</article-title><source>Vaccine</source><volume>39</volume><fpage>2190</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.03.038</pub-id><pub-id pub-id-type="pmid">33771389</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sago</surname><given-names>CD</given-names></name><name><surname>Krupczak</surname><given-names>BR</given-names></name><name><surname>Lokugamage</surname><given-names>MP</given-names></name><name><surname>Gan</surname><given-names>Z</given-names></name><name><surname>Dahlman</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cell subtypes within the liver microenvironment differentially interact with lipid nanoparticles</article-title><source>Cellular and Molecular Bioengineering</source><volume>12</volume><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1007/s12195-019-00573-4</pub-id><pub-id pub-id-type="pmid">31719922</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samnuan</surname><given-names>K</given-names></name><name><surname>Blakney</surname><given-names>AK</given-names></name><name><surname>McKay</surname><given-names>PF</given-names></name><name><surname>Shattock</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Design-of-experiments in vitro transcription yield optimization of self-amplifying RNA</article-title><source>F1000Research</source><volume>11</volume><elocation-id>333</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.75677.1</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>MG</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Amici</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>NF-kappaB and virus infection: who controls whom</article-title><source>The EMBO Journal</source><volume>22</volume><fpage>2552</fpage><lpage>2560</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg267</pub-id><pub-id pub-id-type="pmid">12773372</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saraf</surname><given-names>A</given-names></name><name><surname>Gurjar</surname><given-names>R</given-names></name><name><surname>Kaviraj</surname><given-names>S</given-names></name><name><surname>Kulkarni</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Kulkarni</surname><given-names>R</given-names></name><name><surname>Virkar</surname><given-names>R</given-names></name><name><surname>Krishnan</surname><given-names>J</given-names></name><name><surname>Yadav</surname><given-names>A</given-names></name><name><surname>Baranwal</surname><given-names>E</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Raghuwanshi</surname><given-names>A</given-names></name><name><surname>Agarwal</surname><given-names>P</given-names></name><name><surname>Savergave</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><collab>GEMCOVAC-OM Study Investigators</collab></person-group><year iso-8601-date="2024">2024</year><article-title>An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial</article-title><source>Nature Medicine</source><volume>30</volume><fpage>1363</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1038/s41591-024-02955-2</pub-id><pub-id pub-id-type="pmid">38637636</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheper</surname><given-names>GC</given-names></name><name><surname>Proud</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation?</article-title><source>European Journal of Biochemistry</source><volume>269</volume><fpage>5350</fpage><lpage>5359</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1033.2002.03291.x</pub-id><pub-id pub-id-type="pmid">12423333</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>EK</given-names></name><name><surname>Clavarino</surname><given-names>G</given-names></name><name><surname>Ceppi</surname><given-names>M</given-names></name><name><surname>Pierre</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>SUnSET, a nonradioactive method to monitor protein synthesis</article-title><source>Nature Methods</source><volume>6</volume><fpage>275</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1314</pub-id><pub-id pub-id-type="pmid">19305406</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>A</given-names></name><name><surname>Mueller</surname><given-names>O</given-names></name><name><surname>Stocker</surname><given-names>S</given-names></name><name><surname>Salowsky</surname><given-names>R</given-names></name><name><surname>Leiber</surname><given-names>M</given-names></name><name><surname>Gassmann</surname><given-names>M</given-names></name><name><surname>Lightfoot</surname><given-names>S</given-names></name><name><surname>Menzel</surname><given-names>W</given-names></name><name><surname>Granzow</surname><given-names>M</given-names></name><name><surname>Ragg</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The RIN: an RNA integrity number for assigning integrity values to RNA measurements</article-title><source>BMC Molecular Biology</source><volume>7</volume><elocation-id>3</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2199-7-3</pub-id><pub-id pub-id-type="pmid">16448564</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>CE</given-names></name><name><surname>Yao</surname><given-names>T</given-names></name><name><surname>Sotsky</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Chu</surname><given-names>Y-K</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Tower</surname><given-names>NA</given-names></name><name><surname>Noah</surname><given-names>JW</given-names></name><name><surname>McKellip</surname><given-names>S</given-names></name><name><surname>Sosa</surname><given-names>M</given-names></name><name><surname>Rasmussen</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>LH</given-names></name><name><surname>White</surname><given-names>EL</given-names></name><name><surname>Aubé</surname><given-names>J</given-names></name><name><surname>Jonsson</surname><given-names>CB</given-names></name><name><surname>Chung</surname><given-names>D</given-names></name><name><surname>Golden</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus</article-title><source>Journal of Medicinal Chemistry</source><volume>57</volume><fpage>8608</fpage><lpage>8621</lpage><pub-id pub-id-type="doi">10.1021/jm501203v</pub-id><pub-id pub-id-type="pmid">25244572</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hong</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Accurate RNA 3D structure prediction using a language model-based deep learning approach</article-title><source>Nat Methods</source><volume>21</volume><fpage>2287</fpage><lpage>2298</lpage><pub-id pub-id-type="doi">10.1038/s41592-024-02487-0</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Viral encounters with 2’,5’-oligoadenylate synthetase and RNase L during the interferon antiviral response</article-title><source>Journal of Virology</source><volume>81</volume><fpage>12720</fpage><lpage>12729</lpage><pub-id pub-id-type="doi">10.1128/JVI.01471-07</pub-id><pub-id pub-id-type="pmid">17804500</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skidmore</surname><given-names>AM</given-names></name><name><surname>Adcock</surname><given-names>RS</given-names></name><name><surname>Jonsson</surname><given-names>CB</given-names></name><name><surname>Golden</surname><given-names>JE</given-names></name><name><surname>Chung</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Benzamidine ML336 inhibits plus and minus strand RNA synthesis of Venezuelan equine encephalitis virus without affecting host RNA production</article-title><source>Antiviral Research</source><volume>174</volume><elocation-id>104674</elocation-id><pub-id pub-id-type="doi">10.1016/j.antiviral.2019.104674</pub-id><pub-id pub-id-type="pmid">31816348</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snieckute</surname><given-names>G</given-names></name><name><surname>Genzor</surname><given-names>AV</given-names></name><name><surname>Vind</surname><given-names>AC</given-names></name><name><surname>Ryder</surname><given-names>L</given-names></name><name><surname>Stoneley</surname><given-names>M</given-names></name><name><surname>Chamois</surname><given-names>S</given-names></name><name><surname>Dreos</surname><given-names>R</given-names></name><name><surname>Nordgaard</surname><given-names>C</given-names></name><name><surname>Sass</surname><given-names>F</given-names></name><name><surname>Blasius</surname><given-names>M</given-names></name><name><surname>López</surname><given-names>AR</given-names></name><name><surname>Brynjólfsdóttir</surname><given-names>SH</given-names></name><name><surname>Andersen</surname><given-names>KL</given-names></name><name><surname>Willis</surname><given-names>AE</given-names></name><name><surname>Frankel</surname><given-names>LB</given-names></name><name><surname>Poulsen</surname><given-names>SS</given-names></name><name><surname>Gatfield</surname><given-names>D</given-names></name><name><surname>Gerhart-Hines</surname><given-names>Z</given-names></name><name><surname>Clemmensen</surname><given-names>C</given-names></name><name><surname>Bekker-Jensen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Ribosome stalling is a signal for metabolic regulation by the ribotoxic stress response</article-title><source>Cell Metabolism</source><volume>34</volume><fpage>2036</fpage><lpage>2046</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2022.10.011</pub-id><pub-id pub-id-type="pmid">36384144</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobah</surname><given-names>ML</given-names></name><name><surname>Liongue</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SOCS proteins in immunity, inflammatory diseases, and immune-related cancer</article-title><source>Front Med</source><volume>8</volume><elocation-id>727987</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2021.727987</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorgeloos</surname><given-names>F</given-names></name><name><surname>Jha</surname><given-names>BK</given-names></name><name><surname>Silverman</surname><given-names>RH</given-names></name><name><surname>Michiels</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Evasion of antiviral innate immunity by Theiler’s virus L* protein through direct inhibition of RNase L</article-title><source>PLOS Pathogens</source><volume>9</volume><elocation-id>e1003474</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003474</pub-id><pub-id pub-id-type="pmid">23825954</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szczerba</surname><given-names>M</given-names></name><name><surname>Subramanian</surname><given-names>S</given-names></name><name><surname>Trainor</surname><given-names>K</given-names></name><name><surname>McCaughan</surname><given-names>M</given-names></name><name><surname>Kibler</surname><given-names>KV</given-names></name><name><surname>Jacobs</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Small hero with great powers: vaccinia virus E3 Protein and Evasion of the Type I IFN Response</article-title><source>Biomedicines</source><volume>10</volume><elocation-id>235</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10020235</pub-id><pub-id pub-id-type="pmid">35203445</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terenzi</surname><given-names>F</given-names></name><name><surname>deVeer</surname><given-names>MJ</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Williams</surname><given-names>BR</given-names></name><name><surname>Silverman</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The antiviral enzymes PKR and RNase L suppress gene expression from viral and non-viral based vectors</article-title><source>Nucleic Acids Research</source><volume>27</volume><fpage>4369</fpage><lpage>4375</lpage><pub-id pub-id-type="doi">10.1093/nar/27.22.4369</pub-id><pub-id pub-id-type="pmid">10536144</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tregoning</surname><given-names>JS</given-names></name><name><surname>Stirling</surname><given-names>DC</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Flight</surname><given-names>KE</given-names></name><name><surname>Brown</surname><given-names>JC</given-names></name><name><surname>Blakney</surname><given-names>AK</given-names></name><name><surname>McKay</surname><given-names>PF</given-names></name><name><surname>Cunliffe</surname><given-names>RF</given-names></name><name><surname>Murugaiah</surname><given-names>V</given-names></name><name><surname>Fox</surname><given-names>CB</given-names></name><name><surname>Beattie</surname><given-names>M</given-names></name><name><surname>Tam</surname><given-names>YK</given-names></name><name><surname>Johansson</surname><given-names>C</given-names></name><name><surname>Shattock</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines</article-title><source>Molecular Therapy. Nucleic Acids</source><volume>31</volume><fpage>29</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2022.11.024</pub-id><pub-id pub-id-type="pmid">36589712</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valencia</surname><given-names>X</given-names></name><name><surname>Higgins</surname><given-names>JMG</given-names></name><name><surname>Kiener</surname><given-names>HP</given-names></name><name><surname>Lee</surname><given-names>DM</given-names></name><name><surname>Podrebarac</surname><given-names>TA</given-names></name><name><surname>Dascher</surname><given-names>CC</given-names></name><name><surname>Watts</surname><given-names>GFM</given-names></name><name><surname>Mizoguchi</surname><given-names>E</given-names></name><name><surname>Simmons</surname><given-names>B</given-names></name><name><surname>Patel</surname><given-names>DD</given-names></name><name><surname>Bhan</surname><given-names>AK</given-names></name><name><surname>Brenner</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes</article-title><source>The Journal of Experimental Medicine</source><volume>200</volume><fpage>1673</fpage><lpage>1679</lpage><pub-id pub-id-type="doi">10.1084/jem.20041545</pub-id><pub-id pub-id-type="pmid">15611293</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Genderen</surname><given-names>H</given-names></name><name><surname>Kenis</surname><given-names>H</given-names></name><name><surname>Lux</surname><given-names>P</given-names></name><name><surname>Ungeth</surname><given-names>L</given-names></name><name><surname>Maassen</surname><given-names>C</given-names></name><name><surname>Deckers</surname><given-names>N</given-names></name><name><surname>Narula</surname><given-names>J</given-names></name><name><surname>Hofstra</surname><given-names>L</given-names></name><name><surname>Reutelingsperger</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>In vitro measurement of cell death with the annexin A5 affinity assay</article-title><source>Nature Protocols</source><volume>1</volume><fpage>363</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.55</pub-id><pub-id pub-id-type="pmid">17406257</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanluchene</surname><given-names>H</given-names></name><name><surname>Gillon</surname><given-names>O</given-names></name><name><surname>Peynshaert</surname><given-names>K</given-names></name><name><surname>De Smedt</surname><given-names>SC</given-names></name><name><surname>Sanders</surname><given-names>N</given-names></name><name><surname>Raemdonck</surname><given-names>K</given-names></name><name><surname>Remaut</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Less is more: Self-amplifying mRNA becomes self-killing upon dose escalation in immune-competent retinal cells</article-title><source>European Journal of Pharmaceutics and Biopharmaceutics</source><volume>196</volume><elocation-id>114204</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejpb.2024.114204</pub-id><pub-id pub-id-type="pmid">38302048</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venticinque</surname><given-names>L</given-names></name><name><surname>Meruelo</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sindbis viral vector induced apoptosis requires translational inhibition and signaling through Mcl-1 and Bak</article-title><source>Molecular Cancer</source><volume>9</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1186/1476-4598-9-37</pub-id><pub-id pub-id-type="pmid">20152035</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Roretz</surname><given-names>C</given-names></name><name><surname>Gallouzi</surname><given-names>IE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Protein kinase RNA/FADD/caspase-8 pathway mediates the proapoptotic activity of the RNA-binding protein human antigen R (HuR)</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>16806</fpage><lpage>16813</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.087320</pub-id><pub-id pub-id-type="pmid">20353946</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelan</surname><given-names>JN</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Silverman</surname><given-names>RH</given-names></name><name><surname>Weiss</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Zika virus production is resistant to RNase L antiviral activity</article-title><source>Journal of Virology</source><volume>93</volume><fpage>e00313</fpage><lpage>e00319</lpage><pub-id pub-id-type="doi">10.1128/JVI.00313-19</pub-id><pub-id pub-id-type="pmid">31142667</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>YY</given-names></name><name><surname>Sun</surname><given-names>TK</given-names></name><name><surname>Chen</surname><given-names>MS</given-names></name><name><surname>Munir</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>13</volume><elocation-id>1142172</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2023.1142172</pub-id><pub-id pub-id-type="pmid">37009515</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>J</given-names></name><name><surname>Snieckute</surname><given-names>G</given-names></name><name><surname>Martínez</surname><given-names>JF</given-names></name><name><surname>Arendrup</surname><given-names>FSW</given-names></name><name><surname>Asthana</surname><given-names>A</given-names></name><name><surname>Gaughan</surname><given-names>C</given-names></name><name><surname>Lund</surname><given-names>AH</given-names></name><name><surname>Bekker-Jensen</surname><given-names>S</given-names></name><name><surname>Silverman</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Initiation of a ZAKα-dependent ribotoxic stress response by the innate immunity endoribonuclease RNase L</article-title><source>Cell Reports</source><volume>43</volume><elocation-id>113998</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2024.113998</pub-id><pub-id pub-id-type="pmid">38551960</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Bialik</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>BE</given-names></name><name><surname>Iimuro</surname><given-names>Y</given-names></name><name><surname>Kitsis</surname><given-names>RN</given-names></name><name><surname>Srinivasan</surname><given-names>A</given-names></name><name><surname>Brenner</surname><given-names>DA</given-names></name><name><surname>Czaja</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>NF-kappaB inactivation converts a hepatocyte cell line TNF-alpha response from proliferation to apoptosis</article-title><source>The American Journal of Physiology</source><volume>275</volume><fpage>C1058</fpage><lpage>C1066</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.1998.275.4.C1058</pub-id><pub-id pub-id-type="pmid">9755059</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Gamil</surname><given-names>AAA</given-names></name><name><surname>Munang’andu</surname><given-names>HM</given-names></name><name><surname>Evensen</surname><given-names>Ø</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Apoptosis induction by dsrna-dependent protein kinase R (PKR) in EPC cells via caspase 8 and 9 pathways</article-title><source>Viruses</source><volume>10</volume><elocation-id>526</elocation-id><pub-id pub-id-type="doi">10.3390/v10100526</pub-id><pub-id pub-id-type="pmid">30261686</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Hou</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>DD</given-names></name><name><surname>Deng</surname><given-names>B</given-names></name><name><surname>McComb</surname><given-names>DW</given-names></name><name><surname>Irvine</surname><given-names>DJ</given-names></name><name><surname>Weiss</surname><given-names>R</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>LNP-RNA-engineered adipose stem cells for accelerated diabetic wound healing</article-title><source>Nature Communications</source><volume>15</volume><elocation-id>739</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-45094-5</pub-id><pub-id pub-id-type="pmid">38272900</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamura</surname><given-names>Y</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name><name><surname>Bergelson</surname><given-names>S</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Critical role of Smads and AP-1 complex in transforming growth factor-beta -dependent apoptosis</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>36295</fpage><lpage>36302</lpage><pub-id pub-id-type="doi">10.1074/jbc.M006023200</pub-id><pub-id pub-id-type="pmid">10942775</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>SOCS-1 inhibits TNF-alpha-induced cardiomyocyte apoptosis via ERK1/2 pathway activation</article-title><source>Inflammation</source><volume>31</volume><fpage>180</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1007/s10753-008-9063-5</pub-id><pub-id pub-id-type="pmid">18330685</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Regulation of TGF-beta signaling by Smad7</article-title><source>Acta Biochimica et Biophysica Sinica</source><volume>41</volume><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1093/abbs/gmp018</pub-id><pub-id pub-id-type="pmid">19352540</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>IRES-mediated cap-independent translation, a path leading to hidden proteome</article-title><source>Journal of Molecular Cell Biology</source><volume>11</volume><fpage>911</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mjz091</pub-id><pub-id pub-id-type="pmid">31504667</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>N</given-names></name><name><surname>Gros</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>H-R</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Deacon</surname><given-names>DC</given-names></name><name><surname>Maron</surname><given-names>C</given-names></name><name><surname>Muotri</surname><given-names>AR</given-names></name><name><surname>Chi</surname><given-names>NC</given-names></name><name><surname>Fu</surname><given-names>X-D</given-names></name><name><surname>Yu</surname><given-names>BD</given-names></name><name><surname>Dowdy</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Efficient generation of human iPSCs by a synthetic self-replicative RNA</article-title><source>Cell Stem Cell</source><volume>13</volume><fpage>246</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.06.001</pub-id><pub-id pub-id-type="pmid">23910086</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>HG</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Bilbao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Curiel</surname><given-names>DT</given-names></name><name><surname>Mountz</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor necrosis factor alpha-induced apoptosis of human synovial fibroblasts</article-title><source>Arthritis and Rheumatism</source><volume>43</volume><fpage>1094</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(200005)43:5&lt;1094::AID-ANR20&gt;3.0.CO;2-V</pub-id><pub-id pub-id-type="pmid">10817564</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Samuel</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Protein kinase PKR plays a stimulus- and virus-dependent role in apoptotic death and virus multiplication in human cells</article-title><source>Journal of Virology</source><volume>81</volume><fpage>8192</fpage><lpage>8200</lpage><pub-id pub-id-type="doi">10.1128/JVI.00426-07</pub-id><pub-id pub-id-type="pmid">17522227</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>HE</given-names></name><name><surname>Hamson</surname><given-names>EJ</given-names></name><name><surname>Koczorowska</surname><given-names>MM</given-names></name><name><surname>Tholen</surname><given-names>S</given-names></name><name><surname>Chowdhury</surname><given-names>S</given-names></name><name><surname>Bailey</surname><given-names>CG</given-names></name><name><surname>Lay</surname><given-names>AJ</given-names></name><name><surname>Twigg</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>Q</given-names></name><name><surname>Roediger</surname><given-names>B</given-names></name><name><surname>Biniossek</surname><given-names>ML</given-names></name><name><surname>O’Rourke</surname><given-names>MB</given-names></name><name><surname>McCaughan</surname><given-names>GW</given-names></name><name><surname>Keane</surname><given-names>FM</given-names></name><name><surname>Schilling</surname><given-names>O</given-names></name><name><surname>Gorrell</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification of novel natural substrates of fibroblast activation protein-alpha by differential degradomics and proteomics</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>18</volume><fpage>65</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1074/mcp.RA118.001046</pub-id><pub-id pub-id-type="pmid">30257879</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Z</given-names></name><name><surname>McCafferty</surname><given-names>S</given-names></name><name><surname>Opsomer</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Huysmans</surname><given-names>H</given-names></name><name><surname>De Temmerman</surname><given-names>J</given-names></name><name><surname>Lienenklaus</surname><given-names>S</given-names></name><name><surname>Portela Catani</surname><given-names>JP</given-names></name><name><surname>Combes</surname><given-names>F</given-names></name><name><surname>Sanders</surname><given-names>NN</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Corticosteroids and cellulose purification improve, respectively, the in vivo translation and vaccination efficacy of sa-mRNAs</article-title><source>Molecular Therapy</source><volume>29</volume><fpage>1370</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.01.023</pub-id><pub-id pub-id-type="pmid">33484964</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zitzmann</surname><given-names>K</given-names></name><name><surname>Brand</surname><given-names>S</given-names></name><name><surname>De Toni</surname><given-names>EN</given-names></name><name><surname>Baehs</surname><given-names>S</given-names></name><name><surname>Göke</surname><given-names>B</given-names></name><name><surname>Meinecke</surname><given-names>J</given-names></name><name><surname>Spöttl</surname><given-names>G</given-names></name><name><surname>Meyer</surname><given-names>HHHD</given-names></name><name><surname>Auernhammer</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells</article-title><source>Cancer Research</source><volume>67</volume><fpage>5025</fpage><lpage>5032</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2575</pub-id><pub-id pub-id-type="pmid">17510435</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>W</given-names></name><name><surname>Wakimoto</surname><given-names>M</given-names></name><name><surname>Kozaiwa</surname><given-names>N</given-names></name><name><surname>Shirasaka</surname><given-names>Y</given-names></name><name><surname>Oh</surname><given-names>SW</given-names></name><name><surname>Fujiwara</surname><given-names>S</given-names></name><name><surname>Miyachi</surname><given-names>H</given-names></name><name><surname>Kogure</surname><given-names>A</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>PKR and TLR3 trigger distinct signals that coordinate the induction of antiviral apoptosis</article-title><source>Cell Death &amp; Disease</source><volume>13</volume><elocation-id>707</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-022-05101-3</pub-id><pub-id pub-id-type="pmid">35970851</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Development and validation of a microplate assay for longitudinal monitoring of cap-dependent and cap-independent transgene expression and cell number</title><p>Self-amplifying RNA (saRNA) replication can trigger innate immune responses, leading to shutdown of cap-dependent translation and cytotoxicity (<xref ref-type="bibr" rid="bib39">Frolov and Schlesinger, 1994</xref>; <xref ref-type="bibr" rid="bib124">Venticinque and Meruelo, 2010</xref>; <xref ref-type="bibr" rid="bib86">Mastrangelo et al., 2000</xref>; <xref ref-type="bibr" rid="bib41">Frolov et al., 1999</xref>), affecting transgene expression. To monitor subgenomic-driven (cap-dependent) and IRES-driven (cap-independent) transgene expression and cell number longitudinally within live cells over several weeks, we developed a novel microplate-based assay. This approach enables higher throughput than microscopy-based assays, avoids destructive, single time-point methods, and eliminates the labor-intensive sample preparation required for viability staining or western blotting.</p><p>Our assay utilizes dual-reporter saRNA constructs (main text, <xref ref-type="fig" rid="fig1">Figure 1a</xref>) that co-express at least two fluorescent proteins. These constructs report on two distinct modes of translation: mScarlet3 is expressed from the subgenomic RNA via cap-dependent initiation, while EGFP is expressed from an EMCV IRES to report on cap-independent initiation. To concurrently track cell number, cells were pre-stained with BioTracker NIR680, a near-infrared lipophilic carbocyanine membrane dye for long-term fluorescent labeling of cells (<xref ref-type="bibr" rid="bib56">Honig and Hume, 1986</xref>). This design allows for three parameters to be quantified in tandem using an Odyssey M microplate imager: cap-dependent transgene expression (mScarlet3, 520 channel), cap-independent transgene expression (EGFP, 488 channel), and cell number (BioTracker NIR680, 700 channel).</p><p>We validated the assay in primary mouse fibroblast-like synoviocytes (FLS) derived from patellar explants. The identity of these cells was first confirmed by positive immunofluorescent staining for the FLS marker Cadherin-11 (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>; <xref ref-type="bibr" rid="bib67">Lee et al., 2007</xref>; <xref ref-type="bibr" rid="bib121">Valencia et al., 2004</xref>).</p><p>Next, we validated the use of BioTracker NIR680 for indicating cell number and compared its performance to the viability dye calcein AM (<xref ref-type="bibr" rid="bib15">Bratosin et al., 2005</xref>). We observed that mock transfection with the lipid-based agent Lipofectamine MessengerMAX increased the baseline fluorescence of BioTracker NIR680 compared to non-transfected cells (<xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2a and b</xref>). This is likely due to the dye interacting with the lipid components of the transfection reagent, as carbocyanine dyes fluoresce brightly upon integration into lipid bilayers.</p><p>To confirm that BioTracker NIR680 fluorescence still reliably reported changes in cell number despite this baseline shift, we treated mock-transfected cells with the apoptosis inducer staurosporine (<xref ref-type="bibr" rid="bib9">Bertrand et al., 1994</xref>). This treatment caused a significant reduction in BioTracker NIR680 fluorescence, demonstrating its sensitivity to cell death (<xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2c and d</xref>). In comparison, calcein AM fluorescence was unaffected by mock transfection but was similarly reduced by staurosporine. These results support the use of BioTracker NIR680 for tracking relative cell number, as it is spectrally distinct from our reporters and does not require post-transfection staining or wash steps.</p><p>Finally, we addressed the potential for spectral overlap between EGFP and mScarlet3 signals when measured with the Odyssey M imager. Using saRNA constructs expressing only EGFP or mScarlet3 (<xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3a</xref>), we quantified the signal bleed-through between the 488 and 520 channels (<xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3b</xref>). Based on this, we established and applied a linear unmixing algorithm to separate the two fluorescent signals in all subsequent experiments (<xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3c</xref>). We also confirmed that a third fluorescent protein, moxBFP, used as a control in some experiments, produced no detectable signal in either the EGFP or mScarlet3 channels, ensuring no interference.</p><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>Confocal microscopy images confirming fibroblast-like synoviocyte (FLS) identity of primary cells isolated from mouse patellar explants.</title><p>Cells were labelled with BioTracker NIR680 (lipophilic membrane dye) and Hoechst 33342 (nuclear stain). The top row shows cells treated with rabbit anti-cadherin-11 (CDH11) primary antibody, while the bottom row presents the no-primary control to verify specificity. Isolated cells exhibit positive CDH11 immunostaining, an established FLS marker. Scale bar = 200 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-app1-fig1-v2.tif"/></fig><fig id="app1fig2" position="float"><label>Appendix 1—figure 2.</label><caption><title>BioTracker fluorescence indicates cell number following staurosporine-induced apoptosis, despite an increase after mock transfection.</title><p>(<bold>a</bold>) Representative microplate images of FLS stained with BioTracker under three conditions: no transfection control, mock transfection, and mock transfection with 1 μM staurosporine. Scale bar = 5 mm. (<bold>b</bold>) Quantification of BioTracker fluorescence (n=3). BioTracker signal increases after mock transfection but decreases following staurosporine treatment. (<bold>c</bold>) Representative images of the same FLS in panel (a) stained with calcein AM, a viability dye. Scale bar = 5 mm. (<bold>d</bold>) Quantification of calcein AM fluorescence (n=3). Calcein AM fluorescence does not increase after mock transfection but decreases after staurosporine treatment. For panels (b,d): Statistical significance was determined by two-way repeated-measures ANOVA with Dunnett’s multiple comparisons test comparing groups to the no treatment control. **p&lt;0.01 and ***p&lt;0.001. Data are presented as mean ± standard error of the mean.</p><p><supplementary-material id="app1fig2sdata1"><label>Appendix 1—figure 2—source data 1.</label><caption><title>Numerical data used to generate the plots in <xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105978-app1-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-app1-fig2-v2.tif"/></fig><fig id="app1fig3" position="float"><label>Appendix 1—figure 3.</label><caption><title>Linear unmixing corrects spectral overlap of EGFP and mScarlet3 fluorescent signals imaged using the Odyssey M laser scanner.</title><p>(<bold>a</bold>) Schematic of the self-amplifying RNA constructs used for linear unmixing, each expressing a different fluorescent protein: moxBFP, EGFP, and mScarlet3. Constructs were transfected into tSA201 cells. (<bold>b</bold>) Representative microplate images showing fluorescence in the 488 and 520 channels, 1 day after transfection. moxBFP-transfected cells were not detected in either channel. EGFP was primarily detected in the 488 channel, with 11.32% bleed-through into the 520 channel. mScarlet3 was primarily detected in the 520 channel, with 0.94% bleed-through into the 488 channel. Background signal was determined from mock-transfected cells. (<bold>c</bold>) Corrected images using linear unmixing to counteract spectral bleed-through from mScarlet3 and EGFP signals. Scale bars = 5 mm.</p><p><supplementary-material id="app1fig3sdata1"><label>Appendix 1—figure 3—source data 1.</label><caption><title>Whole-plasmid sequencing results for self-amplifying RNA (saRNA) constructs depicted in <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3a</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-105978-app1-fig3-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105978-app1-fig3-v2.tif"/></fig></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.105978.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Comas-Garcia</surname><given-names>Mauricio</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Universidad Autónoma de San Luis Potosí</institution><country>Mexico</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>In this manuscript, Lim and collaborators present an <bold>important</bold> system for developing self-amplifying RNA with <bold>convincing</bold> evidence that it does not provoke a strong host inflammatory response in cultured cells. This approach could be further strengthened going forward by testing these self-amplying RNAs in an in vivo system.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.105978.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors have developed self-amplifying RNAs (saRNAs) encoding additional genes to suppress dsRNA-related inflammatory responses and cytokine release. Their results demonstrate that saRNA constructs encoding anti-inflammatory genes effectively reduce cytotoxicity and cytokine production, enhancing the potential of saRNAs. This work is significant for advancing saRNA therapeutics by mitigating unintended immune activation.</p><p>Strengths:</p><p>This study successfully demonstrates the concept of enhancing saRNA applications by encoding immune-suppressive genes. A key challenge for saRNA-based therapeutics, particularly for non-vaccine applications, is the innate immune response triggered by dsRNA recognition. By leveraging viral protein properties to suppress immunity, the authors provide a novel strategy to overcome this limitation. The study presents a well-designed approach with potential implications for improving saRNA stability and minimizing inflammatory side effects.</p><p>Comments on revisions:</p><p>All comments have been thoroughly addressed, and the manuscript has been significantly improved.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.105978.3.sa2</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Context - this is the 2nd review, of a manuscript that has already undergone some revisions.</p><p>The manuscript explores ways to make self-amplifying RNA (saRNA) more silent through the inclusion of genes to inhibit the innate immune response. The readouts are predominantly expression and cell viability. They take a layered approach, adding multiple genes, as well as altering the capping of the anti-immune genes.</p><p>Strengths:</p><p>As described by the other reviewers, the authors take a stepwise approach to demonstrate that they can lead to sustained expression of the transgene.</p><p>Weaknesses:</p><p>The following weaknesses need some consideration</p><p>(1) The data show sustained expression, but do not directly show amplification. The amount of RFP is constantly decreasing over the time course. There is some evidence for the srIκBα-Smad7-SOCS1 construct. But measuring the RNA itself would be beneficial</p><p>(2) The end construct is very large - it has 12 genes, this may have manufacturing considerations, affecting the translatability.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.105978.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Tony</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Ritoux</surname><given-names>Anne</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Paine</surname><given-names>Luke W</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Ferguson</surname><given-names>Larissa</given-names></name><role specific-use="author">Author</role><aff><institution>MRC Laboratory of Molecular Biology</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Abdul</surname><given-names>Tawab</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Grundy</surname><given-names>Laura J</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>St John Smith</surname><given-names>Ewan</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>The authors have developed self-amplifying RNAs (saRNAs) encoding additional genes to suppress dsRNA-related inflammatory responses and cytokine release. Their results demonstrate that saRNA constructs encoding anti-inflammatory genes effectively reduce cytotoxicity and cytokine production, enhancing the potential of saRNAs. This work is significant for advancing saRNA therapeutics by mitigating unintended immune activation.</p><p>Strengths:</p><p>This study successfully demonstrates the concept of enhancing saRNA applications by encoding immune-suppressive genes. A key challenge for saRNA-based therapeutics, particularly for non-vaccine applications, is the innate immune response triggered by dsRNA recognition. By leveraging viral protein properties to suppress immunity, the authors provide a novel strategy to overcome this limitation. The study presents a well-designed approach with potential implications for improving saRNA stability and minimizing inflammatory side effects.</p></disp-quote><p>We thank Reviewer #1 for their thorough review and for recognizing both the significance of our work and the potential of our strategy to expand saRNA applications beyond vaccines.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>(1) Impact on Cellular Translation:</p><p>The authors demonstrate that modified saRNAs with additional components enhance transgene expression by inhibiting dsRNA-sensing pathways. However, it is unclear whether these modifications influence global cellular translation beyond the expression of GFP and mScarlet-3 (which are encoded by the saRNA itself). Conducting a polysome profiling analysis or a puromycin labeling assay would clarify whether the modified saRNAs alter overall translation efficiency. This additional data would strengthen the conclusions regarding the specificity of dsRNA-sensing inhibition.</p></disp-quote><p>We thank the Reviewer for this insightful suggestion. We performed a puromycin labeling assay to assess global translation rates (Figure 3—figure supplement 1c). This experiment revealed that the E3 construct significantly reduces global protein synthesis, despite driving high levels of saRNAencoded transgene expression (Figure 1d, e). In contrast, the E3-NSs-L* construct mitigated this reduction in global translation while maintaining moderate transgene expression. These findings support our hypothesis that E3 enhances transgene output in part by activating RNase L, which degrades host mRNAs and thereby reduces ribosomal competition. We appreciate the Reviewer’s recommendation of this experiment, which has strengthened the manuscript.</p><disp-quote content-type="editor-comment"><p>(2) Stability and Replication Efficiency of Long saRNA Constructs:</p><p>The saRNA constructs used in this study exceed 16 kb, making them more fragile and challenging to handle. Assessing their mRNA integrity and quality would be crucial to ensure their robustness.</p><p>Furthermore, the replicative capacity of the designed saRNAs should be confirmed. Since Figure 4 shows lower inflammatory cytokine production when encoding srIkBα and srIkBαSmad7-SOCS1, it is important to determine whether this effect is due to reduced immune activation or impaired replication. Providing data on replication efficiency and expression levels of the encoded anti-inflammatory proteins would help rule out the possibility that reduced cytokine production is a consequence of lower replication.</p></disp-quote><p>We thank the Reviewer for these valuable suggestions.</p><p>To assess the integrity of the saRNA constructs, we performed denaturing gel electrophoresis (Supplemental Figure 6c). The native saRNA, E3, and E3-NSs-L* constructs each migrated as a single band. The moxBFP, srIκBα, and srIκBα-Smad7-SOCS1 constructs showed both a full-length transcript and a lower-abundance truncated band (Supplemental Figure 6d), suggestive of a cryptic terminator sequence introduced in a region common to these three constructs.</p><p>To evaluate replicative capacity, we performed qPCR targeting EGFP, which is encoded by all constructs. This analysis revealed that the srIκBα-Smad7-SOCS1 construct exhibited lower replication efficiency than both native saRNA and E3. Several factors may contribute to this difference, including the longer transcript length, reduced molar input when equal mass was used for transfection, prevention of host mRNA degradation due to RNase L inhibition, or the presence of truncated transcripts.</p><p>Given these confounding variables, we revised our approach to analyzing cytokine production. Rather than comparing all six constructs together, we split the analysis into two parts: (1) the effects of dsRNA-sensing pathway inhibition (Figure 4a), and (2) the effects of inflammatory signalling inhibition (Figure 4c). For the latter, we compared srIκBα and srIκBα-Smad7-SOCS1 to moxBFP, as these three constructs are more comparable in size, share the same truncated transcript, and all encode L* to inhibit RNase L. This strategy minimizes the likelihood that differences in the cytokine responses are due to variation in replication efficiency.</p><disp-quote content-type="editor-comment"><p>(3) Comparative Data with Native saRNA:</p><p>Including native saRNA controls in Figures 5-7 would allow for a clearer assessment of the impact of additional genes on cytokine production. This comparison would help distinguish the effect of the encoded suppressor proteins from other potential factors.</p></disp-quote><p>We thank the Reviewer for this helpful suggestion. We have added the native saRNA condition to Figure 5 as a visual reference. However, due to the presence of truncated transcripts in the constructs designed to inhibit inflammatory signalling pathways, the actual amount of full-length saRNA delivered in these conditions is likely lower than expected, despite using equal total RNA mass for transfection. This complicates direct comparisons with constructs targeting dsRNAsensing pathways, which do not show transcript truncation. For this reason, native saRNA was included only as a visual reference and was not used in statistical comparisons with the inflammatory signalling inhibitor constructs.</p><disp-quote content-type="editor-comment"><p>(4) In vivo Validation and Safety Considerations:</p><p>Have the authors considered evaluating the in vivo potential of these saRNA constructs? Conducting animal studies would provide stronger evidence for their therapeutic applicability. If in vivo experiments have not been performed, discussing potential challenges - such as saRNA persistence, biodistribution, and possible secondary effectswould be valuable.</p><p>(5) Immune Response to Viral Proteins:</p><p>Since the inhibitors of dsRNA-sensing proteins (E3, NSs, and L*) are viral proteins, they would be expected to induce an immune response. Analyzing these effects in vivo would add insight into the applicability of this approach.</p></disp-quote><p>We appreciate the Reviewer’s points regarding in vivo validation and safety considerations. While in vivo studies are beyond the scope of the present investigation, we agree that evaluating therapeutic potential, biodistribution, persistence, and secondary effects will be essential for future translation. We have now included a brief discussion of these considerations at the end of the revised discussion. In ongoing work, we are planning follow-up studies incorporating in vivo imaging and functional assessments of saRNA-driven cargo delivery in preclinical models of inflammatory joint pain.</p><p>Regarding the immune response to viral proteins, we agree that this is an important consideration and have now included a clearer discussion of this limitation in the revised manuscript. Specifically, we highlight that encoding multiple viral inhibitors (E3, NSs, and L*), in combination with the VEEV replicase, may increase the likelihood of adaptive immune recognition via MHC class I presentation. This could lead to cytotoxic T cell–mediated clearance of saRNA-transfected cells, thereby limiting therapeutic durability. We emphasize that addressing both intrinsic cytotoxicity and immune-mediated clearance will be essential for advancing the clinical potential of this platform.</p><disp-quote content-type="editor-comment"><p>(6) Streamlining the Discussion Section:</p><p>The discussion is quite lengthy. To improve readability, some content - such as the rationale for gene selection-could be moved to the Results section. Additionally, the descriptions of Figure 3 should be consolidated into a single section under a broader heading for improved coherence.</p></disp-quote><p>Thank you for these helpful suggestions. We have streamlined the Discussion to improve readability and have moved the rationale for gene selection to the results section, as recommended. In addition, we have consolidated the Figure 3 descriptions to improve coherence and to simplify the presentation.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>Lim et al. have developed a self-amplifying RNA (saRNA) design that incorporates immunomodulatory viral proteins, and show that the novel design results in enhanced protein expression in vitro in mouse primary fibroblast-like synoviocytes. They test constructs including saRNA with the vaccinia virus E3 protein and another with E3, Toscana virus NS protein and Theiler's virus L protein (E3 + NS + L), and another with srIκBα-Smad7SOCS1. They have also tested whether ML336, an antiviral, enables control of transgene expression.</p><p>Strengths:</p><p>The experiments are generally well-designed and offer mechanistic insight into the RNAsensing pathways that confer enhanced saRNA expression. The experiments are carried out over a long timescale, which shows the enhance effect of the saRNA E3 design compared to the control. Furthermore, the inhibitors are shown to maintain the cell number, and reduce basal activation factor-⍺ levels.</p></disp-quote><p>We thank Reviewer #2 for their thoughtful and detailed assessment of our manuscript, and for recognizing the mechanistic insights provided by our study. We also appreciate their positive comments on the experimental design, the extended timescale, and the observed effects on transgene expression, cell viability, and basal fibroblast activation factor-α levels.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>One limitation of this manuscript is that the RNA is not well characterized; some of the constructs are quite long and the RNA integrity has not been analyzed. Furthermore, for constructs with multiple proteins, it's imperative to confirm the expression of each protein to confirm that any therapeutic effect is from the effector protein (e.g. E3, NS, L). The ML336 was only tested at one concentration; it is standard in the field to do a dose-response curve. These experiments were all done in vitro in mouse cells, thus limiting the conclusion we can make about mechanisms in a human system.</p></disp-quote><p>Thank you for your detailed feedback. We have added new experiments and clarified limitations in the revised manuscript to address these concerns:</p><p>RNA integrity: We performed denaturing gel electrophoresis on the in vitro transcribed saRNA constructs (Supplemental Figure 7c). Constructs targeting dsRNA-sensing pathways migrated as a single band, while those targeting inflammatory signalling pathways showed both a full-length product and a common, lower-abundance truncated transcript. This suggests that the actual amount of full-length RNA delivered for the constructs inhibiting inflammatory signalling was overestimated. To account for this, we avoided direct comparisons between the two types of constructs and instead focused on comparisons within each type to ensure more meaningful interpretation.</p><p>Confirmation of protein expression: While we acknowledge that direct measurement of each protein would provide additional insight, we believe the functional assays presented offer strong evidence that the encoded proteins are expressed and exert their intended biological effects. Additionally, IRES functionality was confirmed visually using fluorescent protein reporters, supporting the successful expression of downstream genes.</p><p>ML336 concentration–response: We have now performed a concentration–response analysis for ML336 (Figure 8a and b), which demonstrates its ability to modulate transgene expression in a concentration-dependent manner.</p><p>Use of human cells: We agree that testing these constructs in human cells is essential for future translational applications and are actively exploring opportunities to evaluate them in patientderived FLS. However, previous studies have shown that Theiler’s virus L* does not inhibit human RNase L (Sorgeloos et al., PLoS Pathog 2013). As a result, it is highly likely that the E3-NSs-L* construct will not function as intended in human systems. Addressing this limitation will be a priority in our future work, where we aim to develop constructs incorporating inhibitors specific to human RNase L to ensure efficacy in human cells.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>Figure 2c is not indicated.</p></disp-quote><p>Thank you for pointing out this error. It has now been corrected in the revised manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>(1) The Graphical Abstract is a bit confusing; suggest modifying it to represent the study and findings more accurately.</p></disp-quote><p>We have revised the graphical abstract to improve clarity and better reflect the study’s design and main findings. Thank you for the suggestion.</p><disp-quote content-type="editor-comment"><p>(2) The impact of this paper would be greatly improved if these experiments were repeated, at least partially, in human cells. The rationale for mouse cells in vitro is unclear.</p></disp-quote><p>The rationale for developing constructs targeting mouse cells is based on our intention to utilize these constructs in mouse models of inflammatory joint pain in future studies.</p><p>We recognize that incorporating data from human cells would significantly enhance the translational relevance of our work, and we are actively pursuing collaborations to test these constructs in patient-derived FLS. However, a key component of our saRNA constructs—Theiler’s virus L*—has been shown to inhibit mouse, but not human, RNase L (Sorgeloos et al., PLoS Pathog 2013). Consequently, the E3-NSs-L* polyprotein may not function as intended in human cells. To address this limitation, future work will focus on developing constructs that incorporate inhibitors specific to human RNase L, thereby facilitating more effective translation of our findings to human systems.</p><disp-quote content-type="editor-comment"><p>(3) The ML336 was only tested at one concentration and works mildly well, but would be more impactful if tested in a dose-response curve.</p></disp-quote><p>We have now performed a concentration–response analysis for ML336 (Figure 8a and b), which demonstrates its concentration-dependent effects on transgene expression and saRNA elimination. Thank you for the suggestion.</p><disp-quote content-type="editor-comment"><p>(4) Overall, there is not a cohesive narrative to the story, instead it comes off as we tried these three different approaches, and they worked in different contexts.</p></disp-quote><p>We have revised the graphical abstract, results, and discussion to improve the cohesiveness of the manuscript’s narrative and to better integrate the mechanistic rationale linking the different approaches. We appreciate the feedback.</p><disp-quote content-type="editor-comment"><p>(5) The title is not supported by the data; the saRNA is still somewhat cytotoxic, immunostimulatory and the antiviral minimally controls transgene expression; suggest making this reflect the data.</p></disp-quote><p>We have revised the title to better reflect the scope of the data and the mechanistic focus of the study. The updated title emphasizes the pathways targeted and the outcomes demonstrated, while avoiding overstatement. Thank you for this helpful recommendation.</p></body></sub-article></article>